

10/712,456-ALW

Connecting via Winsock to STN

Welcome to STN International! - Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched
NEWS 29 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 33 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 34 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

10/712,456-ALW

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:20:35 ON 29 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:20:53 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2
DICTIONARY FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10712456ALW.str



chain nodes :

6 7 9 11 12 13 14 17 65 66 68 69

ring nodes :

1 2 3 4 5 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 38 39 40 41 42 43 44 45 49 50 51 52 53 54 55 56 57

chain bonds :

1-6 2-12 6-7 6-9 9-11 12-13 12-14 14-17 23-65 33-66 43-69 52-68

ring bonds :

1-2 1-5 2-3 3-4 4-5 20-21 20-25 21-22 22-23 23-24 24-25 24-26 25-29
26-27 27-28 28-29 30-31 30-35 31-32 32-33 33-34 34-35 34-36 35-39 36-37
37-38 38-39 40-41 40-45 41-42 42-43 43-44 44-45 49-50 49-54 50-51 51-52
52-53 53-54 53-55 54-57 55-56 56-57

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 6-7 6-9 9-11 12-13 12-14 14-17 23-65
24-25 24-26 25-29 26-27 27-28 28-29 30-31 30-35 31-32 32-33 33-34 33-66
34-35 34-36 35-39 36-37 37-38 38-39 40-41 40-45 41-42 42-43 43-44 43-69
44-45 52-68 53-55 54-57 55-56 56-57

normalized bonds :

20-21 20-25 21-22 22-23 23-24 49-50 49-54 50-51 51-52 52-53 53-54

isolated ring systems :

containing 1 :

10/712,456-ALW

G1:O,N

G2:Cb,Ak,H

G3:C,O,S,N

G4:C,N

G5:C,N

G6:C,O,N

G7:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 65:CLASS 66:CLASS 68:CLASS 69:CLASS

Element Count :

Node 17: Limited

N,N0-6

O,O0

S,S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:21:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 25149 TO ITERATE

8.0% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.04

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 493492 TO 512468

PROJECTED ANSWERS: 386 TO 1122

L2 3 SEA SSS SAM L1

=> d scan


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-
L-prolyl-L- α -aspartyl-, 3-methyl ester (9CI)

MF C32 H41 N5 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)(4-methoxyphenyl)acetyl]-N-[(1-amino-6-isoquinolinyl)methyl]-, (2S)- (9CI)

MF C26 H28 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Proline, 1-[[(3-chloro-4-cyano-2-methylphenyl) amino] carbonyl]-3-hydroxy-
, methyl ester, (3R)-

MF C15 H16 Cl N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/712,456-ALW

=> s l1 sss ful

FULL SEARCH INITIATED 09:21:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 504112 TO ITERATE

97.8% PROCESSED 492961 ITERATIONS

668 ANSWERS

100.0% PROCESSED 504112 ITERATIONS

670 ANSWERS

SEARCH TIME: 00.00.20

L3 670 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 09:22:16 ON 29 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23

FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 174 L3

=> d l4 1-174 bib hitstr

10/712,456-ALW

L4 ANSWER 1 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:438817 CAPLUS

DN 146:433450

TI Preparation of gallium complexes of N-(carboxylmethyl)azamacrocycles linked to biovectors as PET imaging agents

IN Port, Marc; Corot, Claire; Gautheret, Thierry

PA Guerbet, Fr.

SO PCT Int. Appl., 91pp.


CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007042504	A2	20070419	WO 2006-EP67211	20061009
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	FR 2891830	A1	20070413	FR 2005-10289	20051007
PRAI	FR 2005-10289	A	20051007		
	FR 2006-2975	A	20060405		
IT	934164-64-4P 934164-74-6P				
	RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of gallium complexes of N-(carboxylmethyl)azamacrocycles linked to biovectors as PET imaging agents)				
RN	934164-64-4 CAPLUS				
CN	INDEX NAME NOT YET ASSIGNED				



● 2 H^+

L4 ANSWER 2 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:34978 CAPLUS
DN 146:351552
TI Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats
AU Ostrowski, Jacek; Kuhns, Joyce E.; Lupisella, John A.; Manfredi, Mark C.; Beehler, Blake C.; Krystek, Stanley R., Jr.; Bi, Yingzhi; Sun, Chongqing; Seethala, Ramakrishna; Golla, Rajasree; Sleph, Paul G.; Fura, Aberra; An, Yongmi; Kish, Kevin F.; Sack, John S.; Mookhtiar, Kasim A.; Grover, Gary J.; Hamann, Lawrence G.
CS Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Endocrinology (2007), 148(1), 4-12
CODEN: ENDOAO; ISSN: 0013-7227
PB Endocrine Society
DT Journal
LA English
IT 627531-49-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(characterization of a novel selective androgen receptor modulator and its potent stimulation of skeletal muscle with hypostimulation of prostate in rats)
RN 627531-49-1 CAPLUS
CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW


L4 ANSWER 3 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1331239 CAPLUS
DN 146:155316
TI Design and study of some novel ibuprofen derivatives with potential
nootropic and neuroprotective properties
AU Siskou, Ioanna C.; Rekka, Eleni A.; Kourounakis, Angeliki P.; Chrysseilis,
Michael C.; Tsiakitzis, Kariofyllis; Kourounakis, Panos N.
CS Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian
University of Thessaloniki, Thessaloniki, 54124, Greece
SO Bioorganic & Medicinal Chemistry (2007), 15(2), 951-961
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
IT 919803-09-1P 919803-10-4P 919803-11-5P
919803-12-6P 919803-17-1P 919803-18-2P
919803-19-3P 919803-20-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(ibuprofen derivs. with potential nootropic and neuroprotective
properties)
RN 919803-09-1 CAPLUS
CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-,
2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 919803-10-4 CAPLUS
CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-,
3-(3-pyridinyl)propyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-11-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-mercaptoethyl)-1-[(2S)-2-[4-(2-
methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 919803-12-6 CAPLUS

CN L-Cysteine, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-17-1 CAPLUS

CN L-Proline, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, 2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 919803-18-2 CAPLUS

CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, 2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 919803-19-3 CAPLUS

CN L-Cysteine, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-20-6 CAPLUS

CN L-Cysteine, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 662165-78-8P 919803-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(ibuprofen derivs. with potential nootropic and neuroprotective properties)

RN 662165-78-8 CAPLUS

CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 919803-16-0 CAPLUS

CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 4 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1252166 CAPLUS
DN 146:114246
TI Discovery of Potent, Orally-Active, and Muscle-Selective Androgen Receptor Modulators Based on an N-Aryl-hydroxybicyclohydantoin Scaffold
AU Sun, Chongqing; Robl, Jeffrey A.; Wang, Tammy C.; Huang, Yanting; Kuhns, Joyce E.; Lupisella, John A.; Beehler, Blake C.; Golla, Rajasree; Sleph, Paul G.; Seethala, Ramakrishna; Fura, Aberra; Krystek, Stanley R., Jr.; An, Yongmi; Malley, Mary F.; Sack, John S.; Salvati, Mark E.; Grover, Gary J.; Ostrowski, Jacek; Hamann, Lawrence G.
CS Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
SO Journal of Medicinal Chemistry (2006), 49(26), 7596-7599
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 146:114246
IT 496840-99-4P 918344-29-3P 918344-30-6P
918344-31-7P 918344-32-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryl bicyclohydantoin as selective androgen receptor modulators)
RN 496840-99-4 CAPLUS
CN L-Proline, 1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 918344-29-3 CAPLUS
CN L-Proline, 4-hydroxy-1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 918344-30-6 CAPLUS

CN L-Proline, 4-hydroxy-1-[[4-nitro-1-naphthalenyl]amino]carbonyl]-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 918344-31-7 CAPLUS

CN L-Proline, 3-hydroxy-1-[[4-nitro-1-naphthalenyl]amino]carbonyl]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 918344-32-8 CAPLUS

CN L-Proline, 1-[[4-cyano-1-naphthalenyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.




RE.CNT 20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:920477 CAPLUS
 DN 145:450754
 TI Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes
 AU Berger, Alicia B.; Witte, Martin D.; Denault, Jean-Bernard; Sadaghiani, Amir Masoud; Sexton, Kelly M. B.; Salvesen, Guy S.; Bogoy, Matthew
 CS Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA
 SO Molecular Cell (2006), 23(4), 509-521
 CODEN: MOCEFL; ISSN: 1097-2765
 PB Cell Press
 DT Journal
 LA English
 IT 913253-20-0P
 RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
 (identification of early intermediates of caspase activation using selective inhibitors and activity-based probes)
 RN 913253-20-0 CAPLUS
 CN L-Alaninamide, 1-[(4-hydroxy-3-nitrophenyl)acetyl]-L-prolyl-L-leucyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 6 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:884878 CAPLUS

DN 145:292874

TI Preparation of pyridineacetic acid derivatives as peptidase inhibitors for the treatment of diabetes

IN Maezaki, Hironobu; Suzuki, Nobuhiro

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 98pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090915	A1	20060831	WO 2006-JP304177	20060224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	JP 2006265238	A	20061005	JP 2006-47921	20060224
PRAI	JP 2005-52018	A	20050225		
OS	MARPAT 145:292874				
IT	907609-35-2P 907610-10-0P 907610-93-9P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyridineacetic acid derivs. as peptidase inhibitors for treatment of diabetes)				
RN	907609-35-2 CAPLUS				
CN	2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)-3-pyridinyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 907610-10-0 CAPLUS


10/712,456-ALW

CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-4-(4-methylphenyl)-2,6-bis(2-methylpropyl)-3-pyridinyl]acetyl]-, (2S)-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1


CRN 907610-09-7
CMF C28 H40 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 907610-93-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)-3-pyridinyl]acetyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 907609-35-2
CMF C27 H38 N4 O2

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 907611-13-6P 907611-18-1P 907611-36-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridineacetic acid derivs. as peptidase inhibitors for treatment of diabetes)

RN 907611-13-6 CAPLUS

CN Carbamic acid, [[5-[2-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-2-(2,2-dimethylpropyl)-6-ethyl-4-(4-methylphenyl)-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 907611-18-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 907611-36-3 CAPLUS

CN Carbamic acid, [[5-[2-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-6-methyl-4-(4-methylphenyl)-2-(2-methylpropyl)-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 7 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:847174 CAPLUS
DN 145:347820
TI Antitumor agents 251: Synthesis, cytotoxic evaluation, and
structure-activity relationship studies of phenanthrene-based tylophorine
derivatives (PBTs) as a new class of antitumor agents
AU Wei, Linyi; Brossi, Arnold; Kendall, Ross; Bastow, Kenneth F.;
Morris-Natschke, Susan L.; Shi, Qian; Lee, Kuo-Hsiung
CS Natural Products Research Laboratories, School of Pharmacy, University of
North Carolina, Chapel Hill, NC, 27599, USA
SO Bioorganic & Medicinal Chemistry (2006), 14(19), 6560-6569
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 145:347820
IT 910488-27-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor phenanthrene-based tylophorine derivs.)
RN 910488-27-6 CAPLUS
CN L-Proline, 1-[3-(4,5-dimethoxy-2-nitrophenyl)-2-(4-methoxyphenyl)-1-oxo-2-
propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 8 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:195904 CAPLUS

DN 144:267310

TI T type calcium channel blockers and the treatment of diseases

IN Gray, Lloyd S.; Haverstick, Doris M.

PA University of Virginia Patent Foundation, USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006023881	A2	20060302	WO 2005-US29851	20050822
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005277154	A1	20060302	AU 2005-277154	20050822
	CA 2576186	A1	20060302	CA 2005-2576186	20050822
	EP 1778245	A2	20070502	EP 2005-803731	20050822
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			

PRAI US 2004-603159P P 20040820

WO 2005-US29851 W 20050822

OS MARPAT 144:267310

IT 106789-32-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(T type calcium channel blockers and treatment of diseases including proliferative disorders)

RN 106789-32-6 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 9 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1262237 CAPLUS

DN 144:35272

TI Augmenting B cell depletion by promoting intravascular access

IN Chan, Andrew C.; Gong, Qian; Martin, Flavius

PA Genentech, Inc., USA

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113003	A2	20051201	WO 2005-US12984	20050415
	WO 2005113003	A3	20060316		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005244751	A1	20051201	AU 2005-244751	20050415
	CA 2563432	A1	20051201	CA 2005-2563432	20050415
	US 2005276803	A1	20051215	US 2005-107028	20050415
	EP 1735000	A2	20061227	EP 2005-778447	20050415
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
PRAI	US 2004-563263P	P	20040416		
	WO 2005-US12984	W	20050415		
OS	MARPAT 144:35272				
IT	331471-51-3 331471-52-4 331471-57-9 331471-73-9 331471-89-7 870484-67-6 870484-68-7				
	RL:	THU (Therapeutic use); BIOL (Biological study); USES (Uses) (integrin $\alpha 4$ antagonist; augmenting B cell depletion by promoting intravascular access)			
RN	331471-51-3 CAPLUS				
CN	L-Tyrosine, 1-[(4-aminophenyl)acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/712,456-ALW

RN 331471-52-4 CAPLUS

CN L-Tyrosine, 1-[[4-(acetamino)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331471-57-9 CAPLUS


CN L-Tyrosine, 1-[[4-[2-[(2-carboxyethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 331471-73-9 CAPLUS

CN L-Tyrosine, 1-[[4-[2-[(carboxymethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 331471-89-7 CAPLUS

CN L-Tyrosine, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870484-67-6 CAPLUS


CN L-Tyrosine, L-tyrosyl-4-aminobenzeneacetyl-L-prolyl-, 4-(4-
morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 870484-68-7 CAPLUS


CN L-Tyrosine, N-acetyl-L-tyrosyl-4-aminobenzeneacetyl-L-prolyl-,
4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L4 ANSWER 10 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1242804 CAPLUS
DN 144:6806
TI Preparation of pyrimidine hydantoin analogs which inhibit leukocyte
adhesion mediated by VLA-4
IN Konradi, Andrei W.; Stappenbeck, Frank; Pleiss, Michael A.; Semko,
Christopher; Smith, Jenifer L.
PA Elan Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 11 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1216425 CAPLUS

DN 143:477970

TI Preparation of benzene derivatives containing amide moiety as ACC inhibitors

IN Suzuki, Nobuyasu; Nihei, Yukio; Ichinose, Hidehiro; Tanaka, Hideyuki; Yasa, Noriko; Hatanaka, Toshihiro; Masuzawa, Youko; Nakanishi, Eiji; Kondo, Nobuo

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005108370	A1	20051117	WO 2005-JP7392	20050418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2007105899	A1	20070510	US 2006-549450	20061013
PRAI	JP 2004-122199	A	20040416		
	JP 2004-122200	A	20040416		
	JP 2004-122201	A	20040416		
	JP 2005-21616	A	20050128		
	WO 2005-JP7392	A1	20050418		

OS MARPAT 143:477970

IT 869574-93-6P 869574-94-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzene derivs. containing amide moiety as ACC inhibitors


for

treatment of hyperlipidemia, diabetes, etc.)

RN 869574-93-6 CAPLUS

CN D-Proline, 1-[[[4-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869574-94-7 CAPLUS

10/712,456-ALW

CN L-Proline, 1-[[[4-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 12 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1125507 CAPLUS

DN 143:387379

TI Synthesis of thiocarbamoylproline derivatives for use as coagulation factor inhibitors in the prevention or treatment of thromboembolic diseases or tumors

IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes

PA Merck Patent GmbH, Germany

SO Ger. Offen., 19 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004016605	A1	20051020	DE 2004-102004016605	20040403
	WO 2005097783	A1	20051020	WO 2005-EP2745	20050315
	WO 2005097783	A8	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

PRAI DE 2004-102004016605 A 20040403

OS MARPAT 143:387379

IT 866832-65-7P 866832-66-8P 866832-67-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiocarbamoylproline derivs. as coagulation factor VIIa or Xa inhibitors for prevention or treatment of thromboembolic diseases or tumors)

RN 866832-65-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[(4-ethynylphenyl)amino]thioxomethyl]-4-methoxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866832-66-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[(4-ethynylphenyl)amino]thioxomethyl]-N-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA

10/712,456-ALW

INDEX NAME)


Absolute stereochemistry.



RN 866832-67-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[[4-ethynylphenyl]amino]thioxomethyl]-4-methoxy-N-[2-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 13 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1075769 CAPLUS
DN 143:347450
TI Synthesis of prolinyl derivatives for use in the treatment of
thromboembolic diseases or tumors
IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092849	A1	20051006	WO 2005-EP2306	20050304
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004014945	A1	20051013	DE 2004-102004014945	20040326
	AU 2005225489	A1	20051006	AU 2005-225489	20050304
	CA 2561057	A1	20051006	CA 2005-2561057	20050304
	EP 1735279	A1	20061227	EP 2005-715737	20050304
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
	CN 1938269	A	20070328	CN 2005-80009735	20050304
PRAI	DE 2004-102004014945	A	20040326		
	WO 2005-EP2306	W	20050304		
OS	MARPAT 143:347450				
IT	865853-89-0P 865853-91-4P 865853-93-6P 865853-95-8P 865853-97-0P 865853-99-2P 865854-02-0P 865854-03-1P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of proline derivs. for treatment of thromboembolic diseases or tumors)				
RN	865853-89-0 CAPLUS				
CN	1,2-Pyrrolidinedicarboxamide, N2-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 865853-91-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-93-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865853-95-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-

10/712,456-ALW

1-yl]-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-97-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)iminomethyl]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-99-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865854-02-0 CAPLUS

10/712,456-ALW

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865854-03-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 14 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1020451 CAPLUS

DN 143:305710

TI Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treatment of inflammatory disorders

IN Kranich, Remo; Aydt, Ewald Mirko

PA Revotar Biopharmaceuticals A.-G., Germany

SO Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1577289	A1	20050921	EP 2004-6461	20040318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	WO 2005090284	A1	20050929	WO 2005-EP2920	20050318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732882	A1	20061220	EP 2005-716209	20050318
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	EP 2004-6461	A	20040318		
	WO 2005-EP2920	W	20050318		
OS	MARPAT 143:305710				
IT	864518-46-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(preparation of non-glycosylated/-glycosidic/-peptidic small mol. selectin inhibitors for treatment of inflammatory disorders)				
RN	864518-46-7 CAPLUS				
CN	L-Proline, 1-[(2,3,4-trihydroxyphenyl)acetyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 15 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:983773 CAPLUS
DN 143:286280
TI Preparation of pyrrolizines as modulators of androgen receptor function
IN Li, James J.; Hamann, Lawrence; Augeri, David; Bi, Yingzhi
PA USA
SO U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005197367	A1	20050908	US 2005-70020	20050302
	WO 2005089118	A2	20050929	WO 2005-US6925	20050303
	WO 2005089118	A3	20060223		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1729763	A2	20061213	EP 2005-724465	20050303
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU			
PRAI	US 2004-550154P	P	20040304		
	WO 2005-US6925	W	20050303		
OS	CASREACT 143:286280; MARPAT 143:286280				
IT	864361-85-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of pyrrolizines for treating, preventing, or inhibiting diseases associated with the androgen receptor)				
RN	864361-85-3 CAPLUS				
CN	L-Proline, 1-[(3-chloro-4-cyano-2-methylphenyl)acetyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 16 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:983771 CAPLUS

DN 143:286428

TI Preparation of pyrrolo[1,2-c]oxazoles and pyrrolo[1,2-c]imidazoles as modulators of androgen receptor function

IN Nirschl, Alexandra; Sutton, James C.; Hamann, Lawrence; Wang, Tammy; Zou, Yan; Sun, Chongqing

PA USA

SO U.S. Pat. Appl. Publ., 38 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005197359	A1	20050908	US 2005-70808	20050302
	WO 2005087232	A1	20050922	WO 2005-US7229	20050303
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1722793	A1	20061122	EP 2005-724717	20050303
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LV, MK, YU			
PRAI	US 2004-550042P	P	20040304		
	WO 2005-US7229	W	20050303		
OS	MARPAT 143:286428				
IT	627531-62-8P 627531-64-0P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of pyrrolo[1,2-c]oxazoles and pyrrolo[1,2-c]imidazoles to treating, preventing, or inhibiting diseases associated with the androgen receptor)				
RN	627531-62-8 CAPLUS				
CN	L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 627531-64-0 CAPLUS

10/712,456-ALW

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 17 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:564637 CAPLUS
DN 143:97636
TI Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors
for use in the prevention or treatment of thromboembolic diseases or
tumors
IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058817	A1	20050630	WO 2004-EP13509	20041126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10358814	A1	20050721	DE 2003-10358814	20031216
	AU 2004299197	A1	20050630	AU 2004-299197	20041126
	CA 2549589	A1	20050630	CA 2004-2549589	20041126
	EP 1697318	A1	20060906	EP 2004-820404	20041126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1894210	A	20070110	CN 2004-80037698	20041126
	BR 2004017630	A	20070327	BR 2004-17630	20041126
	IN 2006KN01579	A	20070504	IN 2006-KN1579	20060608
PRAI	DE 2003-10358814	A	20031216		
	WO 2004-EP13509	W	20041126		

OS MARPAT 143:97636


IT 855855-42-4 855855-48-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of prolinylarylacetamides as coagulation factor Xa inhibitors
for prevention or treatment of thromboembolic diseases or tumors)

RN 855855-42-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[[(dimethylamino)acetyl]methylamino]ph
enyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-48-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-
[(methoxyacetyl)methylamino]phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 18 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:430480 CAPLUS
 DN 143:133331
 TI High-performance liquid chromatographic enantioseparation based on
 diastereomer formation with new fluorescent chiral quinoxalines
 AU Katoh, Akira; Yamamoto, Ryoji; Fujimoto, Takeshi; Saito, Ryota
 CS Department of Applied Chemistry, Faculty of Engineering, Seikei
 University, Tokyo, 180-8633, Japan
 SO Heterocycles (2005), 65(5), 1111-1120
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 143:133331
 IT 858114-47-3P 858114-49-5P
 RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic
 preparation); PREP (Preparation)
 (preparation of ibuprofen-derived fluorescent chiral quinoxaline derivative
 and
 study of its high-performance liquid chromatog. enantiosepn.)
 RN 858114-47-3 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-(2,3-di-4-morpholinyl-6-quinoxaliny)-1-[(2S)-
 2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858114-49-5 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-(2,3-di-4-morpholinyl-6-quinoxaliny)-1-[(2R)-
 2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:429392 CAPLUS

DN 142:481940

TI Preparation of 3-phenyl-2,4-pyrrolidinediones as herbicides

IN Fischer, Reiner; Lehr, Stefan; Feucht, Dieter; Loesel, Peter; Malsam, Olga; Bojack, Guido; Auler, Thomas; Hills, Martin Jeffrey; Kehne, Heinz; Rosinger, Christopher Hugh

PA Bayer Cropscience Aktiengesellschaft, Germany

SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044791	A2	20050519	WO 2004-EP12444	20041104
	WO 2005044791	A3	20050811		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10351647	A1	20050609	DE 2003-10351647	20031105
	AU 2004287597	A1	20050519	AU 2004-287597	20041104
	CA 2544548	A1	20050519	CA 2004-2544548	20041104
	EP 1682501	A2	20060726	EP 2004-803102	20041104
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1874995	A	20061206	CN 2004-80032654	20041104
	BR 2004015738	A	20061219	BR 2004-15738	20041104
	JP 2007511476	T	20070510	JP 2006-537248	20041104
PRAI	DE 2003-10351647	A	20031105		
	WO 2004-EP12444	W	20041104		

OS MARPAT 142:481940

IT 852069-60-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of phenylpyrrolidinediones as herbicides)

RN 852069-60-4 CAPLUS

CN L-Proline, 1-[(2-bromo-6-ethyl-4-methylphenyl)acetyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 20 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:409480 CAPLUS

DN 142:463610

TI Preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for the prophylaxis or treatment of diabetes

IN Oi, Satoru; Maezaki, Hironobu; Suzuki, Nobuhiro

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 431 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042488	A1	20050512	WO 2004-JP16457	20041029
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004285807	A1	20050512	AU 2004-285807	20041029
	CA 2543529	A1	20050512	CA 2004-2543529	20041029
	JP 2006016377	A	20060119	JP 2004-315517	20041029
	EP 1678138	A1	20060712	EP 2004-793377	20041029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1886376	A	20061227	CN 2004-80034965	20041029
	BR 2004015960	A	20070116	BR 2004-15960	20041029
	US 2007037807	A1	20070215	US 2006-577561	20060428
	IN 2006KN01220	A	20070427	IN 2006-KN1220	20060510
	NO 2006002516	A	20060725	NO 2006-2516	20060531
PRAI	JP 2003-373776	A	20031031		
	JP 2004-30491	A	20040206		
	JP 2004-165977	A	20040603		
	WO 2004-JP16457	W	20041029		
OS	MARPAT 142:463610				
IT	851585-68-7P, Methyl 1-[[[5-(aminomethyl)-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]amino]carbonyl]pyrrolidine-2-carboxylate dihydrochloride 851586-53-3P, Methyl 1-[[5-(aminomethyl)-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]acetyl]prolinate dihydrochloride				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for prophylaxis or treatment of diabetes)				
RN	851585-68-7 CAPLUS				
CN	Proline, 1-[[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]amino]carbonyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)				




● 2 HCl

RN 851586-53-3 CAPLUS

CN L-Proline, 1-[[[5-[[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, methyl ester, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 851585-69-8P, Methyl 1-[[[5-[[[5-[(tert-butoxycarbonyl)amino]methyl]-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]amino]carbonyl]pyrrolidine-2-carboxylate 851586-54-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for prophylaxis or treatment of diabetes)

RN 851585-69-8 CAPLUS

CN Proline, 1-[[[5-[[[5-[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]amino]carbonyl]-, methyl

10/712,456-ALW


ester (9CI) (CA INDEX NAME)



RN 851586-54-4 CAPLUS

CN L-Proline, 1-[[[5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 21 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:395446 CAPLUS
DN 142:406543
TI TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators
IN Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin Tammie; Nuss, John M.; Parks, Jason Jevious; Schnepf, Kevin Luke; Shi, Xian; Williams, Matthew Alan
PA Exelixis, Inc., USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040355	A2	20050506	WO 2004-US35469	20041022
	WO 2005040355	A3	20050804		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004283313	A1	20050506	AU 2004-283313	20041022
	CA 2542064	A1	20050506	CA 2004-2542064	20041022
	EP 1678121	A2	20060712	EP 2004-796442	20041022
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRAI	US 2003-514377P	P	20031024		
	WO 2004-US35469	W	20041022		
OS	MARPAT 142:406543				
IT	850467-15-1 850467-20-8				
	RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators)				
RN	850467-15-1 CAPLUS				
CN	1,2-Pyrrolidinedicarboxamide, N1-(4-butylphenyl)-N2-[(3,4-dichlorophenyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/712,456-ALW

RN 850467-20-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[(3,4-dichlorophenyl)methyl]-N1-[4-(1-methylethyl)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 22 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:173614 CAPLUS

DN 143:387223

TI Solid-phase synthesis of model libraries of 3 α ,17 β -dihydroxy-16 α -(N-substituted-aminoethyl)-5 α -androstanes for the development of steroidal therapeutic agents

AU Maltais, Rene; Mercier, Caroline; Labrie, Fernand; Poirier, Donald

CS Oncology and Molecular Endocrinology Research Center (Medicinal Chemistry Division), University Laval, Centre Hospitalier Universitaire de Quebec (CHUQ), QC, G1V 4G2, Can.

SO Molecular Diversity (2005), 9(1-3), 67-79

CODEN: MODIF4; ISSN: 1381-1991

PB Springer

DT Journal

LA English

OS CASREACT 143:387223

IT 866591-57-3P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation and antiproliferative activity of; solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androsterane-3 α ,17 β -diols)

RN 866591-57-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrostan-16-yl]ethyl]-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 866592-15-6DP, 3-O-PS-DES resin-bound

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)


(preparation and removal of, from resin; solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androsterane-

10/712,456-ALW


3 α ,17 β -diols)
RN 866592-15-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[(3 α ,5 α ,16 α ,17 β)-3-hydroxy-17-[(tetrahydro-2H-pyran-2-yl)oxy]androstan-16-yl]ethyl]-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 866592-80-5P 866593-33-1P 866593-47-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androsterane-3 α ,17 β -diols)
RN 866592-80-5 CAPLUS
CN Glycinamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrostan-16-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 866593-33-1 CAPLUS


CN L-Isoleucinamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrost-16-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 866593-47-7 CAPLUS

CN L-Phenylalaninamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrost-16-yl]ethyl]- (9CI) (CA INDEX NAME)


10/712,456-ALW

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 23 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:86537 CAPLUS
 DN 143:431977
 TI Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. [Erratum to document cited in CA142:085870]
 AU Chiba, Jun; Machinaga, Nobuo; Takashi, Tohru; Ejima, Akio; Takayama, Gensuke; Yokoyama, Mika; Nakayama, Atsushi; Baldwin, John J.; McDonald, Edward; Moriarty, Kevin J.; Sarko, Christopher R.; Saionz, Kurt W.; Swanson, Robert; Hussain, Zahid; Wong, Angela
 CS Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, 134-8630, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 1259
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 IT 819078-48-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))
 RN 819078-48-3 CAPLUS
 CN Pentanoic acid, 5-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 819078-50-7P 819078-51-8P 819078-52-9P
 819078-53-0P 819078-54-1P 819078-55-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))
 RN 819078-50-7 CAPLUS
 CN Glycine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 819078-51-8 CAPLUS

CN β -Alanine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-52-9 CAPLUS

CN Butanoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-53-0 CAPLUS

CN Hexanoic acid, 6-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 819078-54-1 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 819078-55-2 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 819078-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))

RN 819078-82-5 CAPLUS

CN L-Proline, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 24 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1124627 CAPLUS
DN 142:74838
TI Preparation of pyrrolidin-1,2-dicarboxylic acids and related compounds as
coagulation factor Xa and factor VIIa inhibitors
IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110433	A1	20041223	WO 2004-EP5717	20040527
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10327428	A1	20050105	DE 2003-10327428	20030618
	DE 10329457	A1	20050120	DE 2003-10329457	20030701
	AU 2004246766	A1	20041223	AU 2004-246766	20040527
	CA 2529453	A1	20041223	CA 2004-2529453	20040527
	EP 1633346	A1	20060315	EP 2004-735007	20040527
	EP 1633346	B1	20060823		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004011466	A	20060711	BR 2004-11466	20040527
	CN 1809346	A	20060726	CN 2004-80016955	20040527
	AT 337000	T	20060915	AT 2004-735007	20040527
	JP 2006527708	T	20061207	JP 2006-515798	20040527
	US 2007093472	A1	20070426	US 2005-561227	20051219
PRAI	DE 2003-10327428	A	20030618		
	DE 2003-10329457	A	20030701		
	WO 2004-EP5717	W	20040527		
OS	MARPAT 142:74838				
IT	814263-98-4P 814263-99-5P 814264-00-1P 814264-01-2P 814264-02-3P 814264-03-4P 814264-04-5P 814264-05-6P 814264-06-7P 814264-07-8P 814264-08-9P 814264-09-0P 814264-10-3P 814264-11-4P 814264-12-5P 814264-13-6P 814264-14-7P 814264-15-8P 814264-16-9P 814264-17-0P 814264-18-1P 814264-19-2P 814264-20-5P 814264-21-6P 814264-22-7P 814264-23-8P 814264-24-9P 814264-25-0P 814264-26-1P 814264-27-2P 814264-28-3P 814264-29-4P 814264-30-7P 814264-31-8P 814264-32-9P 814264-33-0P 814264-34-1P 814264-35-2P 814264-36-3P 814264-37-4P 814264-38-5P 814264-39-6P 814264-40-9P 814264-41-0P 814264-42-1P 814264-43-2P 814264-44-3P 814264-45-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				

10/712,456-ALW


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrrolidinyldicarboxylic acids and related compds. as factor
Xa and factor VIIa inhibitors)

RN 814263-98-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(2-oxo-
1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814263-99-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-oxo-
4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-00-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-
4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 814264-01-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-02-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-03-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-04-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 814264-05-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-06-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-07-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-08-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-09-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-10-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-11-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-12-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-13-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-14-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-15-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-16-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-17-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-18-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-19-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1-piperidiny)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-20-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-21-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-22-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(2-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-23-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-24-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-25-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-26-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(2R,4R)-1-[[4-ethynylphenyl]amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-27-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methoxy-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-28-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methoxy-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-29-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-30-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-31-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-32-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propynyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-33-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-34-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-35-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propynyloxy)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-36-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(2,3-dihydroxypropoxy)-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-37-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(5-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-38-5 CAPLUS

CN L-Proline, 1-[4-[[[(2R,4R)-1-[[4-ethynylphenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-39-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-40-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 814264-41-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-42-1 CAPLUS

CN Acetic acid, [[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-5-[[[(4-ethynylphenyl)amino]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-43-2 CAPLUS

CN Acetic acid, [[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-5-[[[(4-ethynylphenyl)amino]carbonyl]-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)

10/712,456-ALW

NAME)


Absolute stereochemistry.



RN 814264-44-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-methyl-6-oxo-1(6H)-pyridazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-45-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[2-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 814264-46-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolidinyldicarboxylic acids and related compds. as factor Xa and factor VIIa inhibitors)


RN 814264-46-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-

10/712,456-ALW

morpholinyl)phenyl]-4-(2-methoxyethoxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 25 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1080794 CAPLUS

DN 142:49214

TI Compounds inhibiting the binding of serum amyloid P component (SAP) for treating osteoarthritis

IN Pepys, Mark B.; Hawkins, Philip Nigel

PA Pentraxin Therapeutics Limited, UK

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108131	A1	20041216	WO 2004-GB2445	20040610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004244815	A1	20041216	AU 2004-244815	20040610
	CA 2528706	A1	20041216	CA 2004-2528706	20040610
	EP 1633345	A1	20060315	EP 2004-736527	20040610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	GB 2420498	A	20060531	GB 2006-229	20040610
	JP 2006527250	T	20061130	JP 2006-516388	20040610
PRAI	GB 2003-13386	A	20030610		
	WO 2004-GB2445	W	20040610		
OS	MARPAT 142:49214				
IT	224624-85-5, Ro 63-7777 224625-47-2, Ro 64-4383				
	RL: PAC (Pharmacological activity); BIOL (Biological study)				
	(compds. inhibiting binding of serum amyloid P component for treating osteoarthritis)				
RN	224624-85-5 CAPLUS				
CN	D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 224625-47-2 CAPLUS

CN D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 26 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1068245 CAPLUS
 DN 142:85870
 TI Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist
 AU Chiba, Jun; Machinaga, Nobuo; Takashi, Tohru; Ejima, Akio; Takayama, Gensuke; Yokoyama, Mika; Nakayama, Atsushi; Baldwin, John J.; McDonald, Edward; Saionz, Kurt W.; Swanson, Robert; Hussain, Zahid; Wong, Angela
 CS Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, 134-8630, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(1), 41-45
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 142:85870
 IT 819078-48-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)
 RN 819078-48-3 CAPLUS
 CN Pentanoic acid, 5-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 819078-50-7P 819078-51-8P 819078-52-9P
 819078-53-0P 819078-54-1P 819078-55-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)
 RN 819078-50-7 CAPLUS
 CN Glycine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 819078-51-8 CAPLUS

CN β -Alanine, 1-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-52-9 CAPLUS

CN Butanoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-53-0 CAPLUS

CN Hexanoic acid, 6-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-54-1 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-55-2 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 819078-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)

RN 819078-82-5 CAPLUS

CN L-Proline, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1037096 CAPLUS

DN 142:23512

TI Preparation of N-acyl proline derivatives and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors

IN Ksander, Gary Michael; Vedananda, Thalaththani Ralalage

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103995	A1	20041202	WO 2004-EP5434	20040519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004240754	A1	20041202	AU 2004-240754	20040519
	CA 2525764	A1	20041202	CA 2004-2525764	20040519
	EP 1638963	A1	20060329	EP 2004-739269	20040519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010779	A	20060627	BR 2004-10779	20040519
	CN 1795193	A	20060628	CN 2004-80014021	20040519
	JP 2007501263	T	20070125	JP 2006-529884	20040519
	US 2006135593	A1	20060622	US 2005-556988	20051115
	NO 2005006056	A	20060217	NO 2005-6056	20051220
PRAI	US 2003-472067P	P	20030520		
	WO 2004-EP5434	W	20040519		
OS	MARPAT 142:23512				
IT	799854-62-9P 799854-63-0P 799854-67-4P 799854-68-5P 799854-71-0P 799854-82-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of N-acyl proline derivs. and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors)				
RN	799854-62-9 CAPLUS				
CN	D-Proline, 1-[2-methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 799854-63-0 CAPLUS

CN D-Proline, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 799854-67-4 CAPLUS

CN D-Proline, 1-[2-methyl-2-[4-[[methyl[[4-(trifluoromethyl)phenyl]acetyl]amino]methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 799854-68-5 CAPLUS

CN D-Proline, 1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-4-methoxyphenyl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 799854-71-0 CAPLUS


CN D-Proline, 1-[[4-[2-[[[4-(trifluoromethyl)phenyl]acetyl]amino]ethyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 799854-82-3 CAPLUS

CN Proline, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 28 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:857399 CAPLUS
DN 141:343478
TI Use of small molecule compounds for immunopotential
IN Valiante, Nicholas
PA Chiron Corporation, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004087153	A2	20041014	WO 2004-US10331	20040329
	WO 2004087153	A3	20050317		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2520124	A1	20041014	CA 2004-2520124	20040329
	US 2005136065	A1	20050623	US 2004-814480	20040329
	EP 1608369	A2	20051228	EP 2004-758593	20040329
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-458888P	P	20030328		
	WO 2004-US10331	W	20040329		
OS	MARPAT 141:343478				
IT	774197-06-7				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(small mol. compds. for immunopotential)			
RN	774197-06-7 CAPLUS				
CN	1,2-Pyrrolidinedicarboxamide, N1-(4-methylphenyl)-5-phenyl-N2-[2-(2-pyridinyl)ethyl]-, (2S,5R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 29 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:759871 CAPLUS

DN 141:277621

TI Preparation of bicyclic compounds as modulators of androgen receptor function

IN Sun, Chong-Qing; Hamann, Lawrence; Augeri, David; Bi, Yingzhi; Robl, Jeffrey; Huang, Yan-Ting; Wang, Tammy; Holubec, Alexandra; Simpkins, Ligaya; Sutton, James C.; Li, James J.

PA USA

SO U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of U.S. Pat. Appl. 2004 19,063.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004181064	A1	20040916	US 2004-780415	20040217
	US 2004019063	A1	20040129	US 2003-438722	20030515
PRAI	US 2002-381616P	P	20020517		
	US 2002-406711P	P	20020829		
	US 2003-438722	A2	20030515		

OS MARPAT 141:277621

IT 627531-32-2P 627531-49-1P 627531-62-8P

627531-63-9P 627531-64-0P 627531-67-3P

627531-68-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic compds. as modulators of androgen receptor function)

RN 627531-32-2 CAPLUS

CN L-Proline, 1-[[[(7-cyano-1-methyl-1H-benzimidazol-4-yl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627531-49-1 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 627531-62-8 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-63-9 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-64-0 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-67-3 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-68-4 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-[[[1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 30 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:670962 CAPLUS
DN 141:332439
TI Titanium Catalysis in the Ugi Reaction of α -Amino Acids with
Aromatic Aldehydes
AU Godet, Thomas; Bonvin, Yannick; Vincent, Guillaume; Merle, Daphne; Thozet,
Alain; Ciufolini, Marco A.
CS Ecole Supérieure de Chimie, Physique et Electronique de Lyon, Laboratoire
de Synthèse et Methodologie Organiques, CNRS UMR 5181, Centre Commun de
Diffraction, Université Claude Bernard Lyon 1, Villeurbanne, 69622,
Fr.
SO Organic Letters (2004), 6(19), 3281-3284
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:332439
IT 771586-55-1P 771586-56-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(temperature-dependent uncatalyzed condensation of an aryl aldehyde and an
aryl isocyanide with L-pyroglutamic acid yields α -
alkoxyarylacetic acid amides)
RN 771586-55-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2R)-(2,4-dimethoxy-3-
methylphenyl)methoxyacetyl]-N-(2,6-dimethylphenyl)-5-oxo-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 771586-56-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2R)-(2,4-dimethoxy-3-
methylphenyl)ethoxyacetyl]-N-(2,6-dimethylphenyl)-5-oxo-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW





RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW



L4 ANSWER 31 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:610128 CAPLUS
DN 141:157478
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
IN Allan, Amy L.; Yoon, Won Hyung; Gladstone, Patricia L.; Ternansky, Robert J.; Parry, Graham; Donate, Fernando; Mazar, Andrew
PA Attenuon, Llc, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063213	A2	20040729	WO 2003-US37895	20031125
	WO 2004063213	A3	20050303		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2506813	A1	20040729	CA 2003-2506813	20031125
	AU 2003298726	A1	20040810	AU 2003-298726	20031125
	US 2004162239	A1	20040819	US 2003-723144	20031125
	US 2005020810	A1	20050127	US 2003-722843	20031125
	EP 1569678	A2	20050907	EP 2003-796483	20031125
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003016550	A	20051004	BR 2003-16550	20031125
	CN 1741808	A	20060301	CN 2003-80109204	20031125
	CN 1741809	A	20060301	CN 2003-80109205	20031125
	JP 2006515866	T	20060608	JP 2005-512876	20031125
	NO 2005003112	A	20050805	NO 2005-3112	20050624
	IN 2005KN01228	A	20070126	IN 2005-KN1228	20050624
PRAI	US 2002-429174P	P	20021125		
	US 2003-475539P	P	20030602		
	WO 2003-US37895	W	20031125		
OS	MARPAT 141:157478				
IT	731003-01-3DP, Indium complexes 731003-01-3P				
	RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of peptides which target tumor and endothelial cells)				
RN	731003-01-3 CAPLUS				
CN	L-Aspartamide, 1-[[[(4-methylphenyl)amino]thioxomethyl]-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-, mono[N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine] deriv. (9CI) (CA INDEX NAME)				



RN 731003-01-3 CAPLUS


CN L-Aspartamide, 1-[[[(4-methylphenyl)amino]thioxomethyl]-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-, mono[N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine] deriv. (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:566894 CAPLUS
 DN 141:273359
 TI Identification of Synthetic Phosphatidylserine Translocases from a Combinatorial Library Prepared by Directed Split-and-Pool Synthesis
 AU Shukla, Rameshwer; Sasaki, Yoshihiro; Krchnak, Viktor; Smith, Bradley D.
 CS Department of Chemistry and Biochemistry and the Walther Center for Cancer Research, University of Notre Dame, Notre Dame, IN, 46556, USA
 SO Journal of Combinatorial Chemistry (2004), 6(5), 703-709
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 IT 757993-84-3P 757993-87-6P 757994-26-6P
 757994-28-8P 757994-98-2P 757995-01-0P
 757995-29-2P 757995-31-6P
 RL: CPN (Combinatorial preparation); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
 (identification of synthetic phosphatidylserine translocases from combinatorial library prepared by directed split-and-pool synthesis)
 RN 757993-84-3 CAPLUS
 CN Glycinamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 757993-87-6 CAPLUS
 CN Glycinamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757994-26-6 CAPLUS


CN L-Lysinamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757994-28-8 CAPLUS


CN L-Lysinamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 757994-98-2 CAPLUS

CN L-Threoninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 757995-01-0 CAPLUS

CN L-Threoninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)




RN 757995-29-2 CAPLUS

10/712,456-ALW


CN L-Phenylalaninamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-
[[[4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757995-31-6 CAPLUS


CN L-Phenylalaninamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-
[[[4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 27

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 33 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:498567 CAPLUS
DN 141:207025
TI Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists
AU McCalmont, William F.; Heady, Tiffany N.; Patterson, Jaclyn R.; Lindenmuth, Michael A.; Haverstick, Doris M.; Gray, Lloyd S.; Macdonald, Timothy L.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, 22904-4319, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3691-3695
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:207025
IT 106789-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzyloxymethyl-substituted pyrrolidines and piperidines as T-type calcium channel antagonists and cancer cell antiproliferative agents)
RN 106789-32-6 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L4 ANSWER 34 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:493686 CAPLUS
 DN 141:54342
 TI Preparation of 2-(2-hydroxybiphenyl-3-yl)-1H-benzimidazole-5-carboxamide derivatives as factor VIIa inhibitors
 IN Kolesnikov, Aleksandr; Rai, Roopa; Shrader, William Dvorak; Torkelson, Steven M.; Wesson, Kieron E.; Young, Wendy B.
 PA Axys Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050637	A2	20040617	WO 2003-US38635	20031203
	WO 2004050637	A3	20040902		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507707	A1	20040617	CA 2003-2507707	20031203
	AU 2003302238	A1	20040623	AU 2003-302238	20031203
	EP 1569912	A2	20050907	EP 2003-810056	20031203
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1745070	A	20060308	CN 2003-80109503	20031203
	JP 2006515839	T	20060608	JP 2004-557602	20031203
	IN 2005KN01065	A	20060818	IN 2005-KN1065	20050603
	US 2006205942	A1	20060914	US 2006-537115	20060320
PRAI	US 2002-430981P	P	20021203		
	WO 2003-US38635	W	20031203		

OS MARPAT 141:54342

IT 706821-83-2P, (2R)-1-[2-[5-(5-Carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetyl]pyrrolidine-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of (hydroxybiphenyl)-1H-benzimidazolecarboxamide derivs. as factor VIIa inhibitors for treating thromboembolic disorders, cancer, or rheumatoid arthritis)

RN 706821-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-[5-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 35 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:452960 CAPLUS

DN 141:28605

TI Open chain prolyl urea-related modulators of androgen receptor function
therapeutic use for nuclear hormone receptor-associated conditions

IN Hamann, Lawrence G.; Augeri, David J.; Manfredi, Mark C.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045518	A2	20040603	WO 2003-US36331	20031113
	WO 2004045518	A3	20041007		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003302084	A1	20040615	AU 2003-302084	20031113
	US 2005059652	A1	20050317	US 2003-712456	20031113
	EP 1567487	A2	20050831	EP 2003-808410	20031113
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	US 2002-426694P	P	20021115		
	WO 2003-US36331	W	20031113		
OS	MARPAT 141:28605				
IT	496841-10-2P 697228-47-0P 697228-51-6P 697228-52-7P 697228-54-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(open chain prolyl urea-related modulators of androgen receptor function therapeutic use for nuclear hormone receptor-associated conditions)				
RN	496841-10-2 CAPLUS				
CN	L-Proline, 1-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/712,456-ALW

RN 697228-47-0 CAPLUS

CN L-Proline, 1-[[[4-cyano-2-ethyl-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697228-51-6 CAPLUS

CN L-Proline, 1-[[[4-cyano-2-ethyl-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697228-52-7 CAPLUS

CN L-Proline, 1-[[[5-chloro-6-cyano-3-pyridinyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697228-54-9 CAPLUS

CN L-Proline, 1-[(4-cyano-1-naphthalenyl)acetyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




10/712,456-ALW

L4 ANSWER 36 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:143100 CAPLUS
DN 140:199315
TI Preparation of iminothiazolidinone amino acid derivatives as inhibitors of
HCV replication
IN Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu,
Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle,
Donald; Gao, Min; Colonno, Richard
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004014852	A2	20040219	WO 2003-US24717	20030808
	WO 2004014852	A3	20040422		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003261434	A1	20040225	AU 2003-261434	20030808
	US 2005069522	A1	20050331	US 2003-637156	20030808
	US 2005096364	A1	20050505	US 2003-637099	20030808
	US 7183302	B2	20070227		
PRAI	US 2002-402661P	P	20020812		
	US 2002-403694P	P	20020815		
	WO 2003-US24717	W	20030808		
OS	MARPAT 140:199315				
IT	657413-75-7P 657413-78-0P 657413-81-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)				
RN	657413-75-7 CAPLUS				
CN	2-Pyrrolidinecarboxamide, 1-[[4-(dimethylamino)phenyl]acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.
Double bond geometry unknown.




—NMe₂

RN 657413-78-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(4-methoxyphenyl)acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




— OMe

RN 657413-81-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-1-[[4-(trifluoromethyl)phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



—CF₃


10/712,456-ALW

L4 ANSWER 37 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142910 CAPLUS
DN 140:199742
TI Preparation of iminothiazolidinone amino acid derivatives as combination
pharmaceutical agents for use as inhibitors of HCV replication
IN Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey
Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael;
Deshpande, Milind; Whitehouse, Darren
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014313	A2	20040219	WO 2003-US25036	20030808
	WO 2004014313	A3	20051215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003264038	A1	20040225	AU 2003-264038	20030808
	US 2005069522	A1	20050331	US 2003-637156	20030808
	US 2005096364	A1	20050505	US 2003-637099	20030808
	US 7183302	B2	20070227		
PRAI	US 2002-402661P	P	20020812		
	US 2002-403694P	P	20020815		
	WO 2003-US25036	W	20030808		
OS	MARPAT 140:199742				
IT	657413-75-7P 657413-78-0P 657413-81-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)				
RN	657413-75-7 CAPLUS				
CN	2-Pyrrolidinecarboxamide, 1-[[4-(dimethylamino)phenyl]acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

Double bond geometry unknown.




NMe₂

RN 657413-78-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(4-methoxyphenyl)acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




— OMe

RN 657413-81-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-1-[[4-(trifluoromethyl)phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



—CF₃

10/712,456-ALW

L4 ANSWER 38 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:972023 CAPLUS

DN 140:27657

TI Bis(dihydroxyaryl) compounds, pharmaceutical compositions containing them, and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease.

IN Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, David L.

PA Proteotech, Inc., USA

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101927	A1	20031211	WO 2003-US17288	20030530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2486869	A1	20031211	CA 2003-2486869	20030530
	AU 2003249678	A1	20031219	AU 2003-249678	20030530
	US 2004127555	A1	20040701	US 2003-452851	20030530
	EP 1511710	A1	20050309	EP 2003-756343	20030530
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005531596	T	20051020	JP 2004-509622	20030530
PRAI	US 2002-385144P	P	20020531		
	US 2002-409100P	P	20020909		
	US 2002-412272P	P	20020920		
	US 2002-435880P	P	20021220		
	US 2003-463104P	P	20030414		
	WO 2003-US17288	W	20030530		

OS MARPAT 140:27657

IT 633699-96-4P, N-(3,4-Dihydroxyphenylacetyl)proline
3,4-dihydroxyanilide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of bis(dihydroxyaryl) compds. as amyloid fibril disrupters for treatment of Alzheimer's, Parkinson's, and type 2 diabetes)

RN 633699-96-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(3,4-dihydroxyphenyl)-1-[(3,4-dihydroxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 39 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971921 CAPLUS
DN 140:19879
TI Drug compositions containing calcium channel antagonists exhibiting
intestinal tract selectivity
IN Hashimoto, Masaki; Takahashi, Kazuyoshi
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101490	A1	20031211	WO 2003-JP6847	20030530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005343790	A	20051215	JP 2002-160187	20020531
	AU 2003241991	A1	20031219	AU 2003-241991	20030530
PRAI	JP 2002-160187	A	20020531		
	WO 2003-JP6847	W	20030530		
OS	MARPAT 140:19879				
IT	477779-14-9P 477779-15-0P 630095-41-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of calcium channel antagonists exhibiting intestinal tract selectivity)				
RN	477779-14-9 CAPLUS				
CN	D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 477779-15-0 CAPLUS
CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 630095-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-4-chlorophenyl)methoxy]phenyl]-1-[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 40 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971920 CAPLUS
DN 140:19878
TI Medicinal compositions containing defined calcium channel antagonists for
treatment for digestive tract disease
IN Yamada, Youji; Takahashi, Kazuyoshi; Hashimoto, Masaki
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101489	A1	20031211	WO 2003-JP6845	20030530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005343791	A	20051215	JP 2002-160188	20020531
	AU 2003241987	A1	20031219	AU 2003-241987	20030530
PRAI	JP 2002-160188	A	20020531		
	WO 2003-JP6845	W	20030530		
OS	MARPAT 140:19878				
IT	477779-14-9P 477779-15-0P 630095-41-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of medicinal compns. containing defined calcium channel antagonists				
	for treatment for digestive tract disease)				
RN	477779-14-9 CAPLUS				
CN	D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 477779-15-0 CAPLUS
CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 630095-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-4-chlorophenyl)methoxy]phenyl]-1-
[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 41 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:931118 CAPLUS

DN 140:5047

TI Preparation of pyrrolo[1,2-c]imidazoles as bicyclic modulators of androgen receptor function

IN Sun, Chongqing; Hamann, Lawrence; Augeri, David; Bi, Yingzhi; Robl, Jeffrey; Huang, Yan-ting; Wang, Tammy; Simpkins, Ligaya; Holubec, Alexandra

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003096980	A2	20031127	WO 2003-US15375	20030515
	WO 2003096980	A3	20041021		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003234609	A1	20031202	AU 2003-234609	20030515
	EP 1506178	A2	20050216	EP 2003-728951	20030515
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005531555	T	20051020	JP 2004-504979	20030515
	NO 2004004809	A	20050214	NO 2004-4809	20041104
PRAI	US 2002-381616P	P	20020517		
	US 2002-406711P	P	20020829		
	WO 2003-US15375	W	20030515		
OS	MARPAT 140:5047				
IT	627531-32-2P 627531-49-1P 627531-62-8P 627531-63-9P 627531-64-0P 627531-67-3P 627531-68-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of pyrrolo[1,2-c]imidazoles as bicyclic modulators of androgen receptor function)				
RN	627531-32-2 CAPLUS				
CN	L-Proline, 1-[[[(7-cyano-1-methyl-1H-benzimidazol-4-yl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 627531-49-1 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-62-8 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-63-9 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-64-0 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-67-3 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627531-68-4 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.





L4 ANSWER 42 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:913043 CAPLUS
 DN 139:386340
 TI FAP-activated anti-tumor prodrugs
 IN Patzelt, Erik; Park, John Edward; Peters, Stefan
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003094972	A2	20031120	WO 2003-EP4713	20030506
	WO 2003094972	A3	20040318		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003233238	A1	20031111	AU 2003-233238	20030506
	US 2004033957	A1	20040219	US 2003-430056	20030506
	EP 1506221	A2	20050216	EP 2003-727438	20030506
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	EP 2002-10552	A	20020510		
	US 2002-386163P	P	20020605		
	WO 2003-EP4713	W	20030506		
OS	MARPAT 139:386340				
IT	623156-76-3P				
	RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (FAP-activated anti-tumor prodrugs)				
RN	623156-76-3 CAPLUS				
CN	5,12-Naphthacenedione, 10-[[3-[[1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-L-prolyl-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A






10/712,456-ALW

L4 ANSWER 43 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:887675 CAPLUS
DN 139:381751
TI Preparation of substituted β -alanine derivatives as cell adhesion inhibitors
IN Durette, Philippe L.; Hagmann, William K.; Kopka, Ihor E.; MacCoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Magriotis, Plato A.
PA Merck & Co., Inc., USA
SO U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 198,680, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6645939	B1	20031111	US 1999-317789	19990524
	WO 2000071572	A1	20001130	WO 2000-US14017	20000519
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1997-66484P	P	19971124		
	US 1998-198680	B2	19981124		
	US 1999-317789	A2	19990524		
OS	MARPAT 139:381751				
IT	225515-65-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted β -alanine derivs. as cell adhesion inhibitors)				
RN	225515-65-1 CAPLUS				
CN	β -Alanine, 1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW


L4 ANSWER 44 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:854948 CAPLUS
DN 140:199074
TI Use of S-proline as chiral auxiliary in α -alkylations of carboxylic acids
AU Srivastava, Stuti; Goswami, Lalit N.; Dikshit, Dinesh K.
CS Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226 001, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2003), 42B(10), 2628-2631
CODEN: IJSBDB; ISSN: 0376-4699
PB National Institute of Science Communication
DT Journal
LA English
OS CASREACT 140:199074
IT 662165-79-9P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(proline chiral auxiliary in asym. alkylation of carboxylic acids)
RN 662165-79-9 CAPLUS
CN L-Proline, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 662165-78-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(proline chiral auxiliary in asym. alkylation of carboxylic acids)
RN 662165-78-8 CAPLUS
CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 45 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:818409 CAPLUS
DN 139:323538
TI Preparation of hydroxamic acid derivatives for use as pharmaceuticals
IN Janser, Philipp; Miltz, Wolfgang; Neumann, Ulf
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084941	A2	20031016	WO 2003-EP3644	20030408
	WO 2003084941	A3	20040325		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			
	RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR			
	CA 2481879	A1	20031016	CA 2003-2481879	20030408
	AU 2003236834	A1	20031020	AU 2003-236834	20030408
	EP 1497273	A2	20050119	EP 2003-735343	20030408
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003009135	A	20050201	BR 2003-9135	20030408
	CN 1649857	A	20050803	CN 2003-809483	20030408
	JP 2005528381	T	20050922	JP 2003-582138	20030408
	US 2006063778	A1	20060323	US 2005-511065	20051003
PRAI	GB 2002-8176	A	20020409		
	WO 2003-EP3644	W	20030408		
OS	MARPAT 139:323538				
IT	612840-78-5P				
	RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of hydroxamic acid derivs. for use as pharmaceuticals)			
RN	612840-78-5 CAPLUS				
CN	1-Pyrrolidinebutanamide, α -ethyl-N-hydroxy- β -(4-methoxyphenyl)- γ -oxo-2-[(phenylamino)carbonyl]-, (α S, β S,2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 46 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:609509 CAPLUS
DN 139:149931
TI FAP-activated antitumor compounds
IN Peters, Stefan; Breitsfelder, Steffen; Park, John Edward; Garin-Chesa,
Pilar; Blech, Stefan Matthias; Lenter, Martin
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1333033	A1	20030806	EP 2002-2222	20020130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003211979	A1	20031113	US 2003-336378	20030103
	CA 2472296	A1	20030807	CA 2003-2472296	20030128
	WO 2003064454	A1	20030807	WO 2003-EP815	20030128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1472277	A1	20041103	EP 2003-734699	20030128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005523264	T	20050804	JP 2003-564074	20030128
PRAI	EP 2002-2222	A	20020130		
	US 2002-355102P	P	20020208		
	WO 2003-EP815	W	20030128		

OS MARPAT 139:149931

IT 573690-73-0P 573690-74-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(FAP-activated antitumor compds.)

RN 573690-73-0 CAPLUS


CN 5,12-Naphthacenedione, 10-[[3-[[1-[[4-(carboxymethyl)phenyl]acetyl]-L-
prolyl-L-alanylglycyl-L-prolyl]amino]-2,3,6-trideoxy- α -L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 573690-74-1 CAPLUS

CN L-Prolinamide, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-N-(4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 47 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:434528 CAPLUS
 DN 139:6763
 TI Preparation of pyrrolidinedicarboxamides and related compounds as
 inhibitors of factor Xa useful for thrombotic disorders
 IN Bigge, Christopher Franklin; Dudley, Danette Andrea; Edmunds, Jeremy John;
 Van Huis, Chad Alan; Casimiro-Garcia, Agustin; Filipski, Kevin James;
 Kohrt, Jeffrey Thomas
 PA Warner-Lambert Company L.L.C., USA
 SO PCT Int. Appl., 389 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045912	A1	20030605	WO 2002-IB4757	20021114
	WO 2003045912	A8	20031002		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003162787	A1	20030828	US 2002-278643	20021023
	US 7030141	B2	20060418		
	CA 2468715	A1	20030605	CA 2002-2468715	20021114
	AU 2002365313	A1	20030610	AU 2002-365313	20021114
	BR 2002014519	A	20041013	BR 2002-14519	20021114
	EP 1465864	A1	20041013	EP 2002-803885	20021114
	EP 1465864	B1	20060315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1582274	A	20050216	CN 2002-823837	20021114
	HU 200402529	A2	20050329	HU 2004-2529	20021114
	JP 2005515985	T	20050602	JP 2003-547364	20021114
	AT 320414	T	20060415	AT 2002-803885	20021114
	EP 1671949	A2	20060621	EP 2006-110738	20021114
	EP 1671949	A3	20060719		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	PT 1465864	T	20060630	PT 2002-803885	20021114
	ES 2259113	T3	20060916	ES 2002-2803885	20021114
	NZ 532384	A	20061027	NZ 2002-532384	20021114
	ZA 2004004085	A	20050905	ZA 2004-4085	20040525
	NO 2004002270	A	20040601	NO 2004-2270	20040601
	US 2005267118	A1	20051201	US 2004-17598	20041220
	US 2005250815	A1	20051110	US 2005-108582	20050418
	US 2006264626	A1	20061123	US 2006-461859	20060802
PRAI	US 2001-334168P	P	20011129		
	US 2002-384895P	P	20020531		
	US 2002-278643	A3	20021023		
	EP 2002-803885	A3	20021114		
	WO 2002-IB33416	A	20021114		
	WO 2002-IB4757	W	20021114		
	US 2004-17598	A3	20041220		
OS	MARPAT 139:6763				

IT 536746-37-9P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-p-tolylamide
 536746-38-0P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-methoxyphenyl)amide]
 536746-43-7P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(3-fluoro-4-methylphenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536746-90-4P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-p-tolylamide 536748-85-3P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-isopropylphenyl)amide] 536748-86-4P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-trifluoromethylphenyl)amide] 536748-88-6P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-ethylphenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-43-6P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-cyanophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-47-0P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-dimethylaminophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-51-6P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-p-tolylamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)
 RN 536746-37-9 CAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 536746-38-0 CAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 536746-43-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 536746-90-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/712,456-ALW



RN 536748-85-3 CAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 536748-86-4 CAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW




RN 536748-88-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 536749-43-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 536749-47-0 CAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 536749-51-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)- (9CI) (CA INDEX NAME)

10/712,456-ALW



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 48 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:396733 CAPLUS
DN 138:396226
TI Combinatorial library-based protein tyrosine phosphatase 1B (PTP1B)
inhibitor and ligand discovery
IN Zhang, Zhong-Yin; Lawrence, David S.
PA Albert Einstein College of Medicine of Yeshiva University, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003041729	A1	20030522	WO 2002-US30492	20020926
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461481	A1	20030522	CA 2002-2461481	20020926
	AU 2002363632	A1	20030526	AU 2002-363632	20020926
	EP 1435989	A1	20040714	EP 2002-803148	20020926
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005509008	T	20050407	JP 2003-543616	20020926
	US 2004191926	A1	20040930	US 2004-490836	20040325
PRAI	US 2001-325009P	P	20010926		
	WO 2002-US30492	W	20020926		

OS MARPAT 138:396226


IT 528550-30-3P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(combinatorial library-based protein tyrosine phosphatase 1B inhibitor and ligand discovery)

RN 528550-30-3 CAPLUS

CN L-Tyrosinamide, 1-[[4-(phosphonooxy)phenyl]acetyl]-L-prolyl-N-(2-mercaptoethyl)-, 24-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 49 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:376987 CAPLUS
DN 138:385215
TI Preparation of isotopically-coded affinity markers for mass spectrometric
analysis of proteins
IN Lerchen, Hans-Georg; Siegmund, Hans-Ulrich; Immler, Dorian; Schumacher,
Andreas; Auriel, Daniel
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040288	A2	20030515	WO 2002-EP12105	20021030
	WO 2003040288	A3	20031211		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10234415	A1	20030522	DE 2002-10234415	20020729
	CA 2466328	A1	20030515	CA 2002-2466328	20021030
	AU 2002340490	A1	20030519	AU 2002-340490	20021030
	EP 1446665	A2	20040818	EP 2002-774759	20021030
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	EP 1477493	A1	20041117	EP 2003-9894	20030515
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 2005049406	A1	20050303	US 2004-494999	20041029
	US 7132295	B2	20061107		
PRAI	DE 2001-10154745	A	20011109		
	DE 2002-10234415	A	20020729		
	WO 2002-EP12105	W	20021030		

OS MARPAT 138:385215

IT 525586-46-3P


RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(preparation of isotopically-coded affinity markers for mass spectrometric anal. of proteins)

RN 525586-46-3 CAPLUS


CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[[4-[[[(2S)-2-[[[2-[4-[[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]acetyl]-1-piperazinyl]-2-oxoethyl]amino]carbonyl]-1-pyrrolidinyl]thioxomethyl]amino]phenyl]methyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



10/712,456-ALW

L4 ANSWER 50 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:249856 CAPLUS
DN 140:104428
TI Identification of a Selectivity Determinant for Inhibition of Tumor
Necrosis Factor- α Converting Enzyme by Comparative Modeling
AU Wasserman, Zelda R.; Duan, James J.-W.; Voss, Matthew E.; Xue, Chu-Biao;
Cherney, Robert J.; Nelson, David J.; Hardman, Karl D.; Decicco, Carl P.
CS Structural Biology and Molecular Design Group, Bristol-Myers Squibb
Company, Wilmington, DE, 19880, USA
SO Chemistry & Biology (2003), 10(3), 215-223
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
IT 301162-35-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(identification of a selectivity determinant for inhibition of tumor
necrosis factor- α converting enzyme by comparative modeling)
RN 301162-35-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 51 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:117794 CAPLUS

DN 138:153537

TI Preparation of imidazole-containing heterobicyclic modulators of androgen receptor function

IN Sun, Chongqing; Robl, Jeffrey A.; Salvati, Mark E.; Wang, Tammy; Hamann, Lawrence; Augeri, David

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011824	A1	20030213	WO 2002-US24185	20020731
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002322794	A1	20030217	AU 2002-322794	20020731
	US 2003055094	A1	20030320	US 2002-209461	20020731
	US 6670386	B2	20031230		
	EP 1414795	A1	20040506	EP 2002-756813	20020731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2004092559	A1	20040513	US 2003-685020	20031014
	US 6992102	B2	20060131		
PRAI	US 2001-309059P	P	20010731		
	US 2002-209461	A3	20020731		
	WO 2002-US24185	W	20020731		
OS	MARPAT 138:153537				
IT	496840-99-4P, (2S)-1-[[[4-Nitro-1-naphthalenyl)amino]carbonyl]-2-pyrrolidinecarboxylic acid methyl ester 496841-10-2P, (2S,3R)-1-[(4-Cyanonaphthalen-1-yl)carbonyl]-3-hydroxypyrrolidine-2-carboxylic acid methyl ester				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of imidazole-containing heterobicyclic modulators of androgen receptor function)				
RN	496840-99-4 CAPLUS				
CN	L-Proline, 1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 496841-10-2 CAPLUS

CN L-Proline, 1-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 52 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:15497 CAPLUS

DN 138:78430

TI Pharmaceutical compositions containing heterocyclic compounds as $\alpha\beta 2$ integrin-mediated adhesion inhibitors for treatment of inflammatory diseases

IN Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 72 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003002834	A	20030108	JP 2002-117406	20020419
PRAI	JP 2001-121235	A	20010419		

OS MARPAT 138:78430

IT 336818-26-9P 336818-28-1P 336818-37-2P


336819-04-6P 481704-25-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as $\alpha\beta 2$ integrin-mediated adhesion inhibitors for treatment of inflammatory diseases)

RN 336818-26-9 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[4-(3,5-dichloro-4-methoxyphenyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336818-28-1 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[4-(3-carboxypropoxy)-3,5-dichlorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 336818-37-2 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 336819-04-6 CAPLUS


CN Proline, 1-[[[4-[bis[(phenylmethoxy)carbonyl]amino]-3,5-dichlorophenyl]amino]carbonyl]-2-[(4-cyanophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 481704-25-0 CAPLUS

CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




10/712,456-ALW

L4 ANSWER 53 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:927415 CAPLUS
DN 138:14080
TI Preparation of dihydrodiaryloxazepine derivatives for treatment of
functional digestive tract diseases
IN Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu, Munetaka; Takahashi,
Kazuyoshi; Hirasawa, Shigeo; Ezaki, Junko
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096891	A1	20021205	WO 2002-JP5193	20020529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002304079	A1	20021209	AU 2002-304079	20020529
	EP 1403258	A1	20040331	EP 2002-730742	20020529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004110742	A1	20040610	US 2003-724179	20031201
PRAI	JP 2001-161988	A	20010530		
	WO 2002-JP5193	W	20020529		
OS	MARPAT 138:14080				
IT	477779-14-9P 477779-15-0P 477779-16-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)				
RN	477779-14-9 CAPLUS				
CN	D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 477779-15-0 CAPLUS
CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 477779-16-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-6-chlorophenyl)methoxy]phenyl]-1-[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 54 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:834766 CAPLUS
DN 137:295248
TI Novel dipeptide and tripeptide mimic compounds for treating Parkinson's disease
IN Wang, Huei-Bo; Li, Jia-Shuai; Tsai, Ming-Jeng; Lu, Shiau-Hua; Hu, You-Pu
PA Taiwan
SO Taiwan., 34 pp.
CODEN: TWXXA5
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	TW 387896	B	20000421	TW 1996-85101959	19960216
PRAI	TW 1996-85101959		19960216		
OS	MARPAT 137:295248				
IT	171860-38-1P				


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipeptide and tripeptide derivs. of L-dopa for treating Parkinson's disease)

RN 171860-38-1 CAPLUS

CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1P 164353-71-3P 171860-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of dipeptide and tripeptide derivs. of L-dopa for treating Parkinson's disease)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171860-39-2 CAPLUS


CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 55 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:813789 CAPLUS
 DN 138:280734
 TI 3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists
 AU Singh, Juswinder; Van Vlijmen, Herman; Lee, Wen-Cherng; Liao, Yusheng; Lin, Ko-Chung; Ateeq, Humayun; Cuervo, Julio; Zimmerman, Craig; Hammond, Charles; Karpusas, Michael; Palmer, Rex; Chattopadhyay, Tapan; Adams, Steven P.
 CS Biogen Inc, Cambridge, MA, 02142, USA
 SO Journal of Computer-Aided Molecular Design (2002), 16(3), 201-211
 CODEN: JCADEQ; ISSN: 0920-654X
 PB Kluwer Academic Publishers
 DT Journal
 LA English
 IT 187737-36-6 251469-34-8 505082-18-8
 505082-20-2 505082-24-6
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists)
 RN 187737-36-6 CAPLUS
 CN L-Aspartic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251469-34-8 CAPLUS
 CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidiny]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505082-18-8 CAPLUS
 CN 5-Hexenoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidiny]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505082-20-2 CAPLUS

CN Butanoic acid, 3-[methyl[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505082-24-6 CAPLUS

CN β -Alanine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 56 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:732372 CAPLUS
 DN 138:39451
 TI A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives
 AU Poirier, Donald; Ciobanu, Liviu C.; Berube, Marie
 CS Centre Hospitalier Universitaire de Quebec (CHUQ), Pavillon CHUL, Oncology and Molecular Endocrinology Research Center, Medicinal Chemistry Division, Laval University, Quebec, QC, G1V 4G2, Can.
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(20), 2833-2838
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:39451
 IT 478415-01-9P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation) (preparation and steroid sulfatase activity of estradiol libraries)
 RN 478415-01-9 CAPLUS
 CN Sulfamic acid, (16 β ,17 β)-16-[3-[[[(2S)-1-[(4-aminophenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]propyl]-17-hydroxyestra-1,3,5(10)-trien-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 478415-31-5P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation) (preparation of estradiol libraries via solid-phase synthesis using multidetachable sulfamate linker)
 RN 478415-31-5 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[(4-aminophenyl)acetyl]-N-[3-[(16 β ,17 β)-3,17-dihydroxyestra-1,3,5(10)-trien-16-yl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 57 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:521702 CAPLUS
 DN 137:93763
 TI Preparation of chiral pyrrolidine derivatives as VLA-4 inhibitors
 IN Nakayama, Atsushi; Machinaga, Nobuo; Yoneda, Yoshiyuki; Sugimoto, Yuichi;
 Chiba, Jun; Watanabe, Toshiyuki; Iimura, Shin
 PA Daiichi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 737 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053534	A1	20020711	WO 2001-JP11641	20011228
	WO 2002053534	A8	20020919		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CN 1483024	A	20011228	CN 2001-821484	20011228
	CA 2430978	A1	20020711	CA 2001-2430978	20011228
	AU 2002219555	A1	20020716	AU 2002-219555	20011228
	EP 1346982	A1	20030924	EP 2001-272548	20011228
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001016608	A	20040629	BR 2001-16608	20011228
	ZA 2003004059	A	20040706	ZA 2003-4059	20011228
	CN 1699363	A	20051123	CN 2005-10073706	20011228
	RU 2290403	C2	20061227	RU 2003-123115	20011228
	IN 2003DN00952	A	20070316	IN 2003-DN952	20030620
	NO 2003002994	A	20030827	NO 2003-2994	20030627
	US 2004110945	A1	20040610	US 2003-451159	20030630
	US 7157487	B2	20070102		
PRAI	JP 2000-402890	A	20001228		
	JP 2001-149923	A	20010518		
	CN 2001-821484	A3	20011228		
	WO 2001-JP11641	W	20011228		
OS	MARPAT 137:93763				
IT	441712-82-9P 441712-83-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of chiral pyrrolidine derivs. as VLA-4 inhibitors)				
RN	441712-82-9 CAPLUS				
CN	Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[5-chloro-2-fluoro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 441712-83-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[3-chloro-4-[(1-isoquinolin-1-ylcarbonyl)amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 441716-31-0P 441716-33-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of chiral pyrrolidine derivs. as VLA-4 inhibitors)

RN 441716-31-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[5-chloro-2-fluoro-4-[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 441716-33-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[3-chloro-4-[(1-isoquinolinylcarbonyl)amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 143 THERE ARE 143 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 58 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:503388 CAPLUS
 DN 137:79229
 TI Preparation of cytostatic glycoconjugates having specifically cleavable
 peptidic linking units
 IN Lerchen, Hans-Georg; Baumgarten, Joerg; Lockhoff, Oswald
 PA Bayer Aktiengesellschaft, Germany
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1219634	A1	20020703	EP 2000-128402	20001227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2002051862	A2	20020704	WO 2001-EP14868	20011217
	WO 2002051862	A3	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002240841	A1	20020708	AU 2002-240841	20011217
	US 2002173452	A1	20021121	US 2001-26237	20011221
PRAI	EP 2000-128402	A	20001227		
	WO 2001-EP14868	W	20011217		
OS	MARPAT 137:79229				
IT	439911-62-3P 439911-64-5P 439911-66-7P 439911-68-9P 439911-69-0P 439911-70-3P 439911-71-4P 439911-72-5P 439911-73-6P 439911-74-7P 439911-75-8P 439911-76-9P 439911-77-0P 439911-78-1P 439911-79-2P 439911-80-5P 439911-81-6P 439911-82-7P 439911-83-8P 439911-84-9P 439911-85-0P 439911-86-1P 439911-87-2P 439911-88-3P 439911-89-4P 439911-90-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of cytostatic glycoconjugates having specifically cleavable peptidic linking units)				
RN	439911-62-3 CAPLUS				
CN	L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry.




RN 439911-64-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-66-7 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-68-9 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl- β -L-galactopyranosyl)oxy]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl



RN 439911-69-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-70-3 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN. 439911-71-4 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-α-aspartyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-72-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-S-methyl-L-cysteiny-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-73-6 CAPLUS



CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439911-75-8 CAPLUS
 CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439911-76-9 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-D-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-77-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-D-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl



RN 439911-78-1 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-alanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-79-2 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-valyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-80-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl- β -L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-81-6 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-seryl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-82-7 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-isoleucyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-83-8 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-α-glutamyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-84-9 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucylglycyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439911-85-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-prolyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-86-1 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-alanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-87-2 CAPLUS

CN L-Valine, 1-[[[4-[[3-O-(carboxymethyl)-6-deoxy-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-88-3 CAPLUS

CN L-Valine, 1-[[[4-(β-D-galactopyranosyloxy)phenyl]amino]thioxomethyl]-
L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-89-4 CAPLUS

CN L-Valine, 1-[[[4-[[6-deoxy-3-O-(2-hydroxyethyl)-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-90-7 CAPLUS

CN L-Valine, 1-[[[4-[[3-O-(2-amino-2-oxoethyl)-6-deoxy-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 439911-98-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation of cytostatic glycoconjugates having specifically cleavable peptidic linking units)

RN 439911-98-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 11. THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 59 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:503334 CAPLUS
DN 137:63479
TI Preparation of conjugates of integrin receptor antagonists and a
cytostatic agent having specifically cleavable linking units
IN Lerchen, Hans-Georg; Baumgarten, Joerg; Lockhoff, Oswald; Albers, Markus;
Schoop, Andreas
PA Bayer Aktiengesellschaft, Germany
SO Eur. Pat. Appl., 127 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1219305	A1	20020703	EP 2000-128401	20001227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2433116	A1	20020704	CA 2001-2433116	20011218
	WO 2002051444	A1	20020704	WO 2001-EP14965	20011218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002235789	A1	20020708	AU 2002-235789	20011218
	EP 1347783	A1	20031001	EP 2001-985899	20011218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004519449	T	20040702	JP 2002-552585	20011218
	US 2002183256	A1	20021205	US 2001-26408	20011221
PRAI	EP 2000-128401	A	20001227		
	WO 2001-EP14965	W	20011218		

OS MARPAT 137:63479

IT 439864-66-1P 439864-67-2P 439864-68-3P
439864-71-8P 439864-73-0P 439864-74-1P
439864-75-2P 439864-76-3P 439864-77-4P
439864-78-5P 439864-79-6P 439864-80-9P
439864-84-3P 439864-85-4P 439864-86-5P
439864-88-7P 439864-89-8P 439864-90-1P
439864-93-4P 439864-94-5P 439864-95-6P
439864-96-7P 439864-97-8P 439864-98-9P
439864-99-0P 439865-00-6P 439865-01-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of conjugates of integrin receptor antagonists and a cytostatic
agent having specifically cleavable linking units)


RN 439864-66-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phe
nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-
3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-
b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C




10/712,456-ALW


CN L-Valine, 1-[[[4-[[[(1R)-2-carboxy-1-[3-[[[3-[[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-68-3 CAPLUS

CN L-Valine, 1-[[[4-[[[(1S)-2-carboxy-1-[3-[[[3-
 [(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]car-
 bonyl]amino]phenyl]amino]thiomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-
 histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-
 pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.








RN 439864-71-8 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyran-3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 439864-73-0 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-74-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-,
6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-75-2 CAPLUS

CN L-Valine, 1-[[[4-[[[(1R)-2-carboxy-1-[3-[[[3-
 [(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]car
 bonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-
 asparaginy]-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-
 pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 439864-76-3 CAPLUS


CN L-Valine, 1-[[[4-[[[(1S)-2-carboxy-1-[3-[[[3-
[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] car
bonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-
asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-
pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-77-4 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-78-5 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-S-methyl-L-cysteiny-,
 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439864-79-6 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino]phe


nyl[sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-
3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-
b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-80-9 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439864-84-3 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-S-methyl-L-cysteinyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




10/712,456-ALW

RN 439864-85-4 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-lysyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-86-5 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-norvalyl-L-asparaginyl-,
6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439864-88-7 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolylglycylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




10/712,456-ALW

RN 439864-89-8 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-histidylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A'



PAGE 1-B








RN 439864-90-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-93-4 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439864-94-5 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome

10/712,456-ALW


thyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-95-6 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-valyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 439864-96-7 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-,
 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-seryl-, 6-[(4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-98-9 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-isoleucyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-99-0 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L- α -glutamyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439865-00-6 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phe


nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucylglycyl-, 6-[(4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439865-01-7 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-prolyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 60 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:487548 CAPLUS
DN 137:63475
TI Preparation of proline benzylamide derivatives as thrombin inhibitors
IN Selnick, Harold G.; Barrow, James C.; Nantermet, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Sanderson, Philip E.; Rittle, Kenneth E.; Morrisette, Matthew M.; Wiscount, Catherine M.; Tran, Lekhanh O.; Lyle, Terry A.; Staas, Donnette D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050056	A1	20020627	WO 2001-US48321	20011214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431588	A1	20020627	CA 2001-2431588	20011214
	AU 2002030836	A5	20020701	AU 2002-30836	20011214
	JP 2004516286	T	20040603	JP 2002-551552	20011214
PRAI	US 2000-256304P	P	20001218		
	US 2001-323184P	P	20010918		
	WO 2001-US48321	W	20011214		
OS	MARPAT 137:63475				
IT	439115-78-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of proline benzylamide derivs. as thrombin inhibitors)				
RN	439115-78-3 CAPLUS				
CN	Benzoic acid, 4-[2-[(2S)-2-[[[2-(aminomethyl)-5-chlorophenyl]methyl]amino]carbonyl]-1-pyrrolidinyl]-1-hydroxy-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)				
CM	1				
CRN	439115-77-2				
CMF	C28 H28 Cl N3 O5				

Absolute stereochemistry.




10/712,456-ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 439117-79-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of proline benzylamide derivs. as thrombin inhibitors)

RN 439117-79-0 CAPLUS

CN Benzoic acid, 4-[2-[(2S)-2-[[[5-chloro-2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]methyl]amino]carbonyl]-1-pyrrolidinyl]-1-hydroxy-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 61 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:408632 CAPLUS

DN 137:5933

TI Preparation of substituted 2-phenyl-1-cyclohexanecarboxamides and related compounds their use in the treatment of cardiovascular, urogenital tract or cerebrovascular diseases.

IN Roehrig, Susanne; Stolle, Andreas; Castro-Palomino, Julio; Hanning, Helmut; Handke, Gabriele; Daviu-Folguera, Noemi; Paulsen, Holger; Pernestorfer, Josef; Mueller, Stephan-Nicholas; Steinhagen, Henning; Thielemann, Wolfgang; Bischoff, Erwin; Ebbinghaus-Kintscher, Ulrich; Ellinghaus, Peter; Huetter, Joachim; Krahn, Thomas; Wunder, Frank; Lustig, Klemens; Schuhmacher, Joachim; Suessmeier, Frank

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042257	A1	20020530	WO 2001-EP13062	20011112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10058461	A1	20020919	DE 2000-10058461	20001124
	CA 2429328	A1	20020530	CA 2001-2429328	20011112
	AU 200224839	A	20020603	AU 2002-24839	20011112
	EP 1339670	A1	20030903	EP 2001-994647	20011112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015611	A	20040106	BR 2001-15611	20011112
	JP 2004522716	T	20040729	JP 2002-544393	20011112
	IN 2003MN00496	A	20060707	IN 2003-MN496	20030509
	US 2004235830	A1	20041125	US 2004-432573	20040422
PRAI	DE 2000-10058461	A	20001124		
	WO 2001-EP13062	W	20011112		

OS MARPAT 137:5933

IT 432044-76-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 2-phenyl-1-cyclohexanecarboxamide derivs. for treatment of cardiovascular, urogenital tract or cerebrovascular diseases)

RN 432044-76-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-[4-(dimethylamino)phenyl]-N1-[[4-[(1R,2R)-2-[[[(1R)-2-hydroxy-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/712,456-ALW


L4 ANSWER 62 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:368495 CAPLUS
DN 136:370002
TI FAP α -activated antitumor compounds
IN Peters, Stefan; Mack, Juergen; Leipert, Dietmar; Eickmeier, Christian;
Park, John-Edward; Lenter, Martin; Garin-Chesa, Pilar
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038590	A1	20020516	WO 2001-EP12812	20011106
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	AU 2002020684	A5	20020521	AU 2002-20684	20011106
	US 2003232742	A1	20031218	US 2001-36224	20011109
PRAI	GB 2000-27552	A	20001110		
	US 2001-262323P	P	20010117		
	WO 2001-EP12812	W	20011106		
OS	MARPAT 136:370002				
IT	423757-45-3P 423757-47-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(FAP α -activated antitumor compds.)				
RN	423757-45-3 CAPLUS				
CN	L-Prolinamide, 1-[[4-(aminomethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-N-(4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A






RN 423757-47-5 CAPLUS

CN L-Prolinamide, 1-[(4-hydroxyphenyl)acetyl]-L-prolyl-L-alanylglycyl-N-(4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 63 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:332684 CAPLUS
DN 136:340999
TI Preparation of amino acid derivatives as rotamase enzyme activity
inhibitors
IN Steiner, Joseph P.; Hamilton, Gregory S.
PA Gpi Nil Holdings, Inc., USA
SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 359,351.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002052410	A1	20020502	US 2001-805249	20010314
	US 7056935	B2	20060606		
	US 5614547	A	19970325	US 1995-479436	19950607
	US 2002013344	A1	20020131	US 1995-551026	19951031
	RU 2269514	C2	20060210	RU 2000-115383	19960605
	US 6509477	B1	20030121	US 1999-359351	19990721
PRAI	US 1995-479436	A1	19950607		
	US 1995-551026	A2	19951031		
	US 1996-693003	B1	19960806		
	US 1999-359351	A2	19990721		
	RU 1997-111860	A3	19960605		
OS	MARPAT 136:340999				
IT	391669-36-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of glyoxalylprolinate and -pipecolate derivs. as rotamase inhibitors)				
RN	391669-36-6 CAPLUS				
CN	L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 232 THERE ARE 232 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 64 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:325632 CAPLUS

DN 137:125380

TI Synthesis of nucleopeptides by employing an enzyme-labile urethane protecting group

AU Jeyaraj, Duraiswamy A.; Prinz, Heino; Waldmann, Herbert

CS Abteilung Chemische Biologie, Max-Planck-Institut für molekulare Physiologie, Dortmund, 44227, Germany

SO Chemistry--A European Journal (2002), 8(8), 1879-1887

CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 137:125380

IT 444343-91-3P

RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)

RN 444343-91-3 CAPLUS



CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-valyl-O-[3'-O-acetyl-2'-deoxy-P-2-propenyl-N-[(2-propenyloxy)carbonyl]-5'-cytidyl]-L-seryl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 444343-87-7P 444343-90-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)

RN 444343-87-7 CAPLUS

CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-seryl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 444343-90-2 CAPLUS

CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-O-[3'-O-acetyl-2'-deoxy-P-2-propenyl-N-[(2-propenyloxy)carbonyl]-5'-cytidyl]-L-seryl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT 444343-74-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)

RN 444343-74-2 CAPLUS

CN L-Proline, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/712,456-ALW

L4 ANSWER 65 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:312019 CAPLUS
DN 136:325828
TI Preparation of dipeptide derivatives as cell adhesion inhibitors
IN Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng; Castro, Alfredo C.;
Zimmerman, Craig N.; Hammond, Charles E.; Liao, Yu-Sheng; Cuervo, Julio
Hernan; Singh, Juswinder
PA Biogen, Inc., USA
SO U.S., 50 pp., Cont.-in-part of U.S. 6,306,840.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6376538	B1	20020423	US 1997-875321	19970919
	US 6306840	B1	20011023	US 1995-376372	19950123
	WO 9622966	A1	19960801	WO 1996-US1349	19960118
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
EP	1142867	A2	20011010	EP 2001-107877	19960118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	AU 766538	B2	20031016	AU 2000-62432	20001002
	US 2003018016	A1	20030123	US 2001-2341	20011023
	US 6630512	B2	20031007		
	US 7001921	B1	20060221	US 2003-625626	20030724
	US 2006166866	A1	20060727	US 2003-679478	20031007
PRAI	US 1995-376372	A2	19950123		
	WO 1996-US1349	W	19960118		
	AU 1996-49115	A3	19960118		
	EP 1996-905316	A3	19960118		
	US 1997-875321	A3	19970919		
	US 2001-935461	A1	20010822		
	US 2001-2341	A1	20011023		
OS	MARPAT 136:325828				
IT	181519-89-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of β -amino acid dipeptide derivs. as cell adhesion inhibitors)				
RN	181519-89-1 CAPLUS				
CN	1,3-Benzodioxole-5-propanoic acid, β -[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (β S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 66 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:276523 CAPLUS
DN 136:295090
TI Preparation of amino acid derivatives for use as thrombin inhibitors
IN Gustafsson, David; Nystrom, Jan-erik
PA Astra AB, Swed.
SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of Appl. No. PCT/SE96/00878.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002042396	A1	20020411	US 2001-995564	20011129
	US 6617320	B2	20030909		
	ZA 9605344	A	19970106	ZA 1996-5344	19960624
	TW 585853	B	20040501	TW 1996-85107577	19960624
	WO 9702284	A1	19970123	WO 1996-SE878	19960702
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	ES 2197240	T3	20040101	ES 1996-922355	19960702
	RU 2262508	C2	20051020	RU 2000-128495	19960702
	US 6337343	B1	20020108	US 2000-537344	20000329
	US 2004087647	A1	20040506	US 2003-606349	20030626
	US 6921758	B2	20050726		
PRAI	SE 1995-2487	A	19950706		
	SE 1995-2504	A	19950707		
	SE 1995-2505	A	19950707		
	SE 1995-3923	A	19951107		
	SE 1995-4349	A	19951205		
	GB 1995-26411	A	19951222		
	WO 1996-SE878	A2	19960702		
	RU 1998-102188	A	19960702		
	US 1996-687466	A3	19960807		
	US 2000-537344	A1	20000329		
	US 2001-995564	A1	20011129		

OS MARPAT 136:295090

IT 187751-57-1P 407626-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid derivative as thrombin inhibitors)

RN 187751-57-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 407626-97-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 187752-83-6P 187753-36-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid derivative as thrombin inhibitors)

RN 187752-83-6 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187753-36-2 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


CCOC(=O)NC(=N)c1ccc(cc1)NC(=O)N2CCSC2C(=O)C(O)c3ccc(Cl)c(O)c3

10/712,456-ALW

L4 ANSWER 67 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:276521 CAPLUS
DN 136:310178
TI Preparation of amino acid derivatives as rotamase enzyme activity
inhibitors
IN Steiner, Joseph P.; Hamilton, Gregory S.
PA USA
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 551,026.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002042377	A1	20020411	US 2001-873298	20010605
	US 5614547	A	19970325	US 1995-479436	19950607
	US 2002013344	A1	20020131	US 1995-551026	19951031
	RU 2269514	C2	20060210	RU 2000-115383	19960605
	US 6509477	B1	20030121	US 1999-359351	19990721
PRAI	US 1995-479436	A1	19950607		
	US 1995-551026	A2	19951031		
	US 1996-693003	B1	19960806		
	US 1999-359351	A2	19990721		
	RU 1997-111860	A3	19960605		
OS	MARPAT 136:310178				
IT	391669-36-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of glyoxalylprolinate and -pipecolate derivs. as rotamase inhibitors)				
RN	391669-36-6 CAPLUS				
CN	L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




L4 ANSWER 68 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:836875 CAPLUS
 DN 136:118718
 TI 2-Aryl-2,2-difluoroacetamide FKBP12 Ligands: Synthesis and X-ray
 Structural Studies
 AU Dubowchik, Gene M.; Vrudhula, Vivekananda M.; Dasgupta, Bireshwar; Ditta,
 Jonathan; Chen, Ti; Sheriff, Steven; Sipman, Karin; Witmer, Mark; Tredup,
 Jeffrey; Vyas, Dolatrai M.; Verdoorn, Todd A.; Bollini, Sagarika;
 Vinitsky, Alexander
 CS Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492-7660, USA
 SO Organic Letters (2001), 3(25), 3987-3990
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:118718
 IT 251909-01-0P 251909-02-1P 391669-22-0P
 391669-24-2P 391669-26-4P 391669-28-6P
 391669-31-1P 391669-33-3P 391669-35-5P
 391669-36-6P 391669-37-7P 391669-38-8P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (preparation, crystal structure and rotamase inhibition activity of
 (aryl)difluoroacetamides as ligands of FKBP12)
 RN 251909-01-0 CAPLUS
 CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251909-02-1 CAPLUS
 CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
 3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-22-0 CAPLUS
 CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,

10/712,456-ALW

1-phenyl-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-24-2 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(phenylmethyl)-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-26-4 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(2-phenylethyl)-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-28-6 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
4-phenyl-1-[2-(3-pyridinyl)ethyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 391669-31-1 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(2-phenylethyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-33-3 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-(3-pyridinyl)propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 391669-36-6 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-37-7 CAPLUS

CN L-Proline, 1-[(3,4,5-trimethoxyphenyl)acetyl]-, 3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-38-8 CAPLUS

CN L-Proline, 1-[(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 69 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:713304 CAPLUS

DN 135:257472

TI Preparation of peptidomimetic ligands for cellular receptors and ion channels

IN Persons, Paul E.; Holland, Joanne M.; Hauske, James R.

PA Sepracor, Inc., USA

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001070684	A2	20010927	WO 2001-US6173	20010227
	WO 2001070684	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2005080271	A1	20050414	US 2003-203279	20030304
	US 7115664	B2	20061003		
	US 2007093522	A1	20070426	US 2006-512056	20060829
PRAI	US 2000-190133P	P	20000316		
	WO 2001-US6173	W	20010227		
	US 2003-203279	A1	20030304		

OS MARPAT 135:257472


IT 361347-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidomimetic ligands for cellular receptors and ion channels)

RN 361347-63-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-(dimethylamino)ethyl]-N2-(phenylmethyl)-N1-[4-(trifluoromethoxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 70 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:615529 CAPLUS
DN 135:180704
TI Synthesis alkylamidoheteroacylamide derivatives as Bax-a inhibitors for
the treatment of apoptosis
IN Halazy, Serge; Schwarz, Matthias; Antonsson, Bruno; Bombrun, Agnes;
Martinou, Jean-claude; Church, Dennis
PA Applied Research Systems Ars Holding N.V., Neth. Antilles
SO Eur. Pat. Appl., 57 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1125925	A1	20010822	EP 2000-810128	20000215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2397651	A1	20010823	CA 2001-2397651	20010213
	WO 2001060798	A1	20010823	WO 2001-EP1579	20010213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1263730	A1	20021211	EP 2001-927666	20010213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003523332	T	20030805	JP 2001-560184	20010213
	AU 784086	B2	20060202	AU 2001-54640	20010213
	US 2003216427	A1	20031120	US 2002-182745	20021226
	US 6770656	B2	20040803		
PRAI	EP 2000-810128	A	20000215		
	WO 2001-EP1579	W	20010213		
OS	MARPAT 135:180704				
IT	355139-04-7P 355139-29-6P 355139-57-0P 355139-83-2P 355140-04-4P 355140-21-5P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Synthesis alkylamidoheteroacylamide derivs. as Bax-a inhibitors for the treatment of apoptosis)				
RN	355139-04-7 CAPLUS				
CN	2-Pyrrolidinecarboxamide, N-(6-aminohexyl)-1-[[4- (phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)				

10/712,456-ALW




RN 355139-29-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(5-aminopentyl)-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 355139-57-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(7-aminoheptyl)-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 355139-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-1-[[4-


10/712,456-ALW

(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 355140-04-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-methyl-N-[2-[2-(methylamino)ethoxy]ethyl]-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 355140-21-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-methyl-N-[6-(methylamino)hexyl]-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



10/712,456-ALW

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 71 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:564780 CAPLUS
DN 135:147400
TI Preparation of hydroxyproline derivatives as anthelmintics and nematocides
IN Chalquest, Richard R.
PA Akkadix Corporation, USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001054498	A1	20010802	WO 2001-US2871	20010129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001049373	A1	20011206	US 2001-770121	20010126
	US 2002002171	A1	20020103	US 2001-771067	20010126
	AU 2001033089	A5	20010807	AU 2001-33089	20010129
	US 2002016330	A1	20020207	US 2001-772262	20010129
PRAI	US 2000-179005P	P	20000128		
	WO 2001-US2871	W	20010129		

OS MARPAT 135:147400


IT 352236-90-9P 352236-91-0P 352237-47-9P
352237-75-3P 352238-03-0P

RL: AGR (Agricultural use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as anthelmintics and nematocide)

RN 352236-90-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(cyclohexylmethoxy)-1-[(3,4-dimethoxyphenyl)acetyl]-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-, (2S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352236-91-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-4-(cyclohexylmethoxy)-1-[(3,4-dimethoxyphenyl)acetyl]-, (2S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 352237-47-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-[[4-(1,1-dimethylethyl)phenyl]methoxy]-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352237-75-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352238-03-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-[(3-methoxyphenyl)methoxy]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 72 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:489369 CAPLUS

DN 135:92538

TI Preparation of N-arylcyanomethylprolineamides and analogs as cathepsin K inhibitors

IN Gabriel, Tobias; Pech, Michael; Wallbaum, Sabine

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047886	A1	20010705	WO 2000-EP12646	20001213
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2395179	A1	20010705	CA 2000-2395179	20001213
	EP 1244621	A1	20021002	EP 2000-990733	20001213
	EP 1244621	B1	20060913		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016699	A	20021105	BR 2000-16699	20001213
	JP 2003519125	T	20030617	JP 2001-549358	20001213
	JP 3808772	B2	20060816		
	AU 783145	B2	20050929	AU 2001-30106	20001213
	AT 339404	T	20061015	AT 2000-990733	20001213
	US 2001008901	A1	20010719	US 2000-745675	20001221
	US 6531612	B2	20030311		
	ZA 2002004397	A	20030901	ZA 2002-4397	20020531
PRAI	EP 1999-125857	A	19991224		
	WO 2000-EP12646	W	20001213		

OS MARPAT 135:92538

IT 348143-28-2P 348143-35-1P 348143-46-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylcyanomethylprolineamides and analogs as cathepsin K inhibitors)

RN 348143-28-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3-chlorophenyl)cyanomethyl]-1-[(3,4,5-trimethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 348143-35-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylcyanomethyl)-1-[(4-ethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348143-46-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[cyano(3,4-dimethoxyphenyl)methyl]-1-[(4-ethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 73 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:319894 CAPLUS
DN 134:326532
TI Preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and
analogues as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion
IN Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall;
Smith, Nicholas; Griffith, Ronald C.
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030781	A2	20010503	WO 2000-US29273	20001019
	WO 2001030781	A3	20011122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2388639	A1	20010503	CA 2000-2388639	20001019
	BR 2000014651	A	20020618	BR 2000-14651	20001019
	JP 2003512468	T	20030402	JP 2001-533134	20001019
	EP 1307455	A2	20030507	EP 2000-976625	20001019
	EP 1307455	B1	20050406		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NZ 518369	A	20030926	NZ 2000-518369	20001019
	AU 778757	B2	20041216	AU 2001-14370	20001019
	AT 292634	T	20050415	AT 2000-976625	20001019
	PT 1307455	T	20050630	PT 2000-976625	20001019
	CN 1651431	A	20050810	CN 2004-10096397	20001019
	ES 2240201	T3	20051016	ES 2000-976625	20001019
	TW 250984	B	20060311	TW 2001-90108415	20010409
	US 6897225	B1	20050524	US 2002-111110	20021016
	HK 1053473	A1	20050909	HK 2003-105854	20030814
	US 2005148602	A1	20050707	US 2005-70335	20050303
PRAI	US 1999-160629P	P	19991020		
	US 2000-209847P	P	20000607		
	WO 2000-US29273	W	20001019		
	US 2002-111110	A3	20021016		
OS	MARPAT 134:326532				
IT	336818-26-9P 336818-28-1P 336818-37-2P 336819-04-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane- 2,4-diones and analogues as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]prolin e derivs.)				
RN	336818-26-9 CAPLUS				
CN	Proline, 2-[(4-bromophenyl)methyl]-1-[[[(3,5-dichloro-4- methoxyphenyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)				

10/712,456-ALW




RN 336818-28-1 CAPLUS

CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[4-(3-carboxypropoxy)-3,5-dichlorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 336818-37-2 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



10/712,456-ALW

RN 336819-04-6 CAPLUS

CN Proline, 1-[[[4-[bis[(phenylmethoxy)carbonyl]amino]-3,5-dichlorophenyl]amino]carbonyl]-2-[(4-cyanophenyl)methyl]-, methyl ester
(9CI) (CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 74 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:228855 CAPLUS

DN 134:252658

TI Preparation of tyrosine derivatives as inhibitors of $\alpha 4$ containing integrin-mediated binding to ligands VCAM-1 and MAdCAM.

IN Jackson, David Y.; Sailes, Frederick C.; Sutherlin, Daniel P.

PA Genentech, Inc., USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021584	A1	20010329	WO 2000-US26326	20000925
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2385882	A1	20010329	CA 2000-2385882	20000925
	EP 1214292	A1	20020619	EP 2000-965417	20000925
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 6469047	B1	20021022	US 2000-669779	20000925
	JP 2003509488	T	20030311	JP 2001-524964	20000925
	AU 780385	B2	20050317	AU 2000-76138	20000925
	US 2004110753	A1	20040610	US 2002-198328	20020716
	US 2004158076	A1	20040812	US 2004-772678	20040204
PRAI	US 1999-156062P	P	19990924		
	US 2000-669779	A1	20000925		
	WO 2000-US26326	W	20000925		
	US 2002-198328	A1	20020716		

OS MARPAT 134:252658


IT 331471-51-3P 331471-52-4P 331471-53-5P
331471-54-6P 331471-57-9P 331471-73-9P
331471-89-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tyrosine derivs. as inhibitors of $\alpha 4$ containing integrin-mediated binding to ligands VCAM-1 and MAdCAM.)

RN 331471-51-3 CAPLUS

CN L-Tyrosine, 1-[(4-aminophenyl)acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331471-52-4 CAPLUS

CN L-Tyrosine, 1-[[4-(acetilamino)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 331471-53-5 CAPLUS

CN L-Tyrosine, (2S)-2-(4-hydroxyphenyl)glycyl-4-aminobenzeneacetyl-L-prolyl-,
4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 331471-54-6 CAPLUS

CN L-Tyrosine, (2S)-N-acetyl-2-(4-hydroxyphenyl)glycyl-4-aminobenzeneacetyl-L-prolyl-, 4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331471-57-9 CAPLUS


CN L-Tyrosine, 1-[[4-[2-[(2-carboxyethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 331471-73-9 CAPLUS

CN L-Tyrosine, 1-[[4-[2-[(carboxymethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-propyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 331471-89-7 CAPLUS

CN L-Tyrosine, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-propyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 75 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:185738 CAPLUS
DN 134:222732
TI Novel processes for preparing oxazepine derivatives via cyclization of
2-(2-bromobenzyloxy)aniline derivative
IN Sekiyama, Takaaki; Matsuzawa, Toshihiro; Yamamoto, Takashi; Yatagai,
Masanobu; Ezaki, Junko
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017980	A1	20010315	WO 2000-JP5967	20000901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000068689	A	20010410	AU 2000-68689	20000901
	EP 1219611	A1	20020703	EP 2000-956884	20000901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2002133004	A1	20020919	US 2002-86781	20020304
PRAI	JP 1999-250298	A	19990903		
	WO 2000-JP5967	W	20000901		
OS	CASREACT 134:222732; MARPAT 134:222732				
IT	329329-16-0P 329329-17-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)				
RN	329329-16-0 CAPLUS				
CN	D-Proline, 1-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 329329-17-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 76 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:137020 CAPLUS
 DN 134:193741
 TI Preparation of peptide derivatives as cell adhesion inhibitors
 IN Lee, Wen-Cherng; Scott, Daniel; Cornebise, Mark; Petter, Russell
 PA Biogen, Inc., USA
 SO PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012186	A1	20010222	WO 2000-US22285	20000814
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2380817	A1	20010222	CA 2000-2380817	20000814
	BR 2000013248	A	20020723	BR 2000-13248	20000814
	HU 200202469	A2	20021128	HU 2002-2469	20000814
	EP 1265606	A1	20021218	EP 2000-959232	20000814
	EP 1265606	B1	20061025		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506491	T	20030218	JP 2001-516532	20000814
	EE 200200070	A	20030415	EE 2002-70	20000814
	US 6630503	B1	20031007	US 2000-638652	20000814
	NZ 517011	A	20040227	NZ 2000-517011	20000814
	AU 780610	B2	20050407	AU 2000-70586	20000814
	AT 343383	T	20061115	AT 2000-959232	20000814
	EP 1741428	A2	20070110	EP 2006-21333	20000814
	EP 1741428	A3	20070509		
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	IN 2002DN00160	A	20061229	IN 2002-DN160	20020207
	ZA 2002001158	A	20030512	ZA 2002-1158	20020211
	NO 2002000725	A	20020408	NO 2002-725	20020213
	BG 106510	A	20021031	BG 2002-106510	20020311
	HK 1051500	A1	20070202	HK 2003-103786	20030527
	US 2004132809	A1	20040708	US 2003-677756	20031003
	US 7034043	B2	20060425		
	US 2006166961	A1	20060727	US 2006-362043	20060227
PRAI	US 1999-148845P	P	19990813		
	EP 2000-959232	A3	20000814		
	US 2000-638652	A1	20000814		
	WO 2000-US22285	W	20000814		
	US 2003-677756	A1	20031003		
OS	MARPAT 134:193741				
IT	327612-34-0P 327612-97-5P 327613-59-2P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of peptide derivs. as cell adhesion inhibitors)				
RN	327612-34-0 CAPLUS				
CN	L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-				

10/712,456-ALW


pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 327612-97-5 CAPLUS



CN L-Lysine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-N6-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327613-59-2 CAPLUS
 CN Butanoic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-N4-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl]-2,4-diamino-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 77 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:31525 CAPLUS
 DN 134:101193
 TI Preparation of peptide boronic acid inhibitors of hepatitis C virus
 protease
 IN Kettner, Charles A.; Jagannathan, Sharada; Forsyth, Timothy Patrick
 PA Du Pont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 258 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002424	A2	20010111	WO 2000-US18655	20000707
	WO 2001002424	A3	20010719		
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2376965	A1	20010111	CA 2000-2376965	20000707
	AU 2000057888	A	20010122	AU 2000-57888	20000707
	EP 1196436	A2	20020417	EP 2000-943413	20000707
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-142561P	P	19990707		
	WO 2000-US18655	W	20000707		
OS	MARPAT 134:101193				
IT	319005-19-1P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of peptide boronic acid inhibitors of hepatitis C virus protease)				
RN	319005-19-1 CAPLUS				
CN	2-Pyrrolidinecarboxamide, N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-butenyl]-1-[(4-methylphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 78 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:12266 CAPLUS

DN 134:86149

TI Preparation of diphenyl ureas as VLA-4 inhibitors

IN Baldwin, John J.; McDonald, Edward; Moriarty, Kevin Joseph; Sarko, Christopher Ronald; Machinaga, Nobuo; Nakayama, Atsushi; Chiba, Jun; Iimura, Shin; Yoneda, Yoshiyuki

PA Daiichi Pharmaceutical Co., Ltd., Japan; Pharmacopeia, Inc.

SO PCT Int. Appl., 511 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000206	A1	20010104	WO 2000-US18079	20000630
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2369308	A1	20010104	CA 2000-2369308	20000630
	EP 1189612	A1	20020327	EP 2000-945035	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000012068	A	20020514	BR 2000-12068	20000630
	JP 2003503350	T	20030128	JP 2001-505915	20000630
	AU 781438	B2	20050526	AU 2000-59031	20000630
	RU 2264386	C2	20051120	RU 2001-135856	20000630
	ZA 2001009203	A	20030207	ZA 2001-9203	20011107
	NO 2001006319	A	20020228	NO 2001-6319	20011221
	US 2003078249	A1	20030424	US 2001-34585	20011228
	US 6756378	B2	20040629		
	US 2004229858	A1	20041118	US 2004-787905	20040226
	US 7179819	B2	20070220		
	US 2007054909	A1	20070308	US 2006-594432	20061108
PRAI	US 1999-141601P	P	19990630		
	US 1999-141602P	P	19990630		
	US 1999-141692P	P	19990630		
	WO 2000-US18079	W	20000630		
	US 2001-34585	A3	20011228		
	US 2004-787905	A3	20040226		

OS MARPAT 134:86149


IT 317353-65-4P 317353-66-5P 317360-89-7P
317360-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di-Ph ureas as VLA-4 inhibitors)

RN 317353-65-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317353-66-5 CAPLUS



CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.





RN 317360-89-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[1-[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 317360-90-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 317358-44-4P 317358-45-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of di-Ph ureas as VLA-4 inhibitors)
 RN 317358-44-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[3-methoxy-4-[[[(2-
 methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-
 pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, cis- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 317358-45-5 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 79 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:725611 CAPLUS
DN 133:276333
TI Anticancer calcium channel blockers
IN Gray, Lloyd S.; Macdonald, Timothy L.; Haverstick, Doris M.; Heady,
Tiffany N.
PA USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059882	A1	20001012	WO 2000-US9310	20000407
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2369588	A1	20001012	CA 2000-2369588	20000407
	EP 1165508	A1	20020102	EP 2000-921867	20000407
	EP 1165508	B1	20040623		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002541142	T	20021203	JP 2000-609394	20000407
	AT 269848	T	20040715	AT 2000-921867	20000407
	US 6946475	B1	20050920	US 2000-544968	20000407
PRAI	US 1999-128143P	P	19990407		
	WO.2000-US9310	W	20000407		
OS	MARPAT 133:276333				
IT	106789-32-6P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (anticancer calcium channel blockers)				
RN	106789-32-6 CAPLUS				
CN	L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/712,456-ALW

L4 ANSWER 80 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:725603 CAPLUS
DN 133:296654
TI Preparation of N-acyl- α -aminohydroxamic acids as matrix
metalloproteinase, TNF- α , and aggrecanase inhibitors
IN Duan, Jingwu
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059874	A1	20001012	WO 2000-US8362	20000330
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2366264	A1	20001012	CA 2000-2366264	20000330
	EP 1165500	A1	20020102	EP 2000-921500	20000330
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541138	T	20021203	JP 2000-609387	20000330
	US 6376665	B1	20020423	US 2000-540057	20000331
	US 2003032803	A1	20030213	US 2002-74357	20020212
	US 6689771	B2	20040210		
PRAI	US 1999-127635P	P	19990402		
	WO 2000-US8362	W	20000330		
	US 2000-540057	A3	20000331		
OS	MARPAT 133:296654				
IT	301162-35-6P 301162-36-7P 301162-55-0P 301162-56-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-acyl- α -aminohydroxamic acids as matrix metalloproteinase, TNF- α , and aggrecanase inhibitors)				
RN	301162-35-6 CAPLUS				
CN	2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 301162-36-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301162-55-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 301162-35-6

10/712,456-ALW

CMF C24 H25 N3 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 301162-56-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 301162-36-7

CMF C24 H25 N3 O4

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 301162-84-5P 301162-85-6P 301162-86-7P
301163-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of N-acyl- α -aminohydroxamic acids as matrix
metalloproteinase, TNF- α , and aggrecanase inhibitors)

RN 301162-84-5 CAPLUS

CN L-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, methyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 301162-85-6 CAPLUS

CN D-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 301162-86-7 CAPLUS

CN D-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 301163-20-2 CAPLUS

CN L-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 81 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:457018 CAPLUS

DN 133:89793

TI Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino acids and related compounds as novel thyroid receptor ligands

IN Hangeland, Jon; Zhang, Minsheng; Caringal, Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu, Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana Maria; Koehler, Konrad

PA Karo Bio AB, Swed.; et al.

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039077	A2	20000706	WO 1999-IB2084	19991223
	WO 2000039077	A3	20000921		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2356319	A1	20000706	CA 1999-2356319	19991223
	BR 9916851	A	20011016	BR 1999-16851	19991223
	EP 1144370	A2	20011017	EP 1999-962486	19991223
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	TR 200101834	T2	20011221	TR 2001-200101834	19991223
	HU 200104666	A2	20020328	HU 2001-4666	19991223
	JP 2002533432	T	20021008	JP 2000-590990	19991223
	AU 758202	B2	20030320	AU 2000-18855	19991223
	NZ 512422	A	20040227	NZ 1999-512422	19991223
	NO 2001002931	A	20010821	NO 2001-2931	20010613
	ZA 2001004932	A	20030115	ZA 2001-4932	20010615
	IN 2001KN00754	A	20050311	IN 2001-KN754	20010720
	US 6989402	B1	20060124	US 2001-868889	20010914
	US 2005282872	A1	20051222	US 2005-189654	20050726
PRAI	GB 1998-28442	A	19981224		
	WO 1999-IB2084	W	19991223		
	US 2001-868889	A3	20010914		
OS	MARPAT 133:89793				
IT	280777-20-OP 280777-26-6P				
	RL:	SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands)			
RN	280777-20-0 CAPLUS				
CN	D-Proline, 1-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 280777-26-6 CAPLUS

CN L-Proline, 1-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 82 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:384175 CAPLUS
DN 133:30959
TI Preparation of prolanylalkanediones and related compounds for treating
neurological disease, vision disorders, and alopecia.
IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-qian
PA GPI Nil Holdings, Inc., USA; Amgen, Inc.
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032588	A2	20000608	WO 1999-US28663	19991203
	WO 2000032588	A3	20010222		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6331537	B1	20011218	US 1999-453571	19991202
	CA 2353460	A1	20000608	CA 1999-2353460	19991203
	BR 9916461	A	20010904	BR 1999-16461	19991203
	EP 1135370	A2	20010926	EP 1999-961930	19991203
	EP 1135370	B1	20031015		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	AU 767468	B2	20031113	AU 2000-18413	19991203
	AT 252078	T	20031115	AT 1999-961930	19991203
	NZ 511673	A	20040326	NZ 1999-511673	19991203
	ZA 2001004397	A	20030829	ZA 2001-4397	20010529
	NO 2001002765	A	20010720	NO 2001-2765	20010605
	NO 318909	B1	20050523		
	BG 105643	A	20020228	BG 2001-105643	20010625
	AU 2004200797	A1	20040325	AU 2004-200797	20040227
PRAI	US 1998-204237	A	19981203		
	US 1999-453571	A	19991202		
	US 1998-87788P	P	19980603		
	AU 1999-17081	A3	19981203		
	WO 1999-US28663	W	19991203		

OS MARPAT 133:30959

IT 251949-15-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prolanylalkanediones and related compds. for treating
neurol. disease, vision disorders, and alopecia)

RN 251949-15-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 83 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:209094 CAPLUS

DN 133:72574

TI Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay

AU Dubowchik, Gene M.; Ditta, Jonathan L.; Herbst, John J.; Bollini, Sagarika; Vinitsky, Alexander

CS Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492-7660, USA

SO Bioorganic & Medicinal Chemistry Letters (2000), 10(6), 559-562
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

IT 278612-52-5P 278612-54-7P

RL: ARG (Analytical reagent use); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); PROC (Process); USES (Uses)
(fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay)


RN 278612-52-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO—



PAGE 1-B




10/712,456-ALW

RN 278612-54-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 278612-50-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay)

RN 278612-50-3 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 84 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:133508 CAPLUS
DN 132:166514
TI heterocyclic carboxylic acid ureas or carbamates for vision and memory disorders.
IN Ross, Douglas T.; Sauer, Hansjorg; Hamilton, Gregory S.; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000009125	A1	20000224	WO 1999-US18234	19990812
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2336152	A1	20000224	CA 1999-2336152	19990812
	AU 9954778	A1	20000306	AU 1999-54778	19990812
	EP 1107754	A1	20010620	EP 1999-941054	19990812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002522494	T	20020723	JP 2000-564628	19990812
PRAI	US 1998-134420	A	19980814		
	WO 1999-US18234	W	19990812		

OS MARPAT 132:166514

IT 251574-40-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heterocyclic carboxylic acid ureas or carbamates for vision and memory disorders)

RN 251574-40-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-hydroxy-N1-(4-methylphenyl)-N2-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 85 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819360 CAPLUS

DN 132:64524

TI Preparation of N-thiazolidinylcarbonylphenylalanine derivatives and analogs as inhibitors of $\alpha 4\beta 1$ mediated cell adhesion

IN Blinn, James R.; Chrusciel, Robert A.; Fisher, Jed F.; Tanis, Steven P.; Thomas, Edward William; Lobl, Thomas J.; Teegarden, Bradley R.

PA Pharmacia and Upjohn Company, USA; Tanabe Seiyaku Co., Ltd.

SO PCT Int. Appl., 308 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967230	A1	19991229	WO 1999-US14233	19990623
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 591026	B	20040611	TW 1999-88110444	19990622
	CA 2342778	A1	19991229	CA 1999-2342778	19990623
	AU 9947116	A	20000110	AU 1999-47116	19990623
	AU 764553	B2	20030821		
	EP 1089989	A1	20010411	EP 1999-930614	19990623
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518491	T	20020625	JP 2000-555884	19990623
	NZ 509010	A	20021025	NZ 1999-509010	19990623
	US 6685617	B1	20040203	US 2001-720088	20010309
PRAI	US 1998-90421P	P	19980623		
	WO 1999-US14233	W	19990623		

OS MARPAT 132:64524

IT 253154-47-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of N-thiazolidinylcarbonylphenylalanine derivs.

and analogs as inhibitors of $\alpha 4\beta 1$ mediated cell adhesion)

RN 253154-47-1 CAPLUS

CN L-Phenylalanine, 1-[[[(4-carboxyphenyl)amino]carbonyl]-L-prolyl-4-[(2,6-dichlorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 86 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:784078 CAPLUS

DN 132:22860

TI Preparation of aza-heterocyclic compounds used to treat neurological disorders and hair loss

IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA; Amgen, Inc.

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962881	A1	19991209	WO 1998-US25573	19981203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333963	A1	19991209	CA 1998-2333963	19981203
	AU 9917081	A	19991220	AU 1999-17081	19981203
	AU 772472	B2	20040429		
	ZA 9811063	A	20000707	ZA 1998-11063	19981203
	BR 9815920	A	20010220	BR 1998-15920	19981203
	EP 1084107	A1	20010321	EP 1998-961866	19981203
	EP 1084107	B1	20070411		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	HU 200102923	A2	20011228	HU 2001-2923	19981203
	HU 200102923	A3	20020128		
	JP 2002516905	T	20020611	JP 2000-552093	19981203
	NZ 508462	A	20040227	NZ 1998-508462	19981203
	AT 359267	T	20070515	AT 1998-961866	19981203
	NO 2000005903	A	20010202	NO 2000-5903	20001121
	NO 320643	B1	20060109		
	BG 105015	A	20010831	BG 2000-105015	20001201
	AU 2004200797	A1	20040325	AU 2004-200797	20040227
PRAI	US 1998-87788P	P	19980603		
	US 1998-101077P	P	19980918		
	AU 1999-17081	A3	19981203		
	WO 1998-US25573	W	19981203		
OS	MARPAT 132:22860				
IT	251949-15-2P 251950-15-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of aza-heterocyclic compds. used to treat neurol. disorders and hair loss)				
RN	251949-15-2 CAPLUS				
CN	L-Proline, 1-[oxo(3,4,5-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

10/712,456-ALW



RN 251950-15-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-cyano-N-ethyl-1-[(4-methylphenyl)oxoacetyl]-
(9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 87 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:784076 CAPLUS

DN 132:22867

TI Preparation of urea and carbamate derivatives of N-heterocyclic carboxylic acids and carboxylic acid isosteres for the treatment of neurodegenerative diseases and alopecia

IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA; Amgen, Inc.

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962879	A1	19991209	WO 1998-US25570	19981203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9811061	A	19991203	ZA 1998-11061	19981203
	CA 2333960	A1	19991209	CA 1998-2333960	19981203
	AU 9916204	A	19991220	AU 1999-16204	19981203
	EP 1082301	A1	20010314	EP 1998-960656	19981203
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	HU 200102847	A2	20011228	HU 2001-2847	19981203
	BR 9815881	A	20020723	BR 1998-15881	19981203
	NO 2000006111	A	20010201	NO 2000-6111	20001201
	BG 105014	A	20010831	BG 2000-105014	20001201
	US 2002007075	A1	20020117	US 2001-771686	20010130
	US 2002042442	A1	20020411	US 2001-847432	20010503
PRAI	US 1998-87844P	P	19980603		
	US 1998-204235	A3	19981203		
	WO 1998-US25570	W	19981203		

OS MARPAT 132:22867

IT 251574-40-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of urea and carbamate derivs. of N-heterocyclic carboxylic acids and carboxylic acid isosteres for the treatment of neurodegenerative diseases and alopecia)

RN 251574-40-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-hydroxy-N1-(4-methylphenyl)-N2-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 88 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:783930 CAPLUS
DN 132:23195
TI Preparation of neurotrophic amino acid difluoroamide agents
IN Vrudhula, Vivekananda M.; Dubowchik, Gene M.; Dasgupta, Bireshwar; Vyas, Dolatrai M.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962511	A1	19991209	WO 1999-US11348	19990521
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333997	A1	19991209	CA 1999-2333997	19990521
	AU 9941975	A	19991220	AU 1999-41975	19990521
	AU 743199	B2	20020124		
	US 6096762	A	20000801	US 1999-316792	19990521
	EP 1087763	A1	20010404	EP 1999-925749	19990521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002516857	T	20020611	JP 2000-551767	19990521
	US 6239146	B1	20010529	US 2000-590808	20000609
PRAI	US 1998-87642P	P	19980602		
	US 1999-316792	A3	19990521		
	WO 1999-US11348	W	19990521		
OS	MARPAT 132:23195				
IT	251909-01-0P 251909-02-1P 251909-03-2P 251909-05-4P 251909-06-5P 251909-08-7P 251909-18-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of neurotrophic amino acid difluoroamide agents)				
RN	251909-01-0 CAPLUS				
CN	L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/712,456-ALW

RN 251909-02-1 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-03-2 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
(1S)-1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-05-4 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1,1-dimethyl-3-phenylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251909-06-5 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 1,3-diphenylpropyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 251909-08-7 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
3-(3,4,5-trimethoxyphenyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-18-9 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
(1R)-1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 251909-15-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of neurotrophic amino acid difluoroamide agents)

RN 251909-15-6 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 89 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:764020 CAPLUS

DN 132:12508

TI Preparation of novel VLA-4 inhibitor (R)-N-[[4-[[[2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl]-3-methyl- β -alanine

IN Lee, Wen-Cherng; Gill, Alan

PA Biogen, Inc., USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9961421	A1	19991202	WO 1999-US11924	19990528
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333656	A1	19991202	CA 1999-2333656	19990528
	AU 9942192	A	19991213	AU 1999-42192	19990528
	AU 764108	B2	20030807		
	EP 1082302	A1	20010314	EP 1999-926019	19990528
	EP 1082302	B1	20031217		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100190	T2	20010521	TR 2001-200100190	19990528
	HU 200102255	A2	20011128	HU 2001-2255	19990528
	JP 2002516309	T	20020604	JP 2000-550827	19990528
	EE 200000698	A	20020617	EE 2000-698	19990528
	EE 4639	B1	20060615		
	NZ 509199	A	20031031	NZ 1999-509199	19990528
	AT 256659	T	20040115	AT 1999-926019	19990528
	PT 1082302	T	20040430	PT 1999-926019	19990528
	ES 2211096	T3	20040701	ES 1999-926019	19990528
	IL 139967	A	20051120	IL 1999-139967	19990528
	SK 285280	B6	20061005	SK 2000-1810	19990528
	NO 2000006023	A	20010117	NO 2000-6023	20001128
	NO 317990	B1	20050117		
	US 6495525	B1	20021217	US 2000-724107	20001128
	ZA 2000007300	A	20020227	ZA 2000-7300	20001208
	BG 105060	A	20010831	BG 2000-105060	20001218
	BG 65021	B1	20061229		
	HK 1035726	A1	20040930	HK 2001-106420	20010911
PRAI	US 1998-87064P	P	19980528		
	WO 1999-US11924	W	19990528		
IT	251469-34-8P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of novel VLA-4 inhibitor [(((methylphenylamino)carbonyl]amino]phenyl]acetyl]prolyl]methyl- β -alanine)

RN 251469-34-8 CAPLUS

CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



IT 251469-33-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel VLA-4 inhibitor [(((methylphenylamino)carbonyl)amino]phenyl]acetyl]prolyl]methyl-β-alanine)

RN 251469-33-7 CAPLUS

CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 90 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:708726 CAPLUS
DN 131:322422
TI Preparation of aminomethyl benzoic ester derivatives as tryptase
inhibitors
IN Waszkowycz, Bohdan; Lively, Sarah Elizabeth; Harrison, Martin James
PA Proteus Molecular Design Limited, UK
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955661	A1	19991104	WO 1999-GB1263	19990423
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9936200	A	19991116	AU 1999-36200	19990423
	EP 1073624	A1	20010207	EP 1999-918168	19990423
	R: CH, DE, ES, FR, GB, IT, LI, SE				
PRAI	GB 1998-8813	A	19980424		
	GB 1998-22432	A	19981014		
	WO 1999-GB1263	W	19990423		

OS MARPAT 131:322422

IT 248587-06-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aminomethyl benzoic ester derivs. as tryptase inhibitors for treatment of asthma)

RN 248587-06-6 CAPLUS


CN L-Proline, 1-[[4-[[4-(aminomethyl)benzoyl]oxy]phenyl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 248587-05-5

CMF C21 H22 N2 O5


Absolute stereochemistry.



CM 2

10/712,456-ALW


CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 91 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:467152 CAPLUS
 DN 131:228993
 TI Synthesis and evaluation of anti-inflammatory activity of
 2-(4-isobutylphenyl)propionyl derivatives of amino acids and peptides
 AU Belagali, S. L.; Himaja, M.
 CS Department of P.G. Studies and Research in Chemistry, Mangalore
 University, Mangalagangothri, 574 199, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1999), 38B(4), 505-507
 CODEN: IJSBDB; ISSN: 0376-4699
 PB National Institute of Science Communication, CSIR
 DT Journal
 LA English
 IT 243868-53-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and evaluation of anti-inflammatory activity of
 (isobutylphenyl)propionyl derivs. of amino acids and peptides)
 RN 243868-53-3 CAPLUS
 CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-L-leucyl-
 L-threonyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 92 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:440760 CAPLUS
 DN 131:199967
 TI Novel protocol for the solid-phase synthesis of peptidyl and
 peptidomimetic P1-argininal derivatives
 AU Siev, Daniel V.; Gaudette, John A.; Semple, J. Edward
 CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
 CA, 92121, USA
 SO Tetrahedron Letters (1999), 40(28), 5123-5127
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 131:199967
 IT 241146-30-5DP, resin-bound 241146-32-7DP, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (solid-phase synthesis of peptidyl and peptidomimetic P1-argininal
 derivs.)
 RN 241146-30-5 CAPLUS
 CN Hexanoic acid, 6-[[[(3S)-3-[[[(2S,4R)-1-[(3,4-dihydroxyphenyl)acetyl]-4-
 (phenylmethoxy)-2-pyrrolidinyl]carbonyl]amino]-1-[imino[[(2-
 propenyloxy)carbonyl]amino]methyl]-2-piperidinyl]oxy]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 241146-32-7 CAPLUS
 CN Hexanoic acid, 6-[[[(3S)-3-[[[(2S,4R)-1-[(4-butoxyphenyl)acetyl]-4-
 (phenylmethoxy)-2-pyrrolidinyl]carbonyl]amino]-1-[imino[[(2-
 propenyloxy)carbonyl]amino]methyl]-2-piperidinyl]oxy]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



IT 241145-97-1P 241145-99-3P

10/712,456-ALW

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of peptidyl and peptidomimetic Pl-argininal
derivs.)

RN 241145-97-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-1-[(3,4-dihydroxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 241145-96-0

CMF C26 H33 N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 241145-99-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-1-[(4-butoxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 241145-98-2

CMF C30 H41 N5 O5

Absolute stereochemistry.




10/712,456-ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 93 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:375282 CAPLUS
DN 131:44656
TI Preparation of N-(4-amidinophenyl)phenylglycineamides as factor
VIIa/tissue factor inhibitors
IN Grobke, Katrin; Ji, Yu-hua; Wallbaum, Sabine; Weber, Lutz
PA F. Hoffmann-La Roche A.-G., Switz.
SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 921116	A1	19990609	EP 1998-122169	19981126
	EP 921116	B1	20030618		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 243192	T	20030715	AT 1998-122169	19981126
	PT 921116	T	20031128	PT 1998-122169	19981126
	ES 2201396	T3	20040316	ES 1998-122169	19981126
	CA 2255180	A1	19990604	CA 1998-2255180	19981202
	NZ 333126	A	20000623	NZ 1998-333126	19981202
	US 6140353	A	20001031	US 1998-204373	19981202
	IL 127361	A	20020912	IL 1998-127361	19981202
	ZA 9811077	A	19990604	ZA 1998-11077	19981203
	NO 9805646	A	19990607	NO 1998-5646	19981203
	AU 9895210	A	19990624	AU 1998-95210	19981203
	AU 739769	B2	20011018		
	MX 9810201	A	20000831	MX 1998-10201	19981203
	RU 2202539	C2	20030420	RU 1998-122314	19981203
	CZ 295105	B6	20050518	CZ 1998-3969	19981203
	HU 9802808	A2	19990628	HU 1998-2808	19981204
	CN 1224714	A	19990804	CN 1998-126979	19981204
	CN 1115330	B	20030723		
	JP 11246507	A	19990914	JP 1998-345875	19981204
	JP 3236267	B2	20011210		
	BR 9805320	A	20000411	BR 1998-5320	19981204
	HR 980614	B1	20030228	HR 1998-614	19981204
	PL 193297	B1	20070131	PL 1998-330104	19981204
	TW 544446	B	20030801	TW 1999-88102291	19990212
	HK 1020941	A1	20031107	HK 1999-106072	19991223
PRAI	EP 1997-121285	A	19971204		
	EP 1998-121374	A	19981110		

OS MARPAT 131:44656

IT 227022-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-amidinophenyl)phenylglycineamides as factor VIIa/tissue factor inhibitors)

RN 227022-04-0 CAPLUS

CN L-Proline, N-[4-(aminoiminomethyl)phenyl]-2-[3-methoxy-4-(phenylmethoxy)phenyl]glycyl-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 227022-03-9

CMF C28 H30 N4 O5

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 64-19-7

CMF C2 H4 O2



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 94 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:354478 CAPLUS

DN 131:5529

TI Preparation of substituted β -alanine derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Kopka, Ihor E.; MacCoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Magriotis, Plato A.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9926921	A1	19990603	WO 1998-US24898	19981124
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309341	A1	19990603	CA 1998-2309341	19981124
AU 9915327	A	19990615	AU 1999-15327	19981124
AU 751950	B2	20020905		
EP 1034164	A1	20000913	EP 1998-959547	19981124
EP 1034164	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001524465	T	20011204	JP 2000-522079	19981124
AT 267168	T	20040615	AT 1998-959547	19981124
ES 2221227	T3	20041216	ES 1998-959547	19981124
PRAI US 1997-66484P	P	19971124		
GB 1997-27215	A	19971223		
WO 1998-US24898	W	19981124		
OS MARPAT 131:5529				
IT 225515-65-1P				
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of substituted β -alanine derivs. as cell adhesion inhibitors)				
RN 225515-65-1 CAPLUS				
CN β -Alanine, 1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



10/712,456-ALW

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 95 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:343650 CAPLUS

DN 130:352548

TI Synthesis of D-proline derivatives for treatment of amyloidosis

IN Hertel, Cornelia; Hoffmann, Torsten; Jakob-Roetne, Roland; Norcross, Roger David

PA F. Hoffmann-La Roche A.-G., Switz.

SO Eur. Pat. Appl., 77 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 915088	A1	19990512	EP 1998-119986	19981022
	EP 915088	B1	20020918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 224366	T	20021015	AT 1998-119986	19981022
	PT 915088	T	20030131	PT 1998-119986	19981022
	ES 2182203	T3	20030301	ES 1998-119986	19981022
	HU 9802465	A1	20001228	HU 1998-2465	19981026
	US 6103910	A	20000815	US 1998-179652	19981027
	CA 2252163	A1	19990430	CA 1998-2252163	19981028
	NZ 332530	A	20000526	NZ 1998-332530	19981028
	IL 126787	A	20031210	IL 1998-126787	19981028
	ZA 9809889	A	19990430	ZA 1998-9889	19981029
	AU 9889599	A	19990520	AU 1998-89599	19981029
	AU 750734	B2	20020725		
	JP 11209343	A	19990803	JP 1998-307719	19981029
	JP 3048558	B2	20000605		
	TW 585854	B	20040501	TW 1998-87117984	19981029
	CZ 296252	B6	20060215	CZ 1998-3463	19981029
	NO 9805059	A	19990503	NO 1998-5059	19981030
	NO 312064	B1	20020311		
	CN 1217327	A	19990526	CN 1998-123674	19981030
	BR 9804378	A	20000613	BR 1998-4378	19981030
	SG 74094	A1	20000718	SG 1998-4381	19981030
	RU 2201937	C2	20030410	RU 1998-120057	19981030
	HR 980572	B1	20040630	HR 1998-572	19981030
	US 6262089	B1	20010717	US 2000-505375	20000216
	US 6512001	B1	20030128	US 2000-636076	20000810
	US 2003100770	A1	20030529	US 2002-186781	20020701
	US 6740760	B2	20040525		
PRAI	EP 1997-119031	A	19971031		
	EP 1998-113851	A	19980724		
	US 1998-179652	A3	19981027		
	US 2000-505375	A3	20000216		
	US 2000-636076	A3	20000810		

OS MARPAT 130:352548

IT 224626-74-8P 224626-82-8P 224626-85-1P

224627-09-2P 224627-32-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(synthesis of D-proline derivs. for treatment of amyloidosis)

RN 224626-74-8 CAPLUS

CN D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224626-82-8 CAPLUS

CN L-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224626-85-1 CAPLUS

CN D-Proline, 1,1'-[1,4-naphthalenediylbis(1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224627-09-2 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(2-methyl-1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224627-32-1 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis[4,4-difluoro-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 224624-85-5P 224625-47-2P 224625-54-1P


224625-56-3P 224625-66-5P 224625-98-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of D-proline derivs. for treatment of amyloidosis)

RN 224624-85-5 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224625-47-2 CAPLUS

CN D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224625-54-1 CAPLUS

CN L-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224625-56-3 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224625-66-5 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(2-methyl-1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224625-98-3 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis[4,4-difluoro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 96 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:141228 CAPLUS

DN 130:182769

TI Preparation of heterocyclic peptide derivatives as growth hormone secretagogues

IN Dodge, Jeffrey Alan; Hauser, Kenneth Lee; Heiman, Mark Louis; Jones, Scott Alan; Alt, Charles Arthur; Bryant, Henry Uhlman; Cohen, Jeffrey Daniel; Copp, James Densmore; Fahey, Kennan Joseph; Gritton, William Harlan; Jungheim, Louis Nickolaus; Kennedy, Joseph Henry; Lugar, Charles Willis, III; Muehl, Brian Stephen; Palkowitz, Alan David; Ratz, Andrew Michael; Rhodes, Gary Anthony; Robey, Robert Lewis; Seyler, David Edward; Shepherd, Timothy Alan; Thrasher, Kenneth Jeff; Trankle, William George

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 876 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9908699	A1	19990225	WO 1998-US17229	19980819
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 1998CA01422	A	20050325	IN 1998-CA1422	19980807
ZA 9807385	A	20000418	ZA 1998-7385	19980817
EP 933365	A2	19990804	EP 1998-306622	19980818
EP 933365	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TW 577879	B	20040301	TW 1998-87113593	19980818
CA 2302467	A1	19990225	CA 1998-2302467	19980819
AU 9890256	A	19990308	AU 1998-90256	19980819
AU 738204	B2	20010913		
BR 9811948	A	20000822	BR 1998-11948	19980819
HU 200002392	A2	20001028	HU 2000-2392	19980819
TR 200000930	T2	20001121	TR 2000-200000930	19980819
JP 2001515046	T	20010918	JP 2000-509436	19980819
CA 2340344	A1	20000302	CA 1999-2340344	19990219
WO 2000010565	A1	20000302	WO 1999-US3525	19990219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9926868	A	20000314	AU 1999-26868	19990219
EP 1112071	A1	20010704	EP 1999-907136	19990219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523368	T	20020730	JP 2000-565886	19990219
HR 2000000090	A1	20010430	HR 2000-90	20000217
NO 2000000823	A	20000412	NO 2000-823	20000218
MX 200001738	A	20001211	MX 2000-1738	20000218

10/712,456-ALW

US	6639076	B1	20031028	US	2001-762529	20010417
US	2004122234	A1	20040624	US	2003-453833	20030603
US	6992097	B2	20060131			
PRAI	US 1997-56142P	P	19970819			
EP	1998-306621	A	19980818			
EP	1998-306622	A	19980818			
WO	1998-US17229	W	19980819			
WO	1999-US3525	W	19990219			
US	2001-762529	A3	20010417			
OS	MARPAT 130:182769					
IT	220536-67-4P					
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)					
	(preparation of heterocyclic peptide derivs. as growth hormone secretagogues)					
RN	220536-67-4	CAPLUS				
CN	D-Proline, 2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)					

Absolute stereochemistry.



●2 HCl

IT	220530-00-7P					
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)					
	(preparation of heterocyclic peptide derivs. as growth hormone secretagogues)					
RN	220530-00-7	CAPLUS				
CN	D-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)					

Absolute stereochemistry.


RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 97 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:141226 CAPLUS
DN 130:209977
TI Treatment of congestive heart failure with growth hormone secretagogues
IN Kauffman, Raymond Francis; Palkowitz, Alan David
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 775 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908697	A1	19990225	WO 1998-US17201	19980819
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807383	A	20000217	ZA 1998-7383	19980817
	EP 898963	A2	19990303	EP 1998-306621	19980818
	EP 898963	A3	20030709		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9803168	A	20000111	BR 1998-3168	19980818
	CA 2300848	A1	19990225	CA 1998-2300848	19980819
	AU 9894715	A	19990308	AU 1998-94715	19980819
	JP 2001515045	T	20010918	JP 2000-509434	19980819
	JP 2002523368	T	20020730	JP 2000-565886	19990219
	US 6329342	B1	20011211	US 2000-485924	20000218
	US 2004122234	A1	20040624	US 2003-453833	20030603
	US 6992097	B2	20060131		
PRAI	US 1997-56135P	P	19970819		
	EP 1998-306621	A	19980818		
	EP 1998-306622	A	19980818		
	WO 1998-US17201	W	19980819		
	WO 1999-US3525	W	19990219		
	US 2001-762529	A3	20010417		
OS	MARPAT 130:209977				
IT	220536-67-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(treatment of congestive heart failure with growth hormone secretagogues)				
RN	220536-67-4 CAPLUS				
CN	D-Proline, 2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester, dihydrochloride (9CI)				
	(CA INDEX NAME)				


Absolute stereochemistry.



●2 HCl

IT 220530-00-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (treatment of congestive heart failure with growth hormone secretagogues)
 RN 220530-00-7 CAPLUS
 CN D-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino-α-(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 98 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:799992 CAPLUS

DN 130:52724

TI Preparation of heterocyclic dipeptide derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Van Riper, Gail M.; Schmidt, Jack A.; Kevin, Nancy J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853814	A1	19981203	WO 1998-US10940	19980529
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6903075	B1	20050607	US 1998-86327	19980528
	CA 2291778	A1	19981203	CA 1998-2291778	19980529
	EP 1001764	A1	20000524	EP 1998-926122	19980529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002512625	T	20020423	JP 1999-500934	19980529
	WO 9964395	A1	19991216	WO 1998-US11623	19980611
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9880595	A	19991230	AU 1998-80595	19980611
PRAI	US 1997-48017P	P	19970529		
	GB 1997-14314	A	19970707		
	US 1997-66525P	P	19971125		
	GB 1998-686	A	19980114		
	US 1997-47856P	P	19970529		
	WO 1998-US10940	W	19980529		
	WO 1998-US11623	A	19980611		

OS MARPAT 130:52724

IT 217452-38-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217452-38-5 CAPLUS

CN L-Norleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 99 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:749736 CAPLUS
DN 130:110572
TI Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy
AU Niculescu-Duvaz, Dan; Niculescu-Duvaz, Ion; Friedlos, Frank; Martin, Janet; Spooner, Robert; Davies, Lawrence; Marais, Richard; Springer, Caroline J.
CS UK
SO Journal of Medicinal Chemistry (1998), 41(26), 5297-5309
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 219591-73-8P
RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of self-immolative nitrogen mustard prodrugs for suicide gene therapy)
RN 219591-73-8 CAPLUS
CN L-Proline, 1-[[[4-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]phenyl]amino]carbonyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 219591-75-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of self-immolative nitrogen mustard prodrugs for suicide gene therapy)
RN 219591-75-0 CAPLUS
CN L-Proline, 1-[[[4-(hydroxymethyl)phenyl]amino]carbonyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 100 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:709057 CAPLUS
DN 129:343718
TI Preparation of heterocyclic derivatives as antithrombotic agents
IN Van Boeckel, Constant Adriaan Anton; Van Galen, Philippus Johannes Marie;
Rewinkel, Johannes Bernardus Maria
PA Akzo Nobel N.V., Neth.
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847876	A1	19981029	WO 1998-EP2455	19980421
	W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 228123	B	20050221	TW 1998-87105306	19980408
	ZA 9803176	A	19981021	ZA 1998-3176	19980415
	IN 1998MA00835	A	20050304	IN 1998-MA835	19980420
	CA 2287558	A1	19981029	CA 1998-2287558	19980421
	AU 9876486	A	19981113	AU 1998-76486	19980421
	EP 975600	A1	20000202	EP 1998-924206	19980421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001523240	T	20011120	JP 1998-545041	19980421
	EP 1505062	A1	20050209	EP 2004-105699	19980421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6194409	B1	20010227	US 1999-403327	19991019
	US 6444672	B1	20020903	US 2000-550954	20000417
	US 6432955	B1	20020813	US 2000-679232	20001004
	US 2003130270	A1	20030710	US 2002-178441	20020620
	US 6797710	B2	20040928		
PRAI	EP 1997-201227	A	19970424		
	EP 1998-924206	A3	19980421		
	WO 1998-EP2455	W	19980421		
	US 1999-403327	A3	19991019		
	US 2000-679232	A3	20001004		
OS	MARPAT 129:343718				
IT	215450-75-2P 215450-76-3P 215450-77-4P 215450-83-2P 215450-93-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic derivs. as antithrombotic agents)				
RN	215450-75-2 CAPLUS				
CN	L-Prolinamide, N-acetyl-2-[4-(methoxycarbonyl)phenyl]glycyl-N-[(1-amino-6-isoquinolinyl)methyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 215450-76-3 CAPLUS

CN L-Prolinamide, N-acetyl-2-(4-cyanophenyl)glycyl-N-[(1-amino-6-isoquinoliny)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215450-77-4 CAPLUS

CN L-Prolinamide, N-acetyl-2-[4-(trifluoromethyl)phenyl]glycyl-N-[(1-amino-6-isoquinoliny)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215450-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)[4-(trifluoromethyl)phenyl]acetyl]-N-[(1-amino-6-isoquinoliny)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 215450-93-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)(4-methoxyphenyl)acetyl]-N-[(1-amino-6-isoquinolinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 101 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:572297 CAPLUS

DN 129:203270

TI Preparation of prolinamide derivatives as thrombin inhibitors

IN Lumma, William C.; Tucker, Thomas J.; Witherup, Keith M.; Brady, Stephen F.; Whitter, Willie L.; Vacca, Joseph P.; Coburn, Craig; Shafer, Jules A.

PA Merck and Co., Inc., USA

SO U.S., 24 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5798377	A	19980825	US 1996-734148	19961021
PRAI	US 1996-734148		19961021		
OS	MARPAT 129:203270				
IT	190509-75-2P				


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prolinamide derivs. as thrombin inhibitors)

RN 190509-75-2 CAPLUS

CN L-Prolinamide, (2R)-2-(4-hydroxy-3-methoxyphenyl)glycyl-N-[(2,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 102 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:505485 CAPLUS

DN 129:230962

TI 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a Potent Human NK1 Tachykinin Receptor Antagonist with Good Oral Analgesic Activity in Chronic Pain Models

AU Walpole, C.; Ko, S. Y.; Brown, M.; Beattie, D.; Campbell, E.; Dickenson, F.; Ewan, S.; Hughes, G. A.; Lemaire, M.; Lerpiniere, J.; Patel, S.; Urban, L.

CS Novartis Institute for Medical Sciences, London, WC1E 6BN, UK

SO Journal of Medicinal Chemistry (1998), 41(17), 3159-3173

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 180047-07-8P 212700-34-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

.(preparation of potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models)

RN 180047-07-8 CAPLUS

CN L-Alaninamide, 1-[[[(4-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212700-34-0 CAPLUS

CN L-Alaninamide, 1-[[[(4-cyanophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 103 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:157415 CAPLUS
DN 128:205136
TI Preparation of acylated amino acid derivatives for multi-drug resistance
therapies and immune suppression.
IN Armistead, David M.; Harding, Matthew W.; Saunders, Jeffrey O.; Boger,
Joshua S.
PA Vertex Pharmaceuticals Inc., USA
SO U.S., 34 pp., Cont.-in-part of U.S. 5,620,971.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5723459	A	19980303	US 1995-377315	19950124
	US 5620971	A	19970415	US 1994-217982	19940325
PRAI	US 1991-697785	B2	19910509		
	US 1992-881152	B2	19920511		
	US 1992-952299	B2	19920928		
	US 1993-127814	B2	19930928		
	US 1994-217982	A2	19940325		

OS MARPAT 128:205136


IT 145913-35-5P 159997-77-0P 159997-78-1P
159997-95-2P 160072-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance
therapies and immune suppression.)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-
pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-
pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160072-11-7 CAPLUS


CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph

PAGE 2-A



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 104 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:106085 CAPLUS

DN 128:176149

TI Molecular model for VLA-4 inhibitors, and inhibitor identification

IN Singh, Juswinder; Zheng, Zhongli; Sprague, Peter; Van Vlijmen, Herman W. T.; Castro, Alfredo C.; Adams, Steven P.

PA Biogen, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804913	A1	19980205	WO 1997-US13008	19970724
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2261974	A1	19980205	CA 1997-2261974	19970724
	AU 9737385	A	19980220	AU 1997-37385	19970724
	CN 1230110	A	19990929	CN 1997-197953	19970724
	HU 9903142	A2	20000128	HU 1999-3142	19970724
	HU 9903142	A3	20000628		
	CN 1478472	A	20040303	CN 2003-2003146679	19970724
	SG 124234	A1	20060830	SG 2001-200100382	19970724
	AT 339196	T	20061015	AT 1997-934289	19970724
	KR 2000029538	A	20000525	KR 1999-700595	19990125
	US 6552216	B1	20030422	US 1999-236784	19990125
	BG 64470	B1	20050430	BG 1999-103193	19990222
	BG 108806	A	20050430	BG 1999-108806	19990222
	BG 64902	B1	20060831		
	AU 759063	B2	20030403	AU 2001-91330	20011114
PRAI	US 1996-22890P	P	19960725		
	US 1996-32786P	P	19961206		
	US 1997-57002P	P	19970630		
	AU 1997-37386	A3	19970724		
	WO 1997-US13008	W	19970724		
OS	MARPAT 128:176149				
IT	203181-31-1				
	RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(mol. model for VLA-4 inhibitors, and inhibitor identification)				
RN	203181-31-1 CAPLUS				
CN	Butanoic acid, 3-[[[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, [R-(R*,R*)]]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 105 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:45153 CAPLUS
DN 128:97538
TI Discovery and Development of the Novel Potent Orally Active Thrombin Inhibitor N-(9-Hydroxy-9-fluorene-carboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460): Coapplication of Structure-Based Design and Rapid Multiple Analog Synthesis on Solid Support
AU Brady, Stephen F.; Stauffer, Kenneth J.; Lumma, William C.; Smith, Graham M.; Ramjit, Harri G.; Lewis, S. Dale; Lucas, Bobby J.; Gardell, Steven J.; Lyle, Elizabeth A.; Appleby, Sandra D.; Cook, Jacquelynn J.; Holahan, Marie A.; Stranieri, Maria T.; Lynch, Joseph J., Jr.; Lin, Jiunn H.; Chen, I.-Wu; Vastag, Kari; Naylor-Olsen, Adel M.; Vacca, Joseph P.
CS Departments of Medicinal Chemistry Biological Chemistry Pharmacology Drug Metabolism and Molecular Design and Diversity, Merck Research Laboratories, West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (1998), 41(3), 401-406
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 201211-44-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(isolation of the potent orally active thrombin inhibitor
N-(9-Hydroxy-9-fluorene-carboxy)prolyl trans-4-Aminocyclohexylmethyl
Amide (L-372,460) and coapplication of structure-based design and rapid
multiple analog synthesis)
RN 201211-44-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(4-aminocyclohexyl)methyl]-1-[(3,4,5-trimethoxyphenyl)acetyl]-, [1(S)-trans]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 106 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:1496 CAPLUS

DN 128:75673

TI Preparation of amino acid derivatives and their use as thrombin inhibitors

IN Gustafsson, David; Nystrom, Jan-erik

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9746577	A1	19971211	WO 1997-SE989	19970605
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	IN 1996DE01427	A	20050311	IN 1996-DE1427	19960627
	ZA 9704542	A	19971208	ZA 1997-4542	19970523
	IN 1997DE01389	A	20050311	IN 1997-DE1389	19970526
	CA 2255625	A1	19971211	CA 1997-2255625	19970605
	AU 9731140	A	19980105	AU 1997-31140	19970605
	AU 723420	B2	20000824		
	EP 910573	A1	19990428	EP 1997-926356	19970605
	EP 910573	B1	20030129		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9709560	A	19990810	BR 1997-9560	19970605
	CN 1226895	A	19990825	CN 1997-196864	19970605
	CN 1129604	B	20031203		
	NZ 332964	A	20000825	NZ 1997-332964	19970605
	JP 2000512631	T	20000926	JP 1998-500502	19970605
	HU 200002404	A2	20001028	HU 2000-2404	19970605
	HU 200002404	A3	20010228		
	AT 231883	T	20030215	AT 1997-926356	19970605
	ES 2191840	T3	20030916	ES 1997-926356	19970605
	US 6255301	B1	20010703	US 1997-860871	19970714
	NO 9805700	A	19990205	NO 1998-5700	19981204
	NO 317135	B1	20040823		
	KR 2000016401	A	20000325	KR 1998-709975	19981205
	US 2002019371	A1	20020214	US 2001-844427	20010430
	US 6838478	B2	20050104		
PRAI	SE 1996-2263	A	19960607		
	WO 1997-SE989	W	19970605		
	US 1997-860871	A1	19970714		
OS	MARPAT 128:75673				
IT	200213-43-0P 200213-92-9P 200213-93-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of amino acid derivs. as thrombin inhibitors)				
RN	200213-43-0 CAPLUS				
CN	2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)				

10/712,456-ALW

Absolute stereochemistry.




● HCl

RN 200213-92-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200213-93-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, [S-(R*,R*)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 200215-27-6P 200215-28-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid derivs. as thrombin inhibitors)

RN 200215-27-6 CAPLUS

CN Carbamic acid, [[4-[[[1-[3-hydroxy-2-[3-methoxy-4-(phenylmethoxy)phenyl]-1-oxopropyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200215-28-7 CAPLUS

CN Carbamic acid, [[4-[[[1-[3-hydroxy-2-[3-methoxy-4-(phenylmethoxy)phenyl]-1-oxopropyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CCOC(=O)NC(=N)c1ccc(cc1)NC(=O)N2SCCN2C(=O)S[C@H](O)c3ccc(OC)cc3OCC4=CC=CC=C4

10/712,456-ALW

L4 ANSWER 107 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:735919 CAPLUS

DN 127:346664

TI Preparation of di-and tripeptide L-dopa mimetics as compounds for treatment of Parkinson's disease

IN Wang, Hui-po; Lee, Jia-shuai; Tsai, Ming-cheng; Lu, Hsiao-hwa; Hu, Oliver Yoa-pu; Luo, Wen-lin

PA Department of Health, the Executive Yuan, Republic of China, Taiwan

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5686423	A	19971111	US 1996-602361	19960216
PRAI	US 1996-602361		19960216		
OS	MARPAT 127:346664				
IT	171860-38-1P				


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of di-and tripeptide L-dopa mimetics as compds. for treatment of Parkinson's disease)

RN 171860-38-1 CAPLUS

CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1P 164353-71-3P 171860-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of di-and tripeptide L-dopa mimetics as compds. for treatment of Parkinson's disease)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171860-39-2 CAPLUS

CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 108 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:594714 CAPLUS

DN 127:247960

TI Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains

IN Holt, Dennis A.; Keenan, Terence P.; Guo, Tao; Laborde, Edgardo; Wu, Yang

PA Ariad Gene Therapeutics, Inc., USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9731898	A1	19970904	WO 1997-US3137	19970228
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2244363	A1	19970904	CA 1997-2244363	19970228
	CA 2244363	C	20061114		
	AU 9719809	A	19970916	AU 1997-19809	19970228
	AU 731826	B2	20010405		
	EP 888303	A1	19990107	EP 1997-907937	19970228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000505475	T	20000509	JP 1997-531139	19970228
	US 6133456	A	20001017	US 1997-808276	19970228
	US 6150527	A	20001121	US 1997-808274	19970228
	US 2002161240	A1	20021031	US 2002-86506	20020228
	US 2003036654	A1	20030220	US 2002-86770	20020228
	US 2004006233	A1	20040108	US 2003-461705	20030613
PRAI	US 1996-12432P	P	19960228		
	US 1996-24861P	P	19960828		
	US 1996-33035P	P	19961210		
	US 1994-292598	B2	19940818		
	US 1995-479694	A2	19950607		
	US 1995-793016	B2	19950818		
	US 1997-808274	A1	19970228		
	US 1997-808276	A1	19970228		
	WO 1997-US3137	W	19970228		
	US 1997-793016	B1	19971201		
	US 2000-690581	B1	20001017		
	US 2000-690797	B1	20001017		
	US 2002-86770	A1	20020228		
OS	MARPAT 127:247960				
IT	195514-55-7P, AP 1972				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(synthetic derivs. of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains)				
RN	195514-55-7 CAPLUS				
CN	L-Proline, 1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-, (1R)-1-[3-(carboxymethoxy)phenyl]-3-(3,4-dimethoxyphenyl)propyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



10/712,456-ALW

L4 ANSWER 109 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:564959 CAPLUS
DN 127:156266
TI Molecular Modeling and 3D-QSAR Studies on the Interaction Mechanism of
Tripeptidyl Thrombin Inhibitors with Human α -Thrombin
AU Jiang, Hualiang; Chen, Kaixian; Tang, Yun; Chen, Jianzhong; Li, Quan;
Wang, Qinmi; Ji, Ruyun
CS Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Shanghai, 200031, Peop. Rep. China
SO Journal of Medicinal Chemistry (1997), 40(19), 3085-3090
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 141972-92-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(tripeptidyl thrombin inhibitors interaction with human
 α -thrombin)
RN 141972-92-1 CAPLUS
CN L-Prolinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-
hydroxyphenyl)glycyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 110 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:400089 CAPLUS

DN 127:13457

TI Peptide derivative thrombin inhibitors, preparation and activity thereof, and pharmaceutical compositions

IN Lumma, William C.; Tucker, Thomas J.; Witherup, Keith M.; Brady, Stephen F.; Whitter, Willie L.; Vacca, Joseph P.; Coburn, Craig; Shafer, Jules A.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9715190	A1	19970501	WO 1996-US16865	19961021
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2233860	A1	19970501	CA 1996-2233860	19961021
	AU 9674634	A	19970515	AU 1996-74634	19961021
	AU 709088	B2	19990819		
	EP 858262	A1	19980819	EP 1996-936804	19961021
	EP 858262	B1	20021204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 11514378	T	19991207	JP 1996-516702	19961021
	AT 228760	T	20021215	AT 1996-936804	19961021
	ES 2186807	T3	20030516	ES 1996-936804	19961021
PRAI	US 1995-6076P	P	19951024		
	GB 1996-5163	A	19960312		
	US 1996-23164P	P	19960805		
	WO 1996-US16865	W	19961021		

OS MARPAT 127:13457

IT 190509-75-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(peptide derivative thrombin inhibitors, preparation and activity thereof, and pharmaceutical compns.)

RN 190509-75-2 CAPLUS

CN L-Prolinamide, (2R)-2-(4-hydroxy-3-methoxyphenyl)glycyl-N-[(2,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 111 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:307496 CAPLUS
DN 126:272378
TI Methods and compositions for stimulating neurite growth using compounds
with affinity for FKBP12 in combination with neurotrophic factors
IN Armistead, David M.
PA Vertex Pharmaceuticals Incorporated, USA
SO S. African, 54 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 9604852	A	19960729	ZA 1996-4852	19960607
	US 6037370	A	20000314	US 1995-486004	19950608
	CA 2222430	A1	19961227	CA 1996-2222430	19960606
	WO 9641609	A2	19961227	WO 1996-US10123	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9661119	A	19970109	AU 1996-61119	19960606
	EP 831812	A2	19980401	EP 1996-918469	19960606
	EP 831812	B1	20051207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202104	A	19981216	CN 1996-195690	19960606
	BR 9609333	A	19991013	BR 1996-9333	19960606
	NZ 310339	A	20000327	NZ 1996-310339	19960606
	NZ 501709	A	20001027	NZ 1996-501709	19960606
	JP 2002502355	T	20020122	JP 1997-503275	19960606
	IL 122346	A	20020523	IL 1996-122346	19960606
	IL 136118	A	20021201	IL 1996-136118	19960606
	RU 2197240	C2	20030127	RU 1998-100456	19960606
	PL 185798	B1	20030731	PL 1996-328723	19960606
	AT 311875	T	20051215	AT 1996-918469	19960606
	EP 1666037	A2	20060607	EP 2005-26521	19960606
	EP 1666037	A3	20060621		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	ES 2255077	T3	20060616	ES 1996-918469	19960606
	US 6124328	A	20000926	US 1997-795956	19970228
	AU 2000043801	A	20000907	AU 2000-43801	20000703
	AU 757406	B2	20030220		
	US 6326387	B1	20011204	US 2000-616539	20000714
PRAI	US 1995-486004	A	19950608		
	AU 1996-61119	A3	19960606		
	EP 1996-918469	A3	19960606		
	IL 1996-122346	A3	19960606		
	NZ 1996-310339	A1	19960606		
	WO 1996-US10123	W	19960606		
	US 1997-795956	A3	19970228		

OS MARPAT 126:272378

IT 145913-35-5 159997-77-0 159997-78-1
159997-95-2 188615-72-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


10/712,456-ALW

(comps. with affinity for FKBP12 in combination with neurotrophic factors for stimulating neurite growth)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188615-72-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)methyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 112 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:276774 CAPLUS

DN 126:343875

TI Preparation of acylated amino acid derivatives for multi-drug resistance therapies and immune suppression.

IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.

PA Vertex Pharmaceuticals Incorporated, USA

SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 881,152, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5620971	A	19970415	US 1994-217982	19940325
	US 5723459	A	19980303	US 1995-377315	19950124
PRAI	US 1991-697785	B2	19910509		
	US 1992-881152	B2	19920511		
	US 1992-952299	B2	19920928		
	US 1993-127814	B2	19930928		
	US 1994-217982	A2	19940325		

OS MARPAT 126:343875

IT 145913-35-5P 159997-77-0P 159997-78-1P


159997-95-2P 160072-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance therapies and immune suppression.)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160072-11-7 CAPLUS


CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph

PAGE 2-A



10/712,456-ALW

L4 ANSWER 113 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:207658 CAPLUS

DN 126:199840

TI Preparation of peptide derivatives as cell adhesion inhibitors

IN Lin, Ko-Chung; Adams, Steven P.; Castro, Alfredo C.; Zimmerman, Craig N.; Cuervo, Julio Hernan; Lee, Wen-Cherng; Hammond, Charles E.; Carter, Mary Beth; Almquist, Ronald G.; Ensinger, Carol Lee

PA Biogen, Inc., USA; Lin, Ko-Chung; Adams, Steven, P.; Castro, Alfredo, C.; Zimmerman, Craig, N.; Cuervo, Julio, Hernan; Lee, Wen-Cherng; Hammond, Charles, E.; Carter, Mary, Beth; et al.

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703094	A1	19970130	WO 1996-US11570	19960711
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	US 6248713	B1	20010619	US 1995-498237	19950711
	CA 2226868	A1	19970130	CA 1996-2226868	19960711
	AU 9664894	A	19970210	AU 1996-64894	19960711
	AU 716276	B2	20000224		
	EP 842196	A1	19980520	EP 1996-924444	19960711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1193325	A	19980916	CN 1996-196380	19960711
	HU 9802202	A2	19990128	HU 1998-2202	19960711
	BR 9609782	A	19990309	BR 1996-9782	19960711
	JP 11511124	T	19990928	JP 1996-505989	19960711
	NZ 312950	A	20000128	NZ 1996-312950	19960711
	EE 3694	B1	20020415	EE 1997-362	19960711
	EE 200200384	A	20021015	EE 2002-384	19960711
	PL 188446	B1	20050228	PL 1996-324491	19960711
	IL 122783	A	20050831	IL 1996-122783	19960711
	RO 121032	B1	20061130	RO 1998-33	19960711
	TW 570927	B	20040111	TW 1996-85108493	19960712
	FI 9800033	A	19980305	FI 1998-33	19980109
	NO 9800097	A	19980311	NO 1998-97	19980109
	BG 63876	B1	20030430	BG 1998-102241	19980210
	US 6239108	B1	20010529	US 1998-983391	19980810
	US 6596687	B1	20030722	US 2000-482296	20000113
	AU 758886	B2	20030403	AU 2000-36445	20000525
	US 6875743	B1	20050405	US 2000-724139	20001128
PRAI	US 1995-498237	A	19950711		
	AU 1996-64894	A3	19960711		
	WO 1996-US11570	W	19960711		
	US 1998-983391	A1	19980810		
OS	MARPAT 126:199840				
IT	187736-26-1P	187736-27-2P	187736-28-3P		
	187736-29-4P	187736-30-7P	187736-31-8P		
	187736-32-9P	187736-33-0P	187736-34-1P		
	187736-35-2P	187736-36-3P	187736-97-6P		
	187736-98-7P	187737-36-6P	187738-01-8P		
	187738-02-9P	187738-03-0P	187738-05-2P		
	187738-06-3P	187738-07-4P	187738-08-5P		


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide derivs. as cell adhesion inhibitors)

RN 187736-26-1 CAPLUS

CN L- α -Asparagine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-27-2 CAPLUS

CN L-Leucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-28-3 CAPLUS

CN L-Valinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-29-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-30-7 CAPLUS

CN L- α -Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-31-8 CAPLUS

CN L-Threoninamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187736-32-9 CAPLUS

CN L-Methioninamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187736-33-0 CAPLUS

CN D-Aspartamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-34-1 CAPLUS

CN D- α -Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187736-35-2 CAPLUS


CN L-Tryptophanamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 187736-36-3 CAPLUS

CN D-Serinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-97-6 CAPLUS

CN L- α -Asparagine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-98-7 CAPLUS

CN L-Valinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187737-36-6 CAPLUS

CN L-Aspartic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-01-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187738-02-9 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L-α-aspartyl-, 3-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187738-03-0 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L-α-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-05-2 CAPLUS

CN L-α-Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187738-06-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187738-07-4 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-08-5 CAPLUS

CN L-Glutamic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 114 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:205101 CAPLUS
DN 126:199834
TI Preparation of amino acid derivatives as thrombin inhibitors
IN Gustafsson, David; Nystroem, Jan-Erik
PA Astra Aktiebolag, Swed.; Gustafsson, David; Nystroem, Jan-Erik
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9702284	A1	19970123	WO 1996-SE878	19960702
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	ZA 9605344	A	19970106	ZA 1996-5344	19960624
	TW 585853	B	20040501	TW 1996-85107577	19960624
	CA 2226256	A1	19970123	CA 1996-2226256	19960702
	AU 9663253	A	19970205	AU 1996-63253	19960702
	AU 709710	B2	19990902		
	EP 836615	A1	19980422	EP 1996-922355	19960702
	EP 836615	B1	20030423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1195354	A	19981007	CN 1996-196781	19960702
	HU 9802315	A2	19990128	HU 1998-2315	19960702
	BR 9609447	A	19990302	BR 1996-9447	19960702
	JP 11508591	T	19990727	JP 1996-505071	19960702
	NZ 311854	A	20000623	NZ 1996-311854	19960702
	RU 2176645	C2	20011210	RU 1998-102188	19960702
	AT 238342	T	20030515	AT 1996-922355	19960702
	PL 185606	B1	20030630	PL 1996-324483	19960702
	PT 836615	T	20030930	PT 1996-922355	19960702
	ES 2197240	T3	20040101	ES 1996-922355	19960702
	EE 4500	B1	20050615	EE 1997-354	19960702
	NZ 509474	A	20050826	NZ 1996-509474	19960702
	SK 284695	B6	20050908	SK 1997-1804	19960702
	RU 2262508	C2	20051020	RU 2000-128495	19960702
	US 6051568	A	20000418	US 1996-687466	19960807
	NO 9800015	A	19980225	NO 1998-15	19980102
	HK 1008995	A1	20030905	HK 1998-109754	19980807
	US 6337343	B1	20020108	US 2000-537344	20000329
	US 2002042396	A1	20020411	US 2001-995564	20011129
	US 6617320	B2	20030909		
	US 2004087647	A1	20040506	US 2003-606349	20030626
	US 6921758	B2	20050726		
PRAI	SE 1995-2487	A	19950706		
	SE 1995-2504	A	19950707		
	SE 1995-2505	A	19950707		
	SE 1995-3923	A	19951107		
	SE 1995-4349	A	19951205		
	GB 1995-26411	A	19951222		
	RU 1998-102188	A	19960702		
	WO 1996-SE878	W	19960702		
	US 1996-687466	A3	19960807		
	US 2000-537344	A1	20000329		

10/712,456-ALW

US 2001-995564 A1 20011129
OS MARPAT 126:199834
IT 187751-57-1P 187751-58-2P 187751-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as thrombin inhibitors)
RN 187751-57-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187751-58-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 187751-57-1
CMF C22 H26 N4 O5


Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2


10/712,456-ALW



RN 187751-93-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-, monohydrochloride, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 187752-83-6P 187753-36-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of amino acid derivs. as thrombin inhibitors)

RN 187752-83-6 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187753-36-2 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



L4 ANSWER 115 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:151521 CAPLUS

DN 126:157396

TI Preparation of 3-phenylheterocycloalkyl-2,4-dione enols as pesticides and herbicides

IN Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Dollinger, Markus; Santel, Hans-Joachim; Graff, Alan; Andersch, Wolfram

PA Bayer A.-G., Germany

SO Ger. Offen., 135 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19603332	A1	19970102	DE 1996-19603332	19960131
	CA 2225830	A1	19970123	CA 1996-2225830	19960617
	CA 2532743	A1	19970123	CA 1996-2532743	19960617
	WO 9702243	A1	19970123	WO 1996-EP2601	19960617
	W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9663561	A	19970205	AU 1996-63561	19960617
	AU 707357	B2	19990708		
	EP 835243	A1	19980415	EP 1996-922817	19960617
	EP 835243	B1	20030129		
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL				
	CN 1193960	A	19980923	CN 1996-196456	19960617
	HU 9802279	A2	19990128	HU 1998-2279	19960617
	BR 9609301	A	19990525	BR 1996-9301	19960617
	JP 11510481	T	19990914	JP 1996-504750	19960617
	ES 2189877	T3	20030716	ES 1996-922817	19960617
	IN 1996DE01384	A	20050701	IN 1996-DE1384	19960624
	ZA 9605516	A	19970206	ZA 1996-5516	19960628
	TW 410141	B	20001101	TW 1996-85107798	19960628
	US 5994274	A	19991130	US 1997-981610	19971223
	US 6251830	B1	20010626	US 1999-360510	19990726
	US 2002022575	A1	20020221	US 2001-839481	20010420
	US 6469196	B2	20021022		
	CN 1362397	A	20020807	CN 2001-138493	20011114
	US 2003144504	A1	20030731	US 2002-197720	20020718
	US 6759548	B2	20040706		
PRAI	DE 1995-19523850	A1	19950630		
	DE 1996-19603332	A	19960131		
	CA 1996-2225830	A3	19960617		
	WO 1996-EP2601	W	19960617		
	US 1997-981610	A3	19971223		
	US 1999-360510	A3	19990726		
	US 2001-839481	A3	20010420		
OS	MARPAT 126:157396				
IT	186748-83-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation of 3-phenylheterocycloalkyl-2,4-dione enols as pesticides and herbicides)				
RN	186748-83-4 CAPLUS				
CN	Proline, 1-[(2-bromo-4,6-dimethylphenyl)acetyl]-4,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)				


10/712,456-ALW




L4 ANSWER 116 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:127734 CAPLUS
 DN 126:220788
 TI The conformational change responsible for AT1 receptor activation is dependent upon two Juxtaposed asparagine residues on transmembrane helixes III and VII
 AU Balmforth, Anthony J.; Lee, Alison J.; Warburton, Philip; Donnelly, Dan; Ball, Stephen G.
 CS Inst. Cardiovascular Res., Univ. Leeds, Leeds, LS2 9JT, UK
 SO Journal of Biological Chemistry (1997), 272(7), 4245-4251
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 IT 188013-77-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (conformational change responsible for AT1 receptor activation is dependent upon two Juxtaposed asparagine residues on transmembrane helixes III and VII)
 RN 188013-77-6 CAPLUS
 CN Angiotensin II, 5-L-isoleucine-6-[(2S)-2-(4-aminophenyl)glycine]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 117 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:41800 CAPLUS

DN 126:74741

TI Alkyl dihalogenated phenyl-substituted keto enols useful as pesticides and herbicides

IN Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Dollinger, Markus; Santel, Hans-Joachim; et al.

PA Bayer A.-G., Germany; Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; et al.

SO PCT Int. Appl., 231 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9635664	A1	19961114	WO 1996-EP1781	19960429
	W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	DE 19545467	A1	19961114	DE 1995-19545467	19951206
	IN 1996DE00865	A	20050311	IN 1996-DE865	19960423
	CA 2220440	A1	19961114	CA 1996-2220440	19960429
	AU 9657626	A	19961129	AU 1996-57626	19960429
	EP 825982	A1	19980304	EP 1996-914146	19960429
	EP 825982	B1	20021127		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	CN 1189153	A	19980729	CN 1996-195072	19960429
	CN 1131209	B	20031217		
	BR 9608229	A	19981229	BR 1996-8229	19960429
	JP 11505220	T	19990518	JP 1996-533707	19960429
	ES 2184858	T3	20030416	ES 1996-914146	19960429
	CN 1473814	A	20040211	CN 2003-2003136022	19960429
	ZA 9603633	A	19961125	ZA 1996-3633	19960508
	US 6316486	B1	20011113	US 1997-945664	19971031
	US 6380246	B1	20020430	US 1999-404424	19990923
	US 2003199572	A1	20031023	US 2001-17695	20011214
	US 6858741	B2	20050222		
	US 2005164885	A1	20050728	US 2004-903550	20040730
PRAI	DE 1995-19516258	A	19950509		
	DE 1995-19545467	A	19951206		
	WO 1996-EP1781	W	19960429		
	WO 1996-EP17871	W	19960429		
	US 1997-945664	B3	19971031		
	US 1997-945665	A3	19971031		
	US 1999-404424	A3	19990923		
	US 2001-17695	A3	20011214		

OS MARPAT 126:74741

IT 185152-87-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of alkyl dihalophenyl-substituted keto enols as pesticides and herbicides)

RN 185152-87-8 CAPLUS

CN Proline, 1-[(2,6-dichloro-4-methylphenyl)acetyl]-4,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW



L4 ANSWER 118 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:9927 CAPLUS

DN 126:144109

TI Preparation of substituted bicyclic 3-arylpyrrolidine-2,4-dione derivatives as insecticides, acaricides, and herbicides

IN Santel, Hans J.; Schmidt, Robert R.; Wachendorff-neumann, Ulrike; Erdelen, Christoph; Bretschneider, Thomas; Fischer, Reiner; Hagemann, Hermann; Kruger, Bernd-wieland; Lurssen, Klaus

PA Bayer A.-G., Germany

SO U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 134,430, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5585384	A	19961217	US 1994-292111	19940817
	DE 4102778	A1	19920806	DE 1991-4102778	19910131
	US 5288874	A	19940222	US 1992-826303	19920124
	US 5693663	A	19971202	US 1996-700264	19960820
PRAI	DE 1991-4102778	A	19910131		
	US 1992-826303	A3	19920124		
	US 1993-134430	B2	19931008		
	US 1994-292111	A3	19940817		

OS CASREACT 126:144109; MARPAT 126:144109


IT 144946-35-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of substituted bicyclic arylpyrrolidinedione derivs. as insecticides, acaricides, and herbicides)

RN 144946-35-0 CAPLUS

CN Proline, 4,5-dimethyl-1-[(2,4,6-trimethylphenyl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 144946-36-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of substituted bicyclic arylpyrrolidinedione derivs. as insecticides, acaricides, and herbicides)

RN 144946-36-1 CAPLUS

CN L-Proline, 4-hydroxy-1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



L4 ANSWER 119 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:593835 CAPLUS
 DN 125:248489
 TI Preparation of dipeptide derivatives as cell adhesion inhibitors
 IN Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng; Castro, Alfredo C.;
 Zimmerman, Craig N.; Hammond, Charles E.; Liao, Yu-Sheng; Cuervo, Julio
 Hernan; Singh, Juswinder
 PA Biogen, Inc., USA
 SO PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9622966	A1	19960801	WO 1996-US1349	19960118
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
	US 6306840	B1	20011023	US 1995-376372	19950123
	CA 2211181	A1	19960801	CA 1996-2211181	19960118
	AU 9649115	A	19960814	AU 1996-49115	19960118
	AU 718926	B2	20000504		
	EP 805796	A1	19971112	EP 1996-905316	19960118
	EP 805796	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	BR 9606778	A	19980106	BR 1996-6778	19960118
	CN 1177343	A	19980325	CN 1996-192270	19960118
	HU 9702461	A2	19980428	HU 1997-2461	19960118
	HU 223350	B1	20040628		
	JP 10513160	T	19981215	JP 1996-523071	19960118
	EP 1142867	A2	20011010	EP 2001-107877	19960118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	AT 229498	T	20021215	AT 1996-905316	19960118
	ES 2183937	T3	20030401	ES 1996-905316	19960118
	CZ 291556	B6	20030416	CZ 1997-2340	19960118
	PT 805796	T	20030430	PT 1996-905316	19960118
	EE 4111	B1	20030815	EE 1997-172	19960118
	SK 283724	B6	20031202	SK 1997-987	19960118
	PL 187313	B1	20040630	PL 1996-321848	19960118
	RO 119885	B1	20050530	RO 1997-1369	19960118
	TW 500714	B	20020901	TW 1996-85100690	19960122
	IL 116846	A	20021110	IL 1996-116846	19960122
	NO 9703384	A	19970919	NO 1997-3384	19970722
	NO 320914	B1	20060213		
	FI 9703087	A	19970922	FI 1997-3087	19970722
	BG 63383	B1	20011231	BG 1997-101841	19970821
	US 6376538	B1	20020423	US 1997-875321	19970919
	HK 1005241	A1	20030822	HK 1998-104006	19980508
	AU 766538	B2	20031016	AU 2000-62432	20001002
	US 2003083267	A1	20030501	US 2001-935461	20010822
	US 6624152	B2	20030923		
	US 2003018016	A1	20030123	US 2001-2341	20011023
	US 6630512	B2	20031007		
	US 7001921	B1	20060221	US 2003-625626	20030724
	US 2006166866	A1	20060727	US 2003-679478	20031007

10/712,456-ALW

PRAI	US 1995-376372	A2	19950123
AU	1996-49115	A3	19960118
EP	1996-905316	A3	19960118
WO	1996-US1349	W	19960118
US	1997-875321	A3	19970919
US	2001-935461	A1	20010822
US	2001-2341	A1	20011023

OS MARPAT 125:248489


IT 181519-89-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of β -amino acid dipeptide derivs. as cell adhesion inhibitors)

RN 181519-89-1 CAPLUS

CN 1,3-Benzodioxole-5-propanoic acid, β -[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (β S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 121 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:440544 CAPLUS
DN 125:114472
TI Preparation of pyrrolidinecarboxylic acid derivatives as angiotensin II antagonists.
IN Yanagisawa, Hiroaki; Kanezaki, Takuo; Amamiya, Yosha; Furusawa, Juji; Mizuno, Makoto
PA Sankyo Co, Japan
SO Jpn. Kokai Tokkyo Koho, 259 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08092207	A	19960409	JP 1995-189453	19950725
PRAI	JP 1995-189453	A	19950725		
	JP 1994-174452		19940726		

OS MARPAT 125:114472


IT 178866-87-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178866-87-0 CAPLUS

CN L-Proline, 1-[(4-hydroxyphenyl)acetyl]-4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178867-28-2P 178868-48-9P 178868-49-0P
178868-50-3P 178868-51-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178867-28-2 CAPLUS

CN L-Proline, 4-azido-1-[[4-(methoxymethoxy)phenyl]acetyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 178868-48-9 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-49-0 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[(1-oxobutyl)[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178868-50-3 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[(1-oxobutyl)[[2'-[1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 178868-51-4 CAPLUS

CN L-Proline, 1-[(4-hydroxyphenyl)acetyl]-4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 122 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:334305 CAPLUS
DN 125:75231
TI Intestinal absorption studies on peptide mimetic α -methyldopa
prodrugs
AU Wang, Hui-Po; Lu, Hsiao-Hwa; Lee, Jia-Shuai; Cheng, Chih-Yuan; Mah,
Jin-Ran; Ku, Ching-Yi; Hsu, Wenlie; Yen, Chen-Fang; Lin, Chun-Jung; et al.
CS College Medicine, National Taiwan University, Taipei, Taiwan
SO Journal of Pharmacy and Pharmacology (1996), 48(3), 270-276
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
IT 178620-95-6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(intestinal absorption studies on peptide mimetic methyldopa prodrugs)
RN 178620-95-6 CAPLUS
CN L-Tyrosine, 3-hydroxy-N-[1-[D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]- α -
methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 123 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:857584 CAPLUS
DN 124:30395
TI Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug
AU Wang, Hui-Po; Lee, Jia-Shuai; Tsai, Ming-Cheng; Lu, Hsiao-Hwa; Hsu, Wenlie
CS School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(19), 2195-8
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
IT 171860-38-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)
RN 171860-38-1 CAPLUS
CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)
RN 146622-05-1 CAPLUS
CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 171860-39-2P

10/712,456-ALW


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)

RN 171860-39-2 CAPLUS

CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME).

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 124 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:835486 CAPLUS
DN 123:257395
TI Imidazolyl amino acid derivatives as angiotensin II antagonists
IN Boyd, Donald B.; Hauser, Kenneth L.; Lifer, Sherryl L.; Marshall, Winston S.; Palkowitz, Alan D.; Pfeifer, William; Reel, Jon K.; Simon, Richard L.; Steinberg, Mitchell I.; et al.
PA Eli Lilly and Co., USA
SO U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 892,867, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5401851	A	19950328	US 1993-49917	19930420
	CA 2097462	A1	19931204	CA 1993-2097462	19930601
	HU 64328	A2	19931228	HU 1993-1603	19930601
	IL 105877	A	19980715	IL 1993-105877	19930601
	NO 9302005	A	19931206	NO 1993-2005	19930602
	EP 573271	A1	19931208	EP 1993-304264	19930602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9339985	A	19940120	AU 1993-39985	19930602
	AU 667903	B2	19960418		
	RU 2110515	C1	19980510	RU 1993-46497	19930602
	CN 1085897	A	19940427	CN 1993-107578	19930603
	CN 1045768	B	19991020		
	JP 07304752	A	19951121	JP 1993-133212	19930603
	PL 173340	B1	19980227	PL 1993-299176	19930603
	US 5484780	A	19960116	US 1994-355778	19941214
PRAI	US 1992-892867	B2	19920603		
	US 1993-49917	A	19930420		

OS CASREACT 123:257395; MARPAT 123:257395


IT 157177-14-5P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(imidazolyl amino acid derivs. as angiotensin II antagonists)

RN 157177-14-5 CAPLUS

CN L-Proline, 4-[4-[2-(2-carboxy-1-pyrrolidinyl)-2-oxoethyl]phenoxy]-1-[1-oxo-2-[4-[(2-sulfo benzoyl)amino]-1H-imidazol-1-yl]octyl]-, [1(S*), 2 α , 4 α (R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 774227-02-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(imidazolyl amino acid derivs. as angiotensin II antagonists)


RN 774227-02-0 CAPLUS

CN L-Proline, 4-[4-[2-[(2S)-2-carboxy-1-pyrrolidinyl]-2-oxoethyl]phenoxy]-,

10/712,456-ALW

2-methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 125 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:733495 CAPLUS
DN 124:9454
TI Tripeptide antithrombotic agents
IN Gesellchen, Paul D.; Shuman, Robert T.
PA Eli Lilly and Co., USA
SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 756,091.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5430023	A	19950704	US 1993-121134	19930914
	IL 99527	A	19970814	IL 1991-99527	19910919
	CA 2052013	A1	19920329	CA 1991-2052013	19910923
	CA 2052013	C	20010130		
	HU 59162	A2	19920428	HU 1991-3037	19910923
	HU 217441	B	20000128		
	ZA 9107572	A	19930323	ZA 1991-7572	19910923
	CZ 285980	B6	19991215	CZ 1991-2913	19910923
	SK 281731	B6	20010710	SK 1991-2913	19910923
	NO 9103773	A	19920330	NO 1991-3773	19910926
	NO 309984	B1	20010430		
	AU 9184780	A	19920402	AU 1991-84780	19910926
	AU 645347	B2	19940113		
	RU 2077538	C1	19970420	RU 1991-5001658	19910926
	KR 219993	B1	19991001	KR 1991-16772	19910926
	AT 211147	T	20020115	AT 1995-201960	19910926
	ES 2169105	T3	20020701	ES 1995-201960	19910926
	AT 234857	T	20030415	AT 1991-308785	19910926
	ES 2194835	T3	20031201	ES 1991-308785	19910926
	FI 9104566	A	19920329	FI 1991-4566	19910927
	FI 107733	B1	20010928		
	CN 1060472	A	19920422	CN 1991-109042	19910927
	CN 1036399	B	19971112		
	BR 9104181	A	19920602	BR 1991-4181	19910927
	JP 04257600	A	19920911	JP 1991-249093	19910927
	JP 3023019	B2	20000321		
	EP 643073	A1	19950315	EP 1994-306667	19940912
	EP 643073	B1	19971126		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	ZA 9407015	A	19960312	ZA 1994-7015	19940912
	AT 160574	T	19971215	AT 1994-306667	19940912
	ES 2110186	T3	19980201	ES 1994-306667	19940912
	IL 110933	A	19981227	IL 1994-110933	19940912
	PL 176448	B1	19990531	PL 1994-305009	19940912
	CZ 286139	B6	20000112	CZ 1994-2220	19940912
	CA 2131982	A1	19950315	CA 1994-2131982	19940913
	CA 2131982	C	20030729		
	FI 9404231	A	19950315	FI 1994-4231	19940913
	NO 9403402	A	19950315	NO 1994-3402	19940913
	NO 310240	B1	20010611		
	AU 9472948	A	19950330	AU 1994-72948	19940913
	AU 674773	B2	19970109		
	HU 67849	A2	19950529	HU 1994-2626	19940913
	HU 220620	B1	20020328		
	BR 9403542	A	19950620	BR 1994-3542	19940913
	JP 07149791	A	19950613	JP 1994-219854	19940914
	CN 1106819	A	19950816	CN 1994-115165	19940914
	CN 1055698	B	20000823		

10/712,456-ALW

RU 2105010	C1	19980220	RU 1994-34734	19940914
HU 9500399	A3	19951030	HU 1995-399	19950622
PRAI US 1990-589553	B2	19900928		
US 1991-756091	A2	19910906		
US 1993-121134	A	19930914		
OS CASREACT 124:9454; MARPAT 124:9454				
IT 141972-92-1P 141972-93-2P 141973-10-6P				
171228-00-5P 171228-01-6P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(tripeptide antithrombotic agents)				
RN 141972-92-1	CAPLUS			
CN	L-Prolinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-(9CI) (CA INDEX NAME)			

Absolute stereochemistry.




RN 141972-93-2 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1
CMF C24 H36 N6 O6


Absolute stereochemistry.




CM 2

10/712,456-ALW

CRN 64-19-7
CMF C2 H4 O2




RN 141973-10-6 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-
(9CI) (CA INDEX NAME)



RN 171228-00-5 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, acetate (9CI) (CA INDEX NAME)

CM 1


CRN 141973-10-6
CMF C25 H38 N6 O6



CM 2

10/712,456-ALW


CRN 64-19-7
CMF C2 H4 O2



RN 171228-01-6 CAPLUS
CN L-Prolinamide, N-acetyl-D-2-(4-methoxyphenyl)glycyl-N-[4-
[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, acetate (9CI) (CA INDEX
NAME)


CM 1

CRN 141973-12-8
CMF C22 H32 N6 O5



CM 2

CRN 64-19-7
CMF C2 H4 O2



10/712,456-ALW

L4 ANSWER 126 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:620916 CAPLUS

DN 123:40809

TI Synthesis of α -methyldopa prodrugs containing dipeptide moieties as tools for intestinal delivery

AU Wang, Hui-Po; Cheng, Chih-Yuan; Ma, Jin-Ran; Lee, Jia-Shuai

CS Coll. Med., Natl. Taiwan Univ., Taipei, Taiwan

SO Journal of the Chinese Chemical Society (Taipei) (1995), 42(3), 561-7

CODEN: JCCTAC; ISSN: 0009-4536

PB Chinese Chemical Society

DT Journal

LA English

IT 164353-64-4


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 164353-64-4 CAPLUS

CN L-Alanine, 2-(3,4-dihydroxyphenyl)-N-[1-[D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 164353-71-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

IT 146622-05-1P 164353-69-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 164353-69-9 CAPLUS

CN L-Alanine, 2-(3,4-dihydroxyphenyl)-N-[1-[N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 127 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:304927 CAPLUS

DN 122:82085

TI Preparation of acyclic peptides as cardiovascular agents (natriuretics).

IN Voges, Klaus Peter; Henning, Rolf; Huebsch, Walter; Lenfers, Jan Bernd;
Beuck, Martin; Theiss, Gudrun; Stasch, Johannes Peter; Hirth-Dietrich,
Claudia

PA Bayer A.-G., Germany

SO Ger. Offen., 73 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4242946	A1	19940623	DE 1992-4242946	19921218
	CA 2151961	A1	19940707	CA 1993-2151961	19931206
	WO 9414840	A1	19940707	WO 1993-EP3431	19931206
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9456970	A	19940719	AU 1994-56970	19931206
	EP 674655	A1	19951004	EP 1994-902694	19931206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	DE 1992-4242946	A	19921218		
	WO 1993-EP3431	W	19931206		
OS	MARPAT 122:82085				
IT	160344-79-6P 160344-80-9P 160344-81-0P				
	160344-82-1P 160344-84-3P 160344-85-4P				
	160344-86-5P 160344-87-6P 160344-88-7P				
	160344-89-8P 160344-90-1P 160344-91-2P				
	160344-92-3P 160344-93-4P 160344-94-5P				
	160344-96-7P 160344-98-9P 160344-99-0P				
	160345-00-6P 160345-02-8P 160345-03-9P				
	160345-04-0P 160345-05-1P 160345-06-2P				
	160345-20-0P 160345-21-1P 160345-23-3P				
	160345-24-4P 160345-25-5P 160345-27-7P				
	160345-28-8P 160345-29-9P 160345-30-2P				
	160345-31-3P 160345-32-4P 160345-33-5P				
	160345-34-6P 160345-35-7P 160345-36-8P				
	160345-37-9P 160345-38-0P 160345-46-0P				
	160345-47-1P 160345-48-2P 160345-49-3P				
	160345-50-6P 160345-51-7P 160345-52-8P				
	160345-56-2P 160345-58-4P 160345-62-0P				
	160345-64-2P 160345-65-3P 160345-66-4P				
	160345-67-5P 160345-68-6P 160345-69-7P				
	160345-74-4P 160345-76-6P 160345-77-7P				
	160345-78-8P 160345-79-9P 160345-82-4P				
	160345-83-5P 160345-84-6P 160345-85-7P				
	160345-86-8P 160345-87-9P 160345-88-0P				
	160345-89-1P 160345-90-4P 160345-91-5P				
	160345-92-6P 160345-93-7P 160345-94-8P				
	160345-95-9P 160345-96-0P 160345-97-1P				
	160345-98-2P 160345-99-3P 160346-00-9P				
	160346-01-0P 160346-02-1P 160346-04-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(preparation of, as cardiovascular agent)				
RN	160344-79-6 CAPLUS				


CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)-N5-[(phenylmethoxy)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A

CC(C)CNCC1=CC=CC=C1

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 160344-81-0 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-trans-4-(phenylmethoxy)-L-prolyl-L-isoleucyl-L-α-aspartyl-N5-formyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160344-82-1 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-trans-4-(phenylmethoxy)-L-prolyl-L-isoleucyl-L-α-aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-84-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160344-85-4 CAPLUS


CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160344-86-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)


10/712,456-ALW

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160344-87-6 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160344-88-7 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-89-8 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160344-90-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-

10/712,456-ALW

isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160344-91-2 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(4-fluorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160344-92-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(3-fluorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160344-93-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[[(4-chlorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160344-94-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160344-96-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-acetyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160344-98-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW





RN 160344-99-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[bis[(3-fluorophenyl)methyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-00-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-(benzoylamino)phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-02-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-[(phenylmethoxy)carbonyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-03-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(3-fluorobenzoyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 160345-04-0 CAPLUS

CN L-Isoleucinamide, 1-[(4-aminophenyl)acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-05-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-(acetamino)phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-06-2 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-20-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-21-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-phenylalanyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-23-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N-(2-methylbutyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-24-4 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N5-[(1,1-dimethylethoxy)carbonyl]-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



— OBU-t

RN 160345-25-5 CAPLUS
 CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-27-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-ornithyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 —NH_2

RN 160345-28-8 CAPLUS



CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-2-methylalanyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160345-29-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-30-2 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 160345-31-3 CAPLUS



CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-2-methylalanyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160345-32-4 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-N-methylglycyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-33-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N-(2-methylbutyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-34-6 CAPLUS


CN L-Norvalinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Pr-n

RN 160345-35-7 CAPLUS


CN L-Norvalinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -glutamyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Pr-n

10/712,456-ALW

RN 160345-36-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

—NH₂



=O

—(CH₂)₃—NH₂

RN 160345-37-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L-asparaginyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-38-0 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-46-0 CAPLUS


CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160345-47-1 CAPLUS

CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-48-2 CAPLUS

CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-49-3 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-50-6 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/712,456-ALW

RN 160345-51-7 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-52-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW





RN 160345-56-2 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(4-fluorophenyl)methyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-alpha-aspartyl-L-arginy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-58-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-[(1,1-dimethylethoxy)carbonyl]-L-ornithyl-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● Li



RN 160345-62-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

—CO₂H

RN 160345-64-2 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-

10/712,456-ALW


prolylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-65-3 CAPLUS



CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-2-methylalanyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-66-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-arginyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160345-67-5 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L-alpha-aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 160345-68-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-3-methyl-L-valyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 160345-69-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-N-methylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-74-4 CAPLUS


CN L-Lysinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160345-76-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-77-7 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-norvalyl-L-arginyl- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.





PAGE 1-B



RN 160345-78-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-N-methylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-79-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-norvalyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-82-4 CAPLUS

CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-glutaminyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-83-5 CAPLUS

CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L-glutaminy-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 160345-84-6 CAPLUS


CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -glutamyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 160345-85-7 CAPLUS

CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-1-aminocyclopentanecarbonyl-L- α -glutamyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-86-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-87-9 CAPLUS


CN L-Lysinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-88-0 CAPLUS

10/712,456-ALW


CN L-Lysinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 160345-89-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-90-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-D-prolyl-N-methylglycyl-L-α-aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-92-6 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-N5-[(1,1-dimethylethoxy)carbonyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 160345-93-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-propyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-94-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-propyl-L-isoleucyl-L-α-glutamyl-N5-acetyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-95-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-96-0 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(cyclohexylmethyl)-N5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 160345-97-1 CAPLUS
 CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)-N5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/712,456-ALW

RN 160345-98-2 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -glutamyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160345-99-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 160346-02-1 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-2-carboxyglycyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 160346-04-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-3-methyl-L-valyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 128 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:304926 CAPLUS

DN 122:82084

TI Preparation of sulfur-containing peptides as antihypertensives.

IN Voges, Klaus Peter; Henning, Rolf; Lenfers, Jan Bernd; Dressel, Juergen; Beuck, Martin; Theiss, Gudrun; Stasch, Johannes Peter; Hirth-Dietrich, Claudia; Bischoff, Erwin

PA Bayer A.-G., Germany

SO Ger. Offen., 37 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4242945	A1	19940623	DE 1992-4242945	19921218
	CA 2151959	A1	19940707	CA 1993-2151959	19931206
	WO 9414839	A1	19940707	WO 1993-EP3430	19931206
	W:			AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN	
	RW:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9456969	A	19940719	AU 1994-56969	19931206
	EP 674654	A1	19951004	EP 1994-902693	19931206
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	
	JP 08504779	T	19960521	JP 1993-514731	19931206
PRAI	DE 1992-4242945	A	19921218		
	WO 1993-EP3430	W	19931206		
OS	MARPAT 122:82084				
IT	160344-71-8P 160344-72-9P 160344-73-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as intermediate for peptide derivative natriuretic)				
RN	160344-71-8 CAPLUS				
CN	L-Isoleucine, N-[1-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]acetyl]-L-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 160344-72-9 CAPLUS

CN L-Isoleucine, N-[1-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]acetyl]-L-prolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 160344-73-0 CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as natriuretic)

RN 160344-18-3 CAPLUS

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 160344-19-4 CAPLUS

CN L-Ornithinamide, 1-[[4-[[2-[(3-mercapto-1-oxopropyl)amino]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 160344-27-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160344-35-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[2-[(mercaptoacetyl)amino]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)



RN 160344-36-5 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[1-oxo-3-phenyl-2-[[[(triphenylmethyl)thio]acetyl]amino]propyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-61-6 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160344-68-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-arginyl-, (R)- (9CI) (CA INDEX NAME)





RN 160344-69-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160401-07-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl-, (S)- (9CI). (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






10/712,456-ALW

L4 ANSWER 129 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:304885 CAPLUS
DN 122:106532
TI Preparation of amino acid- and peptideamides as tachykinin antagonists
IN Esser, Franz; Schnorrenberg, Gerd; Dollinger, Horst; Jung, Birgit;
Buerger, Erich
PA Boehringer Ingelheim KG, Germany; Boehringer Ingelheim International GmbH
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9405693	A1	19940317	WO 1993-EP2329	19930828
	W: AU, BG, BY, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 4243496	A1	19940310	DE 1992-4243496	19921222
	DE 4315437	A1	19941110	DE 1993-4315437	19930508
	EP 610487	A1	19940817	EP 1993-919208	19930828
	EP 610487	B1	19991110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07501085	T	19950202	JP 1993-506852	19930828
	AU 677792	B2	19970508	AU 1993-49547	19930828
	AU 9349547	A	19940329		
	CN 1086222	A	19940504	CN 1993-117349	19930903
	FI 9401987	A	19940429	FI 1994-1987	19940429
	NO 9401611	A	19940502	NO 1994-1611	19940502
	GR 3032395	T3	20000531	GR 2000-400089	20000114
PRAI	DE 1992-4229447	A	19920903		
	DE 1992-4243496	A	19921222		
	DE 1993-4315437	A	19930508		
	WO 1993-EP2329	W	19930828		
OS	MARPAT 122:106532				
IT	159136-74-0P 160342-34-7P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as neurokinin antagonist)				
RN	159136-74-0 CAPLUS				
CN	Butanamide, 1-[(3,4-dimethoxyphenyl)acetyl]-trans-4-hydroxy-L-prolyl-N-methyl-4-phenyl-N-(phenylmethyl)-L-2-amino- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 160342-34-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-hydroxy-N-[2-[4-(2-methylphenyl)-1-piperazinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-1-[(4-nitrophenyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/712,456-ALW



● HCl


10/712,456-ALW

L4 ANSWER 130 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:274880 CAPLUS
DN 122:55896
TI 1-(2-oxoacetyl)piperidine-2-carboxylic acid derivatives as
multi-drug-resistant cancer cell sensitizers
IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9407858	A1	19940414	WO 1993-US9145	19930927
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	NZ 314207	A	20001222	NZ 1993-314207	19930727
	IL 107109	A	19990312	IL 1993-107109	19930926
	AU 9351648	A	19940426	AU 1993-51648	19930927
	AU 690082	B2	19980423		
	EP 662958	A1	19950719	EP 1993-922748	19930927
	EP 662958	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08502256	T	19960312	JP 1994-509216	19930927
	JP 3635493	B2	20050406		
	HU 72046	A2	19960328	HU 1995-890	19930927
	RU 2158258	C2	20001027	RU 1995-110938	19930927
	CZ 287396	B6	20001115	CZ 1995-769	19930927
	RO 117791	B1	20020730	RO 1995-599	19930927
	AT 229506	T	20021215	AT 1993-922748	19930927
	PT 662958	T	20030430	PT 1993-922748	19930927
	CA 2144962	C	20030520	CA 1993-2144962	19930927
	ES 2188595	T3	20030701	ES 1993-922748	19930927
	SK 284129	B6	20040908	SK 1995-389	19930927
	CN 1088577	A	19940629	CN 1993-118201	19930928
	CN 1086386	B	20020619		
	CN 1494906	A	20040512	CN 2002-2002108738	19930928
	FI 9501454	A	19950327	FI 1995-1454	19950327
	NO 9501162	A	19950529	NO 1995-1162	19950327
	NO 305596	B1	19990628		
	HK 1013992	A1	20030815	HK 1998-115242	19981223
PRAI	US 1992-952299	A	19920928		
	WO 1993-US9145	W	19930927		
OS	MARPAT 122:55896				
IT	159997-02-1P 159997-17-8P 159997-77-0P				
	159997-78-1P 159997-95-2P 160072-11-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as sensitizer for multi-drug-resistant cancer cells)				
RN	159997-02-1 CAPLUS				
CN	L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester, (S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/712,456-ALW



RN 159997-17-8 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160072-11-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph

L4 ANSWER 131 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:239986 CAPLUS

DN 122:32011

TI Imidazolyl-substituted prolinamides

IN Mueller-Gliemann, Matthias; Dressel, Juergen; Fey, Peter; Hanko, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich; Beuck, Martin; Kazda, Stanislav; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 20 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4302957	A1	19940804	DE 1993-4302957	19930203
	EP 610697	A1	19940817	EP 1994-100845	19940121
	EP 610697	B1	19970312		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 150018	T	19970315	AT 1994-100845	19940121
	ES 2099494	T3	19970516	ES 1994-100845	19940121
	US 5459156	A	19951017	US 1994-188615	19940127
	JP 06271573	A	19940927	JP 1994-27586	19940201
PRAI	DE 1993-4302957	A	19930203		
OS	CASREACT 122:32011; MARPAT 122:32011				
IT	159582-52-2P 159582-53-3P 159582-54-4P 159582-55-5P 159582-56-6P 159582-57-7P 159582-58-8P 159582-59-9P 159582-60-2P 159582-61-3P 159582-62-4P 159582-63-5P 159582-64-6P 159582-65-7P 159582-66-8P 159582-67-9P 159582-68-0P 159582-69-1P 159582-70-4P 159582-71-5P 159652-40-1P 159652-41-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as angiotensin antagonist)				
RN	159582-52-2 CAPLUS				
CN	L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/712,456-ALW

RN 159582-53-3 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159582-54-4 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-55-5 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-56-6 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159582-57-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 159582-58-8 CAPLUS


CN 1H-Imidazole-5-carboxylic acid, 2-butyl-1-[[4-[2-(2-carboxy-1-pyrrolidinyl)-1-cyclopentyl-2-oxoethyl]phenyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 159582-59-9 CAPLUS


CN 1H-Imidazole-5-carboxylic acid, 1-[[4-[2-[2-(aminocarbonyl)-1-pyrrolidinyl]-1-cyclopentyl-2-oxoethyl]phenyl]methyl]-2-butyl-4-chloro- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 159582-60-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI)
(CA INDEX NAME)



RN 159582-61-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI) (CA INDEX NAME)


10/712,456-ALW



RN 159582-62-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-63-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-64-6 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-65-7 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-66-8 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[4-[1-cyclopentyl-2-oxo-2-[2-[(phenylmethoxy)carbonyl]-1-pyrrolidinyl]ethyl]phenyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-67-9 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[4-[1-cyclopentyl-2-oxo-2-[2-[(phenylmethoxy)carbonyl]-1-pyrrolidinyl]ethyl]phenyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-68-0 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 159582-69-1 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

CCCC1=CN(C(CO)C1c2ccccc2CN(C3CCCC3)C(=O)SC(=O)SC4CCCC4)C=C(Cl)C2=C1C=C(C=C2)C(=O)OC(C)(C)C


CN Glycinamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)

CCCC1=CN(C(=O)O)C(Cl)=C1CN(CCC1=CC=C(C2CCC(CC2)C(=O)N3CCCC3)C4CCCC4)C5=CC=CC=C5C(=O)N[C@@H](C6=CC=CC=C6)C(=O)N


CN Glycinamide, 1-[[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RN 159652-40-1 CAPLUS
CN Glycinamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)



RN 159652-41-2 CAPLUS
CN Glycinamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 132 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:228863 CAPLUS

DN 122:80946

TI Synthesis and antibacterial activity of novel carbapenems with a catechol or hydroxypyridone moiety

AU Sunagawa, Makoto; Sasaki, Akira; Yamaga, Hiroshi; Shinagawa, Hisatoshi; Fukasawa, Masatomo; Sumita, Yoshihiro

CS Development Res. Laboratories I, Sumitomo Pharmaceuticals Res. Cent., Osaka, 554, Japan

SO Journal of Antibiotics (1994), 47(11), 1354-8

CODEN: JANTAJ; ISSN: 0021-8820

PB Japan Antibiotics Research Association

DT Journal

LA English

IT 141817-33-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of carbapenems with a catechol or hydroxypyridine moiety)

RN 141817-33-6 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 133 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:701326 CAPLUS
DN 121:301326
TI Preparation of new dipeptide derivatives as neurokinin antagonists
IN Schnorrenberg, Gerd; Esser, Franz; Dollinger, Horst; Jung, Birgit;
Buerger, Erich
PA Boehringer Ingelheim KG, Germany
SO Ger. Offen., 49 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4243496	A1	19940310	DE 1992-4243496	19921222
	WO 9405693	A1	19940317	WO 1993-EP2329	19930828
	W: AU, BG, BY, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 610487	A1	19940817	EP 1993-919208	19930828
	EP 610487	B1	19991110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07501085	T	19950202	JP 1993-506852	19930828
	HU 70475	A2	19951030	HU 1994-1323	19930828
	AU 677792	B2	19970508	AU 1993-49547	19930828
	AU 9349547	A	19940329		
	AT 186548	T	19991115	AT 1993-919208	19930828
	ES 2137998	T3	20000101	ES 1993-919208	19930828
	EP 979827	A1	20000216	EP 1999-100929	19930828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	ZA 9306472	A	19940627	ZA 1993-6472	19930902
	US 5596000	A	19970121	US 1993-116090	19930902
	FI 9401987	A	19940429	FI 1994-1987	19940429
	NO 9401611	A	19940502	NO 1994-1611	19940502
	US 5849918	A	19981215	US 1995-460964	19950605
	US 6147212	A	20001114	US 1998-111498	19980708
	GR 3032395	T3	20000531	GR 2000-400089	20000114
PRAI	DE 1992-4229447	A1	19920903		
	DE 1992-4243496	A	19921222		
	DE 1993-4315437	A	19930508		
	EP 1993-919208	A3	19930828		
	WO 1993-EP2329	W	19930828		
	US 1993-116090	A3	19930902		
	US 1995-460964	A3	19950605		
OS	CASREACT 121:301326; MARPAT 121:301326				
IT	159136-74-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as neurokinin antagonist)				
RN	159136-74-0 CAPLUS				
CN	Butanamide, 1-[(3,4-dimethoxyphenyl)acetyl]-trans-4-hydroxy-L-prolyl-N-methyl-4-phenyl-N-(phenylmethyl)-L-2-amino- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 134 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1994:680551 CAPLUS
 DN 121:280551
 TI Preparation of piperidylcarbonylamino derivatives as platelet aggregation inhibitors
 IN Tjoeng, Foe S.; Toth, Mihaly V.
 PA G.D. Searle and Co., USA; Monsanto Co.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9419341	A1	19940901	WO 1994-US513	19940125
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6268380	B1	20010731	US 1993-19923	19930219
	AU 9461236	A	19940914	AU 1994-61236	19940125
PRAI	US 1993-19923	A	19930219		
	WO 1994-US513	W	19940125		
OS	MARPAT 121:280551				
IT	158983-01-8P 158983-02-9P 158983-03-0P 158983-04-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of piperidylcarbonylamino derivs. as platelet aggregation inhibitors)				
RN	158983-01-8 CAPLUS				
CN	β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)				



RN 158983-02-9 CAPLUS
 CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


10/712,456-ALW

CRN 158983-01-8
CMF C23 H28 N6 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 158983-03-0 CAPLUS
CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 158983-04-1 CAPLUS

10/712,456-ALW

CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 158983-03-0
CMF C21 H24 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 158983-09-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidylcarbonylamino derivs. as platelet aggregation inhibitors)

RN 158983-09-6 CAPLUS

CN L-Proline, 1-[[[4-(4-cyanophenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 135 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:558192 CAPLUS

DN 121:158192

TI Preparation of heterocyclyl-substituted L-proline as angiotensin II antagonists

IN Boyd, Donald Bradford; Hauser, Kenneth Lee; Lifer, Sherryl Lynn; Marshall, Winston Stanley; Palkowitz, Alan David; Pfeifer, William; Reel, Jon Kevin; Simon, Richard Lee; Steinberg, Mitchell Irvin; et al.

PA Eli Lilly and Co., USA

SO Eur. Pat. Appl., 56 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 573271	A1	19931208	EP 1993-304264	19930602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5401851	A	19950328	US 1993-49917	19930420
PRAI	US 1992-892867	A	19920603		
	US 1993-49917	A	19930420		

OS MARPAT 121:158192


IT 157177-14-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 157177-14-5 CAPLUS

CN L-Proline, 4-[4-[2-(2-carboxy-1-pyrrolidiny)-2-oxoethyl]phenoxy]-1-[1-oxo-2-[4-[(2-sulfo benzoyl)amino]-1H-imidazol-1-yl]octyl]-, [1(S*),2 α ,4 α (R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 136 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:557541 CAPLUS

DN 121:157541

TI (2-oxoquinolin-1-yl)methylphenylacetic acid antihypertensives and antiatherosclerotics

IN Mueller-Gliemann, Matthias; Dressel, Juergen; Fey, Peter; Hanco, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich; Raddatz, Siegfried; Beuck, Martin; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 17 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 4301900	A1	19940728	DE 1993-4301900	19930125
	EP 608709	A1	19940803	EP 1994-100366	19940112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08003139	A	19960109	JP 1994-18804	19940120
PRAI	DE 1993-4301900	A	19930125		
OS	MARPAT 121:157541				
IT	157312-10-2P 157312-11-3P 157312-12-4P 157312-14-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antihypertensive and antiatherosclerotic)				
RN	157312-10-2 CAPLUS				
CN	L-Proline, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]- , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 157312-11-3 CAPLUS

CN L-Proline, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/712,456-ALW



RN 157312-12-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 157312-14-6 CAPLUS


CN Glycinamide, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-L-prolyl-2-phenyl- (9CI) (CA INDEX NAME)

10/712,456-ALW




L4 ANSWER 137 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1993:626402 CAPLUS
 DN 119:226402
 TI Intramolecular photochemistry in β -turned dipeptide bridged molecules
 AU Tamiaki, Hitoshi; Kiyomori, Ayumu; Maruyama, Kazuhiro
 CS Fac. Sci., Kyoto Univ., Kyoto, 606, Japan
 SO Bulletin of the Chemical Society of Japan (1993), 66(6), 1768-72
 CODEN: BCSJA8; ISSN: 0009-2673
 DT Journal
 LA English
 IT 150881-15-5P 150881-16-6P 150881-17-7P
 150881-18-8P 150881-19-9P 150881-20-2P
 150903-47-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and photolysis of, effect of alkyl chain and conformation on
 quantum yield of)
 RN 150881-15-5 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-propyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 150881-16-6 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-butyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 150881-17-7 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-pentyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 150881-18-8 CAPLUS

CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-hexyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150881-19-9 CAPLUS

CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-heptyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150881-20-2 CAPLUS

CN L-Serinamide, 1-[(4-benzoylphenyl)acetyl]-D-prolyl-N-methyl-O-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150903-47-2 CAPLUS

CN L-Serinamide, 1-[(4-benzoylphenyl)acetyl]-D-prolyl-O-methyl-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 138 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:495338 CAPLUS

DN 119:95338

TI Preparation of 1-[(3,4,5-trimethoxyphenyl)glyoxyl]pipecolic esters as immunosuppressive compounds

IN Armistead, David M.

PA Vertex Pharmaceuticals Inc., USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9219593	A1	19921112	WO 1992-US3913	19920511
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	CA 2102180	A1	19921110	CA 1992-2102180	19920511
	CA 2102180	C	20020723		
	AU 9219957	A	19921221	AU 1992-19957	19920511
	EP 584223	A1	19940302	EP 1992-912076	19920511
	EP 584223	B1	19990811		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 06508125	T	19940914	JP 1992-512042	19920511
	JP 3145709	B2	20010312		
	HU 68332	A2	19950628	HU 1993-3184	19920511
	HU 217621	B	20000328		
	AT 183178	T	19990815	AT 1992-912076	19920511
	ES 2137186	T3	19991216	ES 1992-912076	19920511
	FI 104967	B1	20000515	FI 1993-4925	19931108
	HK 1013994	A1	20000915	HK 1998-115248	19981223
	GR 3031825	T3	20000229	GR 1999-402915	19991111
PRAI	US 1991-697785	A	19910509		
	WO 1992-US3913	A	19920511		
OS	MARPAT 119:95338				
IT	145913-35-5				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(immunosuppressant)				
RN	145913-35-5 CAPLUS				
CN	L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 139 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:169566 CAPLUS
DN 118:169566
TI Highly selective tripeptide thrombin inhibitors
AU Shuman, Robert T.; Rothenberger, Robert B.; Campbell, Charles S.; Smith, Gerald F.; Gifford-Moore, Donetta S.; Gesellchen, Paul D.
CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SO Journal of Medicinal Chemistry (1993), 36(3), 314-19
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 118:169566
IT 146622-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and peptide coupling of, with arginine lactam)
RN 146622-05-1 CAPLUS
CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141972-93-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thrombin-inhibiting activity of)
RN 141972-93-2 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1
CMF C24 H36 N6 O6

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 64-19-7


CMF C2 H4 O2



10/712,456-ALW

L4 ANSWER 140 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:6860 CAPLUS
DN 118:6860
TI Preparation of substituted bicyclic 3-arylpyrrolidine-2,4-dione
derivatives as pesticides and herbicides
IN Santel, Hans Joachim; Schmidt, Robert R.; Wachendorff-Neumann, Ulrike;
Erdelen, Christoph; Bretschneider, Thomas; Fischer, Reiner; Hagemann,
Hermann; Krueger, Bernd Wieland; Luerssen, Klaus
PA Bayer A.-G., Germany
SO Ger. Offen., 44 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4102778	A1	19920806	DE 1991-4102778	19910131
	EP 501129	A1	19920902	EP 1992-100826	19920120
	EP 501129	B1	19990714		
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL				
	ES 2135392	T3	19991101	ES 1992-100826	19920120
	US 5288874	A	19940222	US 1992-826303	19920124
	JP 04338390	A	19921125	JP 1992-34016	19920127
	JP 3216901	B2	20011009		
	ZA 9200643	A	19921028	ZA 1992-643	19920130
	BR 9200318	A	19921006	BR 1992-318	19920131
	US 5585384	A	19961217	US 1994-292111	19940817
	US 5693663	A	19971202	US 1996-700264	19960820
PRAI	DE 1991-4102778	A	19910131		
	US 1992-826303	A3	19920124		
	US 1993-134430	B2	19931008		
	US 1994-292111	A3	19940817		
OS	MARPAT 118:6860				
IT	144946-35-0P 144946-36-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as intermediate for pesticides and herbicides)				
RN	144946-35-0 CAPLUS				
CN	Proline, 4,5-dimethyl-1-[(2,4,6-trimethylphenyl)acetyl]-, ethyl ester				
	(9CI) (CA INDEX NAME)				





RN 144946-36-1 CAPLUS
CN L-Proline, 4-hydroxy-1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester,

10/712,456-ALW

trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L4 ANSWER 142 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:449275 CAPLUS
 DN 117:49275
 TI Preparation of tripeptides as antithrombotic agents
 IN Gesellchen, Paul David; Shuman, Robert Theodore
 PA Eli Lilly and Co., USA
 SO Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 479489	A2	19920408	EP 1991-308785	19910926
	EP 479489	A3	19931013		
	EP 479489	B1	20030319		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 99527	A	19970814	IL 1991-99527	19910919
	CA 2052013	A1	19920329	CA 1991-2052013	19910923
	CA 2052013	C	20010130		
	HU 59162	A2	19920428	HU 1991-3037	19910923
	HU 217441	B	20000128		
	ZA 9107572	A	19930323	ZA 1991-7572	19910923
	CZ 285980	B6	19991215	CZ 1991-2913	19910923
	SK 281731	B6	20010710	SK 1991-2913	19910923
	NO 9103773	A	19920330	NO 1991-3773	19910926
	NO 309984	B1	20010430		
	AU 9184780	A	19920402	AU 1991-84780	19910926
	AU 645347	B2	19940113		
	EP 684258	A2	19951129	EP 1995-201959	19910926
	EP 684258	A3	19960110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	EP 685489	A2	19951206	EP 1995-201960	19910926
	EP 685489	A3	19960110		
	EP 685489	B1	20011219		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	RU 2077538	C1	19970420	RU 1991-5001658	19910926
	EP 837071	A1	19980422	EP 1997-203616	19910926
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	KR 219993	B1	19991001	KR 1991-16772	19910926
	AT 211147	T	20020115	AT 1995-201960	19910926
	ES 2169105	T3	20020701	ES 1995-201960	19910926
	AT 234857	T	20030415	AT 1991-308785	19910926
	ES 2194835	T3	20031201	ES 1991-308785	19910926
	FI 9104566	A	19920329	FI 1991-4566	19910927
	FI 107733	B1	20010928		
	CN 1060472	A	19920422	CN 1991-109042	19910927
	CN 1036399	B	19971112		
	BR 9104181	A	19920602	BR 1991-4181	19910927
	JP 04257600	A	19920911	JP 1991-249093	19910927
	JP 3023019	B2	20000321		
	HU 9500399	A3	19951030	HU 1995-399	19950622
PRAI	US 1990-589553	A	19900928		
	US 1991-756091	A	19910906		
	EP 1991-308785	A3	19910926		
OS	MARPAT 117:49275				
IT	141972-93-2P 141973-11-7P 141973-13-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(preparation of, as antithrombotic)				

10/712,456-ALW

RN 141972-93-2 CAPLUS


CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1

CMF C24 H36 N6 O6


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 141973-11-7 CAPLUS


CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 141973-10-6


CMF C25 H38 N6 O6

10/712,456-ALW



CM 2


CRN 64-19-7
CMF C2 H4 O2



RN 141973-13-9 CAPLUS
CN L-Prolinamide, N-acetyl-D-2-(4-methoxyphenyl)glycyl-N-[4-
[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, monoacetate (9CI) (CA
INDEX NAME)

CM 1


CRN 141973-12-8
CMF C22 H32 N6 O5



CM 2

CRN 64-19-7
CMF C2 H4 O2

10/712,456-ALW





L4 ANSWER 143 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:407729 CAPLUS
 DN 117:7729
 TI Beta-lactam compounds, and their production and use
 IN Sunagawa, Makoto; Sasaki, Akira; Yamaga, Hiroshi; Shinagawa, Hisatoshi;
 Fukasawa, Masatomo; Sumita, Yoshihiro
 PA Sumitomo Pharmaceuticals Co., Ltd., Japan
 SO Eur. Pat. Appl., 129 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 472062	A1	19920226	EP 1991-113384	19910809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 9181724	A	19920213	AU 1991-81724	19910808
	AU 644008	B2	19931202		
	CA 2048887	A1	19920211	CA 1991-2048887	19910809
	JP 05230061	A	19930907	JP 1991-225177	19910809
	JP 3242677	B2	20011225		
PRAI	JP 1990-212102	A	19900810		
	JP 1990-415862	A	19901227		
	JP 1990-416070	A	19901228		
OS	MARPAT 117:7729				
IT	141817-31-4P 141817-32-5P 141817-33-6P				
	141817-37-0P 141817-38-1P 141817-39-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(preparation of, as antimicrobial)				
RN	141817-31-4 CAPLUS				
CN	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[3,4-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A







RN 141817-32-5 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141817-33-6 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 141817-37-0 CAPLUS


CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[3,4-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 β]-ta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 141817-38-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[3,4-dihydroxyphenyl]amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141817-39-2 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[(3,4-dihydroxyphenyl)amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 144 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:6967 CAPLUS

DN 116:6967

TI Preparation of amino acid (4-azolylmethyl)anilides as angiotensin II antagonists

IN Hodges, John C.; Sircar, Ila

PA Warner-Lambert Co., USA

SO U.S., 14 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	US 5041552	A	19910820	US 1990-529071	19900525
	US 5045540	A	19910903	US 1991-684638	19910412
PRAI	US 1990-529071	A3	19900525		
OS	CASREACT 116:6967; MARPAT 116:6967				
IT	137686-02-3P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 137686-02-3 CAPLUS

CN L-Proline, 1-[[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 145 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:471509 CAPLUS
DN 115:71509
TI Asymmetric synthesis of heterocycles using charge transfer complex intermediates
AU Lemaire, Marc; Guy, Alain; Imbert, Dominique; Guette, Jean Paul
CS Lab. Catal. Synth. Org., CNRS, Villeurbanne, 69622, Fr.
SO New Journal of Chemistry (1991), 15(5), 379-84
CODEN: NJCHE5; ISSN: 1144-0546
DT Journal
LA English
OS CASREACT 115:71509
IT 135066-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and attempted oxidative cyclization of, with DDQ)
RN 135066-10-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[4-(1-methylethoxy)phenyl]acetyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105988-50-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, with DDQ)
RN 105988-50-9 CAPLUS
CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 107672-35-5P 135066-17-0P 135066-18-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, with DDQ, morpholinedione from)
RN 107672-35-5 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 135066-17-0 CAPLUS

CN L-Proline, 1-[(4-propoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 135066-18-1 CAPLUS

CN L-Proline, 1-[[4-(1,1-dimethylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 135066-20-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidative cyclization of, with DDQ, morpholinedione via)

RN 135066-20-5 CAPLUS

CN L-Proline, 1-[(4-methoxy-1-naphthalenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 146 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:429390 CAPLUS

DN 115:29390

TI Preparation of N-(pyrrolidinyl-or piperidinylalkyl)dibenzo[b,e][1,4]thiazepines as calcium antagonists for treatment of gastrointestinal motility disorders

IN Alker, David; Bass, Robert J.; Cross, Peter Edward

PA Pfizer Ltd., UK; Pfizer Inc.

SO Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 404359	A1	19901227	EP 1990-305718	19900525
	EP 404359	B1	19940629		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 5071844	A	19911210	US 1990-527616	19900523
	CA 2017535	A1	19901127	CA 1990-2017535	19900525
	CA 2017535	C	20000229		
	NO 9002336	A	19901128	NO 1990-2336	19900525
	AU 9055954	A	19901129	AU 1990-55954	19900525
	DD 294718	A5	19911010	DD 1990-340993	19900525
	HU 58329	A2	19920228	HU 1990-3197	19900525
	ES 2055867	T3	19940901	ES 1990-305718	19900525
	FI 96950	B	19960614	FI 1990-2632	19900525
	FI 96950	C	19960925		
	CN 1047673	A	19901212	CN 1990-103954	19900526
	JP 03017079	A	19910125	JP 1990-138177	19900528
	JP 05007389	B	19930128		
PRAI	GB 1989-12303	A	19890527		

OS MARPAT 115:29390

IT 133714-93-9P 134621-58-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for dibenzothiazepine calcium antagonists)

RN 133714-93-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 134621-58-2 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 147 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:110785 CAPLUS
DN 114:110785
TI Enantioselective α -monofluorination of benzylic derivatives
IN Chebli, Samir; Laurent, Eliane; Marquet, Bernard
PA Rhone-Poulenc Chimie SA, Fr.
SO Fr. Demande, 8 pp.
CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	FR 2641002	A1	19900629	FR 1988-17072	19881223
PRAI	FR 1988-17072		19881223		
OS	MARPAT 114:110785				
IT	130517-54-3				

RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective fluorination of, electrochem.)

RN 130517-54-3 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, 1-methylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 148 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:611511 CAPLUS
DN 113:211511
TI Diastereoselective fluorination at benzylic position by anodic oxidation
AU Kabore, Leopold; Chebli, Samir; Faure, Rene; Laurent, Eliane; Marquet, Bernard
CS Lab. Chim. Org., UCB-Lyon I, Villeurbanne, 69622, Fr.
SO Tetrahedron Letters (1990), 31(22), 3137-40
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 113:211511
IT 130517-60-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of)
RN 130517-60-1 CAPLUS
CN L-Proline, 1-[fluoro(4-methoxyphenyl)acetyl]-, 1-methylethyl ester, (S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 130517-61-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 130517-61-2 CAPLUS
CN L-Proline, 1-[fluoro(4-methoxyphenyl)acetyl]-, 1-methylethyl ester, (R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 130517-54-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(regio- and stereoselective electrochem. fluorination of)
RN 130517-54-3 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




10/712,456-ALW

L4 ANSWER 149 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:591153 CAPLUS
DN 113:191153
TI Preparation of fused 3-arylpyrrolidine-2,4-diones as pesticides
IN Fischer, Reiner; Krebs, Andreas; Marhold, Albrecht; Santel, Hans Joachim;
Schmidt, Robert R.; Luerksen, Klaus; Hagemann, Hermann; Becker, Benedikt;
Schaller, Klaus; Stendel, Wilhelm
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 355599	A1	19900228	EP 1989-114789	19890810
	EP 355599	B1	19930519		
	R: BE, CH, DE, ES, FR, GB, GR, IT, LI, NL				
	DE 3831852	A1	19900222	DE 1988-3831852	19880920
	DE 3913682	A1	19901031	DE 1989-3913682	19890426
	US 5091537	A	19920225	US 1990-564267	19900808
	US 5142065	A	19920825	US 1991-710411	19910605
PRAI	DE 1988-3828404	A	19880820		
	DE 1988-3831852	A	19880920		
	DE 1989-3913682	A	19890426		
	US 1989-391227	A3	19890808		
	US 1990-564267	A3	19900808		
OS	CASREACT 113:191153; MARPAT 113:191153				
IT	129009-78-5P 129009-79-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as intermediate for arylpyrrolidinedione pesticides)				
RN	129009-78-5 CAPLUS				
CN	L-Proline, 1-[(2,4,6-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 129009-79-6 CAPLUS
CN L-Proline, 1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 150 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:633688 CAPLUS

DN 111:233688

TI Preparation and testing of peptidylhydroxamic acid derivatives as collagenase inhibitors

IN Kotake, Shinjiro; Okayama, Tooru; Ohata, Masami; Morikawa, Tadanori; Nagai, Yutaka

PA Fuji Chemicals Industrial Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01146896	A	19890608	JP 1987-305836	19871204
PRAI	JP 1987-305836		19871204		
OS	MARPAT 111:233688				
IT	123984-02-1P 123984-09-8P 123984-10-1P 123984-11-2P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 123984-02-1 CAPLUS

CN Glycinamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-D-leucyl-N-hydroxy-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123984-09-8 CAPLUS

CN L-Alaninamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-L-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123984-10-1 CAPLUS

CN D-Alaninamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-D-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 123984-11-2 CAPLUS

CN L-Valinamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-L-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 123984-26-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of, as intermediate for peptidylhydroxamic acid collagenase inhibitor)

RN 123984-26-9 CAPLUS

CN Glycine, N-[N-[1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl]-D-leucyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 151 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:66645 CAPLUS
DN 110:66645
TI Second harmonic generation by carbamic acid derivatives
IN Tiers, George V. D.
PA Minnesota Mining and Manufacturing Co., USA
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 271251	A1	19880615	EP 1987-310372	19871125
	R: CH, DE, FR, GB, IT, LI, NL, SE				
	AU 8780678	A	19880609	AU 1987-80678	19871104
	AU 620796	B2	19920227		
	JP 63163828	A	19880707	JP 1987-305533	19871202
PRAI	US 1986-937234	A	19861203		
OS	MARPAT 110:66645				
IT	117368-94-2P				


RL: PREP (Preparation)

(preparation of, as optical nonlinear material for second harmonic generation)

RN 117368-94-2 CAPLUS

CN L-Proline, 1-[[[(4-nitrophenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 152 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:611411 CAPLUS
DN 109:211411
TI Studies on pyrrolidinones. Synthesis of N-acylpyroglutamic acids having
bactericide and fungicide properties
AU Rigo, Benoit; Lespagnol, Charles; Pauly, Marc
CS Lab. Synth. Org., Hautes Etud. Ind., Lille, 59046, Fr.
SO Journal of Heterocyclic Chemistry (1988), 25(1), 59-63
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 109:211411
IT 98062-44-3P 117286-67-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antibacterial and antifungal activities of)
RN 98062-44-3 CAPLUS
CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117286-67-6 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 153 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:570824 CAPLUS
DN 109:170824
TI Studies on pyrrolidinones. Synthesis of N-acylpyrroglutamic esters with
bactericide and fungicide properties
AU Rigo, Benoit; Lespagnol, Charles; Pauly, Marc
CS Lab. Synth. Org., Ec. Hautes Etud. Ind., Lille, 59046, Fr.
SO Journal of Heterocyclic Chemistry (1988), 25(1), 49-57
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 109:170824
IT 98062-41-0P 98062-42-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(preparation and antibacterial activity of)
RN 98062-41-0 CAPLUS
CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 98062-42-1 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 154 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1988:510249 CAPLUS

DN 109:110249

TI Preparation of 4-hydroxy-2(5H)-thiophenones and -pyrrolinones as
circulatory system oxygen and radical scavengers

IN Terao, Shinji; Hirata, Minoru

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	-----	-----	-----	-----
PI	EP 262399	A2	19880406	EP 1987-112444	19870827
	EP 262399	A3	19890426		
	EP 262399	B1	19930203		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 63159367	A	19880702	JP 1987-198454	19870807
	JP 08009593	B	19960131		
	US 4925868	A	19900515	US 1987-84177	19870812
	CA 1321390	C	19930817	CA 1987-545176	19870824
	AT 85325	T	19930215	AT 1987-112444	19870827
PRAI	JP 1986-204833	A	19860829		
	EP 1987-112444	A	19870827		

OS MARPAT 109:110249

IT 115882-44-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reaction of, in preparation of circulatory system oxygen
and radical scavengers)

RN 115882-44-5 CAPLUS

CN L-Proline, 1-[[4-(dodecyloxy)phenyl]acetyl]-, ethyl ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 155 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:176711 CAPLUS
DN 106:176711
TI A novel and stereoselective synthesis of (\pm)-cephalotaxine and its analog
AU Yasuda, Shingo; Yamada, Toru; Hanaoka, Miyoji
CS Fac. Pharm. Sci., Kanazawa Univ., Kanazawa, 920, Japan
SO Tetrahedron Letters (1986), 27(18), 2023-6
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 106:176711
IT 107672-34-4P 107672-35-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in stereoselective synthesis of cephalotaxine)
RN 107672-34-4 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107672-35-5 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 156 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:102676 CAPLUS
DN 106:102676
TI N-Acylpyrrolidine derivatives, their preparation, their pharmaceutical composition and use
IN Tanaka, Takaharu; Saitoh, Masayuki; Hashimoto, Masaki; Higuchi, Naoki
PA Suntory, Ltd., Japan
SO Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 201742	A2	19861120	EP 1986-105232	19860416
	EP 201742	A3	19881214		
	EP 201742	B1	19921230		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 61238776	A	19861024	JP 1985-80870	19850416
	JP 06023190	B	19940330		
	US 4701465	A	19871020	US 1986-852711	19860416
	CA 1267149	A1	19900327	CA 1986-506768	19860416
	AT 84025	T	19930115	AT 1986-105232	19860416
PRAI	JP 1985-80870	A	19850416		
	EP 1986-105232	A	19860416		
OS	MARPAT 106:102676				
IT	106789-32-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as anti-amnesic and prolyl endopeptidase inhibitor)				
RN	106789-32-6 CAPLUS				
CN	L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 157 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:32128 CAPLUS
DN 106:32128
TI Asymmetric control of oxidation of aromatic substrates using a
donor-acceptor interaction
AU Lemaire, Marc; Guy, Alain; Imbert, Dominique; Guette, Jean Paul
CS Lab. Chim. Org., Conserv. Natl. Arts Metiers, Paris, 75141, Fr.
SO Journal of the Chemical Society, Chemical Communications (1986), (10),
741-2
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
OS CASREACT 106:32128
IT 105988-50-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidative cyclization of, stereoselective)
RN 105988-50-9 CAPLUS
CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105988-47-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, stereoselective)
RN 105988-47-4 CAPLUS
CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 105988-48-5P 105988-49-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 105988-48-5 CAPLUS
CN L-Proline, 1-[(acetyloxy)[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl
ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 105988-49-6 CAPLUS

CN L-Proline, 1-[(acetyloxy)[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 158 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:627298 CAPLUS
DN 105:227298
TI N-Adamantylpyroglutamides
IN Laruelle, Claude; Lepant, Marcel; Raynier, Bernard
PA Panmedica S. A., Fr.
SO Fr. Demande, 30 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2572399	A1	19860502	FR 1984-16656	19841031
	FR 2572399	B1	19870116		
	EP 187052	A1	19860709	EP 1985-401976	19851010
	EP 187052	B1	19900131		
	R: AT, BE, CH, DE, IT, LI, LU, NL, SE				
	AT 49957	T	19900215	AT 1985-401976	19851010
	US 4661512	A	19870428	US 1985-787995	19851016
	AU 8548846	A	19860508	AU 1985-48846	19851018
	AU 583543	B2	19890504		
	ZA 8508169	A	19860625	ZA 1985-8169	19851024
	ES 548357	A1	19870116	ES 1985-548357	19851030
	JP 61109766	A	19860528	JP 1985-246119	19851031
PRAI	FR 1984-16656	A	19841031		
	EP 1985-401976	A	19851010		
OS	CASREACT 105:227298; MARPAT 105:227298				
IT	105425-10-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and hydrogenolysis of)				
RN	105425-10-3 CAPLUS				
CN	L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 105425-12-5P 105425-22-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pharmaceutical)
RN 105425-12-5 CAPLUS

10/712,456-ALW


CN 2-Pyrrolidinecarboxamide, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105425-22-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)



IT 105425-11-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, chlorination, and amination of)

RN 105425-11-4 CAPLUS

CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 159 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1986:29388 CAPLUS

DN 104:29388

TI Synthesis and effect of affinity-labeled analogs and partial sequences of the bradykinin potentiating nonapeptide BPP9 α (teprotide)

AU Reissmann, S.; Paegelow, I.; Filatova, M. P.; Krit, N. A.; Arold, H.

CS Wissenschaftsbereich Allg. Biochem., Friedrich-Schiller-Univ., Jena, DDR-6900, Ger. Dem. Rep.

SO Pharmazie (1985), 40(5), 314-17

CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA German

IT 99741-86-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation and bradykinin activation response to)


RN 99741-86-3 CAPLUS

CN Bradykinin potentiator B, 1-[1-[[4-[bis(2-chloroethyl)amino]phenyl]acetyl]-L-proline]-2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





10/712,456-ALW

L4 ANSWER 160 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1985:523914 CAPLUS

DN 103:123914

TI Pyroglutamic derivatives, their intermediates and their use as bactericides or fungicides

IN Pauly, Marc

PA Laboratoires Serobiologiques S. A., Fr.

SO Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 135444	A1	19850327	EP 1984-401803	19840912
	EP 135444	B1	19890118		
	R: AT, BE, CH, DE, GB, IT, LI, LU, NL, SE				
	FR 2551751	A1	19850315	FR 1983-14480	19830912
	FR 2551751	B1	19860425		
	JP 60149559	A	19850807	JP 1984-191420	19840912
	AT 40113	T	19890215	AT 1984-401803	19840912
PRAI	FR 1983-14480	A	19830912		
	EP 1984-401803	A	19840912		

OS CASREACT 103:123914; MARPAT 103:123914


IT 98062-41-0 98062-42-1 98062-44-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal and fungicidal activities of)

RN 98062-41-0 CAPLUS

CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 98062-42-1 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 98062-44-3 CAPLUS


CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 161 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1984:423391 CAPLUS
DN 101:23391
TI Derivatives of 2,3,5,6,7,7a-hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazole-5-carboxylic acids
AU Fontanella, L.; Corsico, N.; Diena, A.; Occelli, E.
CS Lab. Ric., Gruppo Lepetit S.p.A., Milan, Italy
SO Farmaco, Edizione Scientifica (1984), 39(2), 133-53
CODEN: FRPSAX; ISSN: 0430-0920
DT Journal
LA Italian
OS CASREACT 101:23391
IT 90513-55-6P 90513-58-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation-saponification of)
RN 90513-55-6 CAPLUS
CN 2,5-Pyrrolidinedicarboxylic acid, 1-[[[4-methylphenyl)amino]carbonyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 90513-58-9 CAPLUS
CN 2,5-Pyrrolidinedicarboxylic acid, 1-[[[4-methoxyphenyl)amino]carbonyl]-, diethyl ester (9CI) (CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 162 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:72508 CAPLUS
DN 98:72508
TI Phenanthroindolizidine and related alkaloids: synthesis of tylophorine,
septicine, and deoxytylophorinine
AU Cragg, John E.; Herbert, Richard B.; Jackson, Frederick B.; Moody,
Christopher J.; Nicolson, Ian T.
CS Dep. Org. Chem., Univ. Leeds, Leeds, LS2 9JT, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
Bio-Organic Chemistry (1972-1999) (1982), (10), 2477-85
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 98:72508
IT 84382-49-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in synthesis of tylophorine)
RN 84382-49-0 CAPLUS
CN L-Proline, 1-[2,3-bis(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]-, methyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

L4 ANSWER 163 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1982:85815 CAPLUS
DN 96:85815
TI Chiral route to some alkaloids through asymmetric iodolactonization
AU Takano, Seiichi; Murakata, Chikara; Imamura, Yoko; Tamura, Nobuhiko;
Ogasawara, Kunio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Heterocycles (1981), 16(8), 1291-4
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
IT 80758-88-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(asym. iodolactonization of)
RN 80758-88-9 CAPLUS
CN L-Proline, 1-[2-(2-butenyl)-2-(3,4-dimethoxyphenyl)-1-oxo-4-hexenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L4 ANSWER 164 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1976:165199 CAPLUS
 DN 84:165199
 TI Chromogenic or fluorescent substrate for enzyme determination
 IN Svendsen, Lars G.
 PA Pentapharm A.-G., Switz.
 SO Ger. Offen., 67 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2527932	A1	19760122	DE 1975-2527932	19750623
	DE 2527932	C2	19830421		
	CH 609154	A5	19790215	CH 1974-9210	19740702
	ZA 7504019	A	19760526	ZA 1975-4019	19750624
	NO 7502386	A	19760105	NO 1975-2386	19750630
	NO 147212	B	19821115		
	NO 147212	C	19830223		
	DD 120715	A5	19760620	DD 1975-186968	19750630
	US 4016042	A	19770405	US 1975-592023	19750630
	CA 1049506	A1	19790227	CA 1975-230464	19750630
	NL 7507802	A	19760106	NL 1975-7802	19750701
	NL 188354	B	19920102		
	NL 188354	C	19920601		
	AU 7582631	A	19770106	AU 1975-82631	19750701
	SE 424635	B	19820802	SE 1975-7545	19750701
	SE 424635	C	19821111		
	BE 830911	A1	19751103	BE 1975-157901	19750702
	FR 2279106	A1	19760213	FR 1975-20756	19750702
	FR 2279106	B1	19810430		
	JP 51029998	A	19760313	JP 1975-81754	19750702
	JP 56022280	B	19810523		
PRAI	CH 1974-9210	A	19740702		
	CH 1975-6088	A	19750509		
IT	59188-48-6P 59188-50-0P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of)				
RN	59188-48-6 CAPLUS				
CN	L-Ornithinamide, 1-[[4-[[(phenylmethoxy) carbonyl] amino] phenyl] acetyl]-L-prolyl-L-phenylalanyl-N5-[imino(nitroamino)methyl]-N-(4-nitrophenyl)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A




—NO₂—NO₂

RN 59188-50-0 CAPLUS

CN L-Argininamide, 1-[(4-aminophenyl)acetyl]-L-prolyl-L-phenylalanyl-N-(4-nitrophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

10/712,456-ALW


L4 ANSWER 165 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1974:507384 CAPLUS
DN 81:107384
TI Interaction of amino acids, peptides and leather powder with isocyanates
shoe adhesive components
AU Balabanaova, E.; Evtimova, R.; Mladenova, L.; Tsyetkov, P.
CS Bulg.
SO Kozharska i Obuvna Promishlenost (1973), 14(3), 8-12
CODEN: KZOPAS; ISSN: 0368-7295
DT Journal
LA Bulgarian
IT 52392-31-1P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 52392-31-1 CAPLUS
CN L-Proline, 1,1',1''-[methylidynetris(4,1-phenyleneiminocarbonyl)]tris-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 166 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1974:121317 CAPLUS
 DN 80:121317
 TI Synthesis of long, hydrophilic, protein-crosslinking reagents
 AU Wetz, K.; Fasold, H.; Meyer, Ch.
 CS Inst. Biochem., Johann Wolfgang Goethe Univ., Frankfurt/Main, Fed. Rep. Ger.
 SO Analytical Biochemistry (1974), 58(2), 347-60
 CODEN: ANBCA2; ISSN: 0003-2697
 DT Journal
 LA English
 IT 52136-94-4P 52136-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, protein crosslinking reagent)
 RN 52136-94-4 CAPLUS
 CN Poly(1,2-pyrrolidinediylcarbonyl), α,α' -[azobis(4,1-phenyleneiminocarbonyl)]bis[ω -hydroxy-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 52136-96-6 CAPLUS
 CN Poly(1,2-pyrrolidinediylcarbonyl), α,α' -[azobis(4,1-phenyleneiminocarbonyl)]bis[ω -[[2-[(iodoacetyl)amino]ethylamino]-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





10/712,456-ALW

L4 ANSWER 167 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:453779 CAPLUS
DN 79:53779

TI Antiinflammatory L-hydroxyproline derivatives

IN Coirre, Paul; Coirre, Bertrand

SO Brit., 5 pp. Addn. to Brit. 1,246,141.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1315633	A	19730502	GB 1971-33362	19710715
PRAI	GB 1971-33362	A	19710715		
IT	38357-44-7P				

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38357-44-7 CAPLUS

CN L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 168 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:124436 CAPLUS
DN 78:124436
TI Analgesic and antiinflammatory L-4-hydroxyproline derivatives
IN Coirre, Paul; Coirre, Bertrand
SO Ger. Offen., 14 pp. Addn. to Ger. Offen. 1,795,327 (See Brit. 1,246,141 CA 75;140679b).
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	DE 2139476	A1	19730215	DE 1971-2139476	19710806
PRAI	DE 1971-2139476	A	19710806		
IT	38357-44-7P				

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38357-44-7 CAPLUS
CN L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 169 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:527056 CAPLUS
DN 77:127056
TI L-Hydroxyproline derivatives active on the metabolism of conjunctival
tissue
IN Coirre, Paul; Coirre, Bertrand; Denis, J. C.; Rambaud, J.; Cahn, Jean
SO Fr. Demande, 9 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2081573	A6	19711210	FR 1970-8942	19700312
	FR 2081573	B2	19730406		
	SE 381653	B	19751215	SE 1971-8659	19710312
PRAI	FR 1970-8942	A	19700312		
IT	38357-44-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	38357-44-7 CAPLUS				
CN	L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 170 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:502249 CAPLUS
DN 77:102249

PA CIBA Ltd.

CODEN: FAXXA3

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 94938		19700123		
PRAI	DE 1967-667		19670117		
IT	38046-01-4P				

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38046-01-4 CAPLUS

CN L-Prolinamide, L-valyl-N6-[(1,1-dimethylethoxy) carbonyl]-L-lysyl-L-valyl-L-tyrosyl- (9CI) (CA INDEX NAME)

[illegible]

10/712,456-ALW

L4 ANSWER 171 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1969:502228 CAPLUS
DN 71:102228
TI Antitubercular cyclopeptides
IN Jolles, Georges
PA Rhone-Poulenc S. A.
SO Ger. Offen., 48 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 1805280	B2	19781130	DE 1968-1805280	19681025
	DE 1805280	C3	19790802		
	FR 1578723	A	19690822	FR 1967-125842	19671025
	FR 94740	E	19691024	FR 1968-144421	19680319
	NL 6814446	A	19690429	NL 1968-14446	19681009
	BR 6803309	D0	19730222	BR 1968-203309	19681021
	BR 6803310	D0	19730222	BR 1968-203310	19681021
	BE 722846	A	19690424	BE 1968-722846	19681024
	GB 1190200	A	19700429	GB 1968-1190200	19681024
	CH 490339	A	19700515	CH 1968-490339	19681024
	CH 490340	A	19700515	CH 1968-490340	19681024
	NO 125142	B	19720724	NO 1968-4227	19681024
	SE 362641	B	19731217	SE 1968-14415	19681024
	JP 49005359	B	19740206	JP 1968-77102	19681024
	PL 79403	B1	19750630	PL 1968-129713	19681024
	PL 79404	B1	19750630	PL 1968-129714	19681024
	SE 388605	B	19761011	SE 1971-8184	19681024
	DK 140591	B	19791008	DK 1968-5146	19681024
	DK 140591	C	19800225		
	ES 359552	A1	19700601	ES 1968-359552	19681025
	ES 359553	A1	19700601	ES 1968-359553	19681025
	AT 286513	B	19701210	AT 1968-10461	19681025
	AT 298669	B	19720525	AT 1968-10463	19681025
	IL 30959	A	19730430	IL 1968-30959	19681025
	CS 151487	B2	19731019	CS 1968-7355	19681025
	AT 311548	B	19731126	AT 1970-5743	19681025
	CS 152310	B2	19731219	CS 1968-7356	19681025
	FI 49399	B	19750228	FI 1968-3037	19681025
	FI 49400	B	19750228	FI 1968-3038	19681025
	DE 1817960	A1	19750710	DE 1968-1817960	19681025
	SU 535902	A3	19761115	SU 1968-1280361	19681025
	US 3719656	A	19730306	US 1969-888045	19691224
	NO 135417	B	19761227	NO 1971-2523	19710701
	DK 7800006	A	19780102	DK 1978-678	19780102
PRAI	FR 1967-125842	A	19671025		
	FR 1968-144421	A	19680319		
	FR 1967-81425	A	19671112		
	FR 1968-44421	A	19680319		
	DK 1968-5146	A	19681024		
	NO 1968-4227	A	19681024		
	US 1968-770436	A2	19681024		

IT 23934-03-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 23934-03-4 CAPLUS

CN Glycine, N-[N-[1-[N-[N-[1-[N-[N-[1-(3-benzoylhydratropoyl)-trans-4-methyl-L-prolyl]-N-methyl-L-threonyl]-L-leucyl]-trans-4-methyl-L-prolyl]-L-leucyl]-N-methyl-L-valyl]-L-prolyl]-N-methyl-D-leucyl]-, ψ -lactone


10/712,456-ALW

(8CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10/712,456-ALW


L4 ANSWER 172 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1960:110095 CAPLUS
DN 54:110095
OREF 54:20895d-g
TI Cancerolytic peptides with directed action
AU Knunyants, I. L.; Golubeva, N. E.; Kil'disheva, O. V.
SO Doklady Akademii Nauk SSSR (1960), 132, 836-8
CODEN: DANKAS; ISSN: 0002-3264
DT Journal
LA Unavailable
IT 103506-10-1P, Proline, 1-[[p-[bis(2-chloroethyl)amino]phenyl]acetyl]-, ethyl ester
RL: PREP (Preparation)
(preparation of)
RN 103506-10-1 CAPLUS
CN Proline, 1-[[p-[bis(2-chloroethyl)amino]phenyl]acetyl]-, ethyl ester (6CI)
(CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 173 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1957:97969 CAPLUS
DN 51:97969
OREF 51:17615b-c
TI Infrared spectra of 3-phenyl-2-thiohydantoins of amino acids
AU Epp, Agnes
CS Natl. Research Council, Saskatoon, Can.
SO Anal. Chem. (1957), 29, 1283-7
CODEN: ANCHAM; ISSN: 0003-2700
DT Journal
LA Unavailable
IT 109068-49-7, Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-
(spectrum of)
RN 109068-49-7 CAPLUS
CN Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-, L- (6CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

L4 ANSWER 174 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1956:73930 CAPLUS
DN 50:73930
OREF 50:13879g-i,13880a-b
TI The 3-o-nitrophenyl- and 3-(p-phenylazophenyl)-2-thio-hydantoins of amino acids
AU Ramachandran, L. K.; McConnell, W. B.
CS Natl. Research Council Can., Saskatoon, Saskatchewan
SO Journal of the American Chemical Society (1956), 78, 1255-7
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
OS CASREACT 50:73930
IT 109068-49-7P, Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-
RL: PREP (Preparation)
(preparation of)
RN 109068-49-7 CAPLUS
CN Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-, L- (6CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

631.76

804.52

STN INTERNATIONAL LOGOFF AT 09:24:36 ON 29 MAY 2007